Central Nervous System
Mission statement
The main objective of the CNS team is to develop innovative and quantitative pre-clinical and clinical MR methods at high and ultra-high magnetic fields, as well as image analysis techniques, in order to improve in vivo the physiological and pathophysiological characterization of both brain and spinal cord.
Preclinical studies of CNS pathological models help refine, reject, or generate hypotheses regarding the mechanistic basis of diseases by providing detailed structural, functional, and metabolic phenotypes/information associated with pathology.
Clinical MR methods developed by researchers and engineers are driven by clinical questions brought by the clinicians of the team specialized in Multiple Sclerosis, Epilepsy and Spinal Cord Injury. Researches focus on the different ways to characterize the anatomical, microstructural, hemodynamic, metabolic, ionic and functional alterations of the Human CNS.
The CNS team also provides through collaborations an academic platform based on the tools developed for the main topics adapted to characterize other CNS diseases (AD, ALS, Stroke, Parkinson, Schizophrenia, Spinal Cord Injury (LIA iLab-Spine) …).
Research Topics
Publications
180164
snc
1
chicago-fullnote-bibliography
50
date
desc
1118
https://crmbm.univ-amu.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A500%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22G9HL6P42%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Agripnidis%20et%20al.%22%2C%22parsedDate%22%3A%222025-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAgripnidis%2C%20Thibault%2C%20Angela%20Ayobi%2C%20Sarah%20Quenet%2C%20Yasmina%20Chaibi%2C%20Christophe%20Avare%2C%20Alexis%20Jacquier%2C%20Nadine%20Girard%2C%20et%20al.%20%26%23x201C%3BPerformance%20of%20an%20Artificial%20Intelligence%20Tool%20for%20Multi-Step%20Acute%20Stroke%20Imaging%3A%20A%20Multicenter%20Diagnostic%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Radiology%20Open%26lt%3B%5C%2Fi%26gt%3B%2015%20%28December%202025%29%3A%20100678.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejro.2025.100678%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejro.2025.100678%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Performance%20of%20an%20artificial%20intelligence%20tool%20for%20multi-step%20acute%20stroke%20imaging%3A%20A%20multicenter%20diagnostic%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Agripnidis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%22%2C%22lastName%22%3A%22Ayobi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Quenet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yasmina%22%2C%22lastName%22%3A%22Chaibi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Avare%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Jacquier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Girard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Hak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Reyre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Brun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed-Ali%22%2C%22lastName%22%3A%22El%20Ahmadi%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20Several%20artificial%20intelligence%20%28AI%29%20tools%20have%20been%20developed%20to%20assist%20in%20the%20stroke%20imaging%20workflow%2C%20which%20remains%20a%20major%20disease%20of%20the%2021st%20century.%20This%20study%20evaluated%20the%20combined%20performance%20of%20an%20FDA-cleared%20and%20CE-marked%20AI-based%20device%20with%20three%20modules%20designed%20to%20detect%20intracerebral%20hemorrhage%20%28ICH%29%2C%20identify%20large%20vessel%20occlusion%20%28LVO%29%2C%20and%20calculate%20Alberta%20Stroke%20Program%20Early%20CT%20Scores%20%28ASPECTS%29.%5CnMATERIALS%20%26amp%3B%20METHODS%3A%20Non-contrast%20CT%20%28NCCT%29%20and%5C%2For%20computed%20tomography%20angiography%20%28CTA%29%20for%20suspicion%20of%20stroke%20acquired%20at%20La%20Timone%20and%20Nord%20University%20hospitals%20%28Marseille%2C%20France%29%20between%20March%202019%20and%20March%202020%20were%20retrospectively%20collected.%20The%20AI%20tool%2C%20CINA-HEAD%20%28Avicenna.AI%29%2C%20processed%20the%20data%20to%20flag%20ICH%2C%20LVO%2C%20and%20calculate%20ASPECTS.%20The%20results%20were%20compared%20to%20ground%20truth%20evaluations%20by%20four%20expert%20neuroradiologists%20to%20compute%20diagnostic%20performances.%5CnRESULTS%3A%20A%20total%20of%20373%20NCCT%20and%20331%20CTA%20from%20405%20patients%20%28mean%20age%2064.9%5Cu202f%5Cu00b1%5Cu202f18.9%5Cu202fSD%2C%2052.6%5Cu202f%25%20female%29%20were%20included.%20The%20AI%20tool%20achieved%20an%20accuracy%20of%2094.6%5Cu202f%25%20%5B95%5Cu202f%25%20CI%3A%2091.8%5Cu202f%25-96.7%5Cu202f%25%5D%20for%20ICH%20detection%20on%20NCCT%20and%20of%2086.4%5Cu202f%25%20%5B95%5Cu202f%25%20CI%3A%2082.2%5Cu202f%25-89.9%5Cu202f%25%5D%20for%20LVO%20identification%20on%20CTA.%20The%20region-based%20ASPECTS%20analysis%20yielded%20an%20accuracy%20of%2088.6%5Cu202f%25%20%5B95%5Cu202f%25%20CI%3A%2087.8%5Cu202f%25-89.3%5Cu202f%25%5D%20and%20the%20dichotomized%20ASPECTS%20classification%20%28ASPECTS%20%5Cu2265%206%29%20achieved%2080.4%5Cu202f%25%20accuracy.%5CnCONCLUSION%3A%20This%20study%20demonstrates%20the%20reliable%2C%20stepwise%20performance%20of%20an%20AI-based%20stroke%20imaging%20tool%20across%20the%20diagnostic%20cascade%20of%20ICH%20and%20LVO%20detection%20and%20ASPECTS%20scoring.%20Such%20robust%20multi-stage%20evaluation%20supports%20its%20potential%20for%20streamlining%20acute%20stroke%20triage%20and%20decision-making.%22%2C%22date%22%3A%222025-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejro.2025.100678%22%2C%22ISSN%22%3A%222352-0477%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KFZ6H27M%22%2C%22W98NEAUQ%22%5D%2C%22dateModified%22%3A%222025-11-27T10%3A56%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22IRDNCDL2%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gauer%20et%20al.%22%2C%22parsedDate%22%3A%222025-11-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGauer%2C%20Lucas%2C%20Roy%20A.%20M.%20Haast%2C%20Mikhael%20Azilinon%2C%20Mohamed%20Mounir%20El%20Mendili%2C%20Julia%20Makhalova%2C%20Hugo%20Dary%2C%20Vera%20Dinkelacker%2C%20et%20al.%20%26%23x201C%3BInvestigating%20Sodium%20Homeostasis%20of%20Structural%20Brain%20Hubs%20in%20Focal%20Epilepsy%20Using%207%20T%20MRI.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBrain%3A%20A%20Journal%20of%20Neurology%26lt%3B%5C%2Fi%26gt%3B%2C%20November%205%2C%202025%2C%20awaf409.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fbrain%5C%2Fawaf409%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fbrain%5C%2Fawaf409%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Investigating%20sodium%20homeostasis%20of%20structural%20brain%20hubs%20in%20focal%20epilepsy%20using%207%20T%20MRI%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucas%22%2C%22lastName%22%3A%22Gauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roy%20A.%20M.%22%2C%22lastName%22%3A%22Haast%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikhael%22%2C%22lastName%22%3A%22Azilinon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamed%20Mounir%22%2C%22lastName%22%3A%22El%20Mendili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Makhalova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Dary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%22%2C%22lastName%22%3A%22Dinkelacker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ben%22%2C%22lastName%22%3A%22Ridley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Bartolomei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%5D%2C%22abstractNote%22%3A%22Besides%20their%20crucial%20role%20in%20cerebral%20connectivity%2C%20brain%20hubs%20are%20regions%20vulnerable%20to%20the%20energy%20deficit%20associated%20with%20various%20brain%20disorders.%20Changes%20in%20sodium%20homeostasis%20of%20cortical%20regions%20have%20been%20observed%20in%20focal%20epilepsy%20and%20may%20reflect%20energy%20failure.%20We%20investigated%20whether%20nodal%20structural%20connectivity%20is%20differently%20affected%20within%20the%20hub%20and%20non-hub%20regions%20by%20ionic%20perturbations%20associated%20with%20focal%20epilepsy.%20Our%20hypothesis%20was%20that%20the%20metabolic%20demands%20of%20hub%20regions%20may%20be%20associated%20with%20a%20distinct%20ionic%20profile%20detectable%20by%20sodium%20MRI%20and%20that%20this%20profile%20is%20altered%20in%20focal%20epilepsy.%20We%20included%2039%20patients%20with%20drug-resistant%20focal%20epilepsy%20and%2021%20age-%20and%20gender-matched%20healthy%20controls.%20Anatomical%2C%20diffusion-weighted%2C%20and%20sodium%20imaging%20was%20performed%20using%20a%207%20Tesla%20MRI%20scanner.%20Patients%20underwent%20pre-surgical%20work-up%2C%20including%20stereo-electroencephalographic%20recordings%20for%20defining%20the%20epileptogenic%20regions.%20Anatomical%20parcellation%20and%20multimodal%20coregistration%20allowed%20the%20use%20of%20parcels%20as%20nodes%20of%20whole-brain%20structural%20connectomes%2C%20linking%20structural%20connectivity%20measures%20to%20epileptogenicity%20and%20sodium%20parameters.%20Sodium%20parameters%20in%20patients%20were%20z-scored%20concerning%20homologous%20parcels%20in%20controls%20to%20allow%20comparison%20across%20regions%20of%20interest.%20Hub%20regions%20had%20higher%20total%20sodium%20concentration%20%28TSC%29%20than%20non-hub%20regions%20in%20both%20patients%20and%20controls%2C%20and%20this%20difference%20was%20not%20observed%20for%20sodium%20signal%20fraction%20%28f%2C%20a%20proxy%20of%20intracellular%20sodium%20homeostasis%29.%20Compared%20to%20controls%2C%20patients%20showed%20increased%20TSC%20in%20both%20epileptogenic%20and%20non-epileptogenic%20zones%2C%20and%20this%20increase%20in%20TSC%20was%20consistent%20in%20both%20hub%20and%20non-hub%20regions.%20On%20the%20contrary%2C%20f%20was%20increased%20only%20within%20the%20epileptogenic%20zones%20and%20was%20not%20affected%20by%20the%20hubness%20of%20a%20region.%20Our%20results%20also%20confirm%20the%20whole%20brain%20increase%20in%20TSC%20and%20the%20local%20increase%20of%20the%20f%20value%20within%20epileptogenic%20zones%20previously%20observed%20in%20focal%20epilepsy%20patients.%20Therefore%2C%20we%20propose%20that%20sodium%20imaging%20can%20probe%20distinct%20tissue%20properties%3A%20TSC%20appears%20sensitive%20to%20microstructural%20alterations%2C%20while%20f%20could%20reflect%20homeostatic%20disruptions%20specific%20to%20epileptogenic%20regions.%22%2C%22date%22%3A%222025-11-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fbrain%5C%2Fawaf409%22%2C%22ISSN%22%3A%221460-2156%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22UP3H3ICX%22%2C%22HVJZKIZG%22%2C%22P66W67T8%22%2C%22F2AGIUQU%22%2C%22XTA6KS7L%22%2C%22FBQIKF54%22%2C%229RMECNPE%22%5D%2C%22dateModified%22%3A%222025-11-12T13%3A35%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22C2999DIC%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Stellmann%20et%20al.%22%2C%22parsedDate%22%3A%222025-11-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BStellmann%2C%20Jan-Patrick%2C%20Adil%20Maarouf%2C%20Mihaela%20Nicolescu%2C%20Cl%26%23xE9%3Bmence%20Boutiere%2C%20Audrey%20Rico%2C%20Wafaa%20Zaaraoui%2C%20Maxime%20Guye%2C%20Jean%20Pelletier%2C%20Jean-Phillipe%20Ranjeva%2C%20and%20Bertrand%20Audoin.%20%26%23x201C%3BEarly%20Structural%20Hub%20Disruption%20Leads%20to%20Premature%20Functional%20Adaption%20in%20Multiple%20Sclerosis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBrain%20Structure%20%26amp%3B%20Function%26lt%3B%5C%2Fi%26gt%3B%20230%2C%20no.%209%20%28November%205%2C%202025%29%3A%20172.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00429-025-03023-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00429-025-03023-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Early%20structural%20hub%20disruption%20leads%20to%20premature%20functional%20adaption%20in%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mihaela%22%2C%22lastName%22%3A%22Nicolescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Phillipe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22In%20Multiple%20Sclerosis%2C%20inflammation%20and%20neurodegeneration%20disrupt%20structural%20and%20functional%20brain%20networks.%20While%20the%20association%20between%20structural%20connectivity%20and%20disability%20is%20rather%20clear%2C%20functional%20connectivity%20changes%20are%20not%20yet%20characterised%20as%20a%20physiological%20response%20to%20the%20disease%2C%20as%20functionally%20meaningful%20adaptation%20or%20as%20a%20deceptive%20response.%20We%20explored%20the%20topology%20of%20brain%20networks%20of%2065%20Multiple%20Sclerosis%20patients%20over%20up%20to%20seven%20years%20in%20comparison%20to%2059%20controls.%20Connectomes%20based%20on%20probabilistic%20tractography%20from%20diffusion%20weighted%20imaging%20and%20resting-state%20MRI%2C%20were%20analysed%20with%20graph%20theory.%20The%20hub%20disruption%20index%20estimated%20connectivity%20perturbation%20in%20relation%20to%20the%20network%20hierarchy.%20In%20controls%2C%20we%20observed%20a%20transient%20increase%20in%20functional%20hub%20connectivity%20in%20the%205th%20and%206th%20age%20decade%20as%20a%20response%20to%20a%20subtle%20diffuse%20loss%20of%20structural%20connectivity%2C%20before%20structural%20and%20functional%20connectomes%20show%20a%20pronounced%20loss%20of%20hub%20connectivity.%20In%20Multiple%20Sclerosis%2C%20structural%20hub%20disruption%20was%20present%20from%20the%20disease%20onset%20while%20the%20transient%20upregulation%20of%20functional%20hub%20connectivity%20in%20the%20middle%20age%20was%20lacking.%20Patients%20seem%20to%20transition%20directly%20into%20an%20exhausted%20hub%20connectivity%20configuration.%20However%2C%20we%20observed%20the%20transient%20functional%20reorganisation%20of%20hubs%20in%20the%20first%20years%20after%20disease%20onset.%20Multiple%20Sclerosis%20patients%20present%20a%20probable%20physiological%20response%20to%20structural%20connectivity%20loss%20very%20early%20in%20the%20disease%2C%20potentially%20leading%20to%20an%20accelerated%20hub%20overload%20with%20accelerated%20neurodegeneration.%20The%20onset%20of%20chronic%20progression%20in%20the%205th%20age%20decade%20might%20be%20partially%20driven%20by%20the%20absence%20of%20the%20physiological%20increased%20hub%20connectivity%20observed%20in%20healthy%20individuals.%22%2C%22date%22%3A%222025-11-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00429-025-03023-2%22%2C%22ISSN%22%3A%221863-2661%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%229L2KHJ5X%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222025-11-06T15%3A36%3A25Z%22%7D%7D%2C%7B%22key%22%3A%2247QU9FZH%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Grass%20et%20al.%22%2C%22parsedDate%22%3A%222025-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGrass%2C%20L.%2C%20S.%20Grimaldi%2C%20and%20P.%20Damier.%20%26%23x201C%3BProdromal%20Parkinson%26%23x2019%3Bs%20Disease.%26%23x201D%3B%20%26lt%3Bi%26gt%3BRevue%20Neurologique%26lt%3B%5C%2Fi%26gt%3B%20181%2C%20no.%209%20%28November%202025%29%3A%20863%26%23x2013%3B80.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.neurol.2025.06.012%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.neurol.2025.06.012%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prodromal%20Parkinson%27s%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Grass%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Grimaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Damier%22%7D%5D%2C%22abstractNote%22%3A%22The%20neurodegenerative%20process%20responsible%20for%20Parkinson%26%23039%3Bs%20disease%20%28PD%29%20begins%20years%20before%20the%20level%20of%20dopamine%20denervation%20of%20the%20basal%20ganglia%20leads%20to%20the%20characteristic%20clinical%20phenotype%20of%20the%20disease.%20During%20the%20past%2020years%2C%20numerous%20symptoms%20that%20may%20occur%20during%20the%20prodromal%20stage%20of%20the%20disease%20have%20been%20identified%3A%20subtle%20motor%20symptoms%2C%20psychocognitive%20disorders%2C%20sleep%20disorders%2C%20sensorial%20dysfunction%2C%20and%20dysautonomia.%20Among%20them%2C%20rapid%20eye%20movement%20sleep%20behaviour%20disorder%20%28RBD%29%20is%20one%20of%20the%20most%20specific.%20The%20follow-up%20of%20cohorts%20of%20subjects%20affected%20by%20this%20disorder%20has%20provided%20valuable%20information%20about%20the%20prodromal%20stage%2C%20including%20evidence%20of%20various%20biological%20or%20imaging%20biomarkers%20associated%20with%20the%20pre-clinical%20stage%20of%20the%20disease.%20From%20all%20the%20knowledge%20acquired%20about%20this%20stage%20of%20the%20disease%2C%20criteria%20for%20diagnosing%20prodromal%20PD%20have%20been%20proposed%20and%20have%20progressively%20improved%20in%20sensitivity%20and%20specificity.%20The%20strong%20focus%20on%20the%20RBD-associated%20prodromal%20stage%20has%2C%20however%2C%20tended%20to%20conceal%20other%2C%20less%20florid%20forms%20of%20prodromal%20PD%2C%20such%20as%20those%20beginning%20with%20mild%20cognitive%20impairment%20or%20mild%20motor%20symptoms%2C%20which%20affected%20subjects%20are%20less%20likely%20to%20notice.%20Here%2C%20we%20review%20the%20various%20symptoms%20observed%20in%20the%20prodromal%20stage%20of%20PD%2C%20progress%20on%20identifying%20relevant%20imaging%20and%20biological%20biomarkers%2C%20and%20recent%20insights%20into%20the%20pathogenesis%20of%20a%20disease%20having%20such%20a%20wide%20spectrum%20of%20presentation%20and%20progression.%20Advances%20in%20knowledge%20about%20prodromal%20PD%20will%20lead%20to%20earlier%20diagnosis%20and%20better%20identification%20of%20prognostic%20factors%2C%20and%2C%20subsequently%2C%20to%20the%20capacity%20to%20initiate%20personalized%20treatment%20and%20potentially%20slow%20down%20the%20degenerative%20process.%22%2C%22date%22%3A%222025-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.neurol.2025.06.012%22%2C%22ISSN%22%3A%220035-3787%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22H8UPCNQI%22%5D%2C%22dateModified%22%3A%222025-11-17T08%3A21%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22MXJEKN4G%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wilson%20et%20al.%22%2C%22parsedDate%22%3A%222025-10-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWilson%2C%20Sarah%2C%20Emmanuelle%20Leray%2C%20Floriane%20Calocer%2C%20Fabien%20Rollot%2C%20Mathieu%20Fauvernier%2C%20Laurent%20Remontet%2C%20Ludivine%20Launay%2C%20et%20al.%20%26%23x201C%3BInfluence%20of%20Geographical%20Accessibility%20to%20Specialist%20and%20Primary%20Care%20Givers%20on%20Excess%20Mortality%20of%20Multiple%20Sclerosis%20Patients%20in%20France.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBMC%20Neurology%26lt%3B%5C%2Fi%26gt%3B%2025%2C%20no.%201%20%28October%2027%2C%202025%29%3A%20441.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12883-025-04459-z%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12883-025-04459-z%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Influence%20of%20geographical%20accessibility%20to%20specialist%20and%20primary%20care%20givers%20on%20excess%20mortality%20of%20multiple%20sclerosis%20patients%20in%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Wilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Floriane%22%2C%22lastName%22%3A%22Calocer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Fauvernier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Remontet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludivine%22%2C%22lastName%22%3A%22Launay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Debouverie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%20De%22%2C%22lastName%22%3A%22Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David-Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Arnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Derache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Guittet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Dejardin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Access%20to%20healthcare%20and%20socioeconomic%20deprivation%20are%20intricately%20linked.%20No%20studies%20have%20been%20led%20to%20measure%20the%20effect%20of%20healthcare%20accessibility%20on%20mortality%20in%20patients%20with%20MS%20so%20far.%20The%20objective%20was%20to%20examine%20the%20influence%20of%20travel%20time%20to%20the%20expert%20MS%20centre%20and%20of%20the%20accessibility%20to%20primary%20healthcare%20services%20on%20excess%20mortality%20in%20MS.%5CnMETHODS%3A%20A%20retrospective%20observational%20cohort%20study%20recruited%20patients%20from%2018%20French%20MS%20expert%20centres%2C%20with%20an%20onset%20of%20MS%20between%201960%20and%202015%20and%20a%20follow-up%20of%20up%20to%2030%5Cu00a0years.%20Primary%20health%20facility%20accessibility%20was%20measured%20by%20the%20Spatial%20aCcessibility%20multiscAlar%20index.%20Specialist%20care%20accessibility%20was%20measured%20by%20road%20travel%20time%20to%20the%20expert%20MS%20centre.%20Excess%20death%20rates%20%28EDR%29%20and%20excess%20hazard%20ratios%20were%20studied%20using%20additive%20excess%20hazard%20models%20with%20multidimensional%20penalised%20splines.%5CnRESULTS%3A%20The%20study%20included%2033%2C697%20patients.%20Patients%20with%20relapsing-onset%20MS%20%28R-MS%29%20with%20a%20travel%20time%20of%2040%5Cu00a0min%20had%20the%20lowest%20EDR%20%28Men%3A%201.2%20deaths%20per%20100%20person-years%20%2895%25CI%20%5B0.8%3B1.8%5D%29%2C%20women%3A%200.8%20deaths%20per%20100%20person-years%2095%25CI%5B0.6%3B1.2%5D%29%2C%20lower%20than%20patients%20who%20lived%20further%20from%20the%20centre.%20No%20effect%20of%20primary%20care%20access%20was%20found%20for%20patients%20with%20R-MS%2C%20and%20no%20effect%20of%20accessibility%20to%20primary%20or%20specialised%20care%20was%20found%20for%20patients%20with%20primary%20progressive%20MS.%5CnCONCLUSION%3A%20This%20study%20reveals%20the%20impact%20of%20travel%20time%20to%20neurologists%20on%20excess%20mortality%20in%20patients%20with%20R-MS%20in%20France.%20This%20distance%20bias%20association%20highlights%20the%20importance%20of%20preventing%20a%20potential%20selection%20of%20patients%20followed%20in%20MS%20expert%20centres.%22%2C%22date%22%3A%222025-10-27%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12883-025-04459-z%22%2C%22ISSN%22%3A%221471-2377%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22HXBUH7GT%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mira%20et%20al.%22%2C%22parsedDate%22%3A%222025-10-23%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMira%2C%20Valentin%2C%20Jan%20Patrick%20Stellman%2C%20and%20Stephan%20Grimaldi.%20%26%23x201C%3BParoxysmal%20Dystonia%3A%20An%20Etiology%20Not%20to%20Be%20Missed%20in%20an%20Older%20Adult%20Patient.%26%23x201D%3B%20%26lt%3Bi%26gt%3BMovement%20Disorders%20Clinical%20Practice%26lt%3B%5C%2Fi%26gt%3B%2C%20October%2023%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmdc3.70407%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmdc3.70407%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Paroxysmal%20Dystonia%3A%20An%20Etiology%20Not%20to%20Be%20Missed%20in%20an%20Older%20Adult%20Patient%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valentin%22%2C%22lastName%22%3A%22Mira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20Patrick%22%2C%22lastName%22%3A%22Stellman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Grimaldi%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222025-10-23%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fmdc3.70407%22%2C%22ISSN%22%3A%222330-1619%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229L2KHJ5X%22%2C%22H8UPCNQI%22%5D%2C%22dateModified%22%3A%222025-10-30T10%3A31%3A39Z%22%7D%7D%2C%7B%22key%22%3A%226ZIM8H2R%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Perriguey%20et%20al.%22%2C%22parsedDate%22%3A%222025-10-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPerriguey%2C%20Marine%2C%20Camille%20Rigollet%2C%20Sean%20A.%20Freeman%2C%20Lisa%20Graille-Avy%2C%20Jean-Christophe%20Lafontaine%2C%20Bruno%20Lemarchant%2C%20Tifanie%20Alberto%2C%20et%20al.%20%26%23x201C%3BPrevalence%20of%20Hypogammaglobulinemia%20after%20Non-Anti-CD20%20Therapies%20and%20Impact%20of%20Switching%20to%20Rituximab%5C%2FOcrelizumab%20in%20Multiple%20Sclerosis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurotherapeutics%26lt%3B%5C%2Fi%26gt%3B%2022%2C%20no.%206%20%28October%201%2C%202025%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.neurot.2025.e00760%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.neurot.2025.e00760%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prevalence%20of%20hypogammaglobulinemia%20after%20non-anti-CD20%20therapies%20and%20impact%20of%20switching%20to%20rituximab%5C%2Focrelizumab%20in%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Rigollet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sean%20A.%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Graille-Avy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Lafontaine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Lemarchant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tifanie%22%2C%22lastName%22%3A%22Alberto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Hil%5Cu00e9zian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Z%5Cu00e9phir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222025-10-01%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.neurot.2025.e00760%22%2C%22ISSN%22%3A%221878-7479%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.neurotherapeuticsjournal.org%5C%2Farticle%5C%2FS1878-7479%2825%2900238-7%5C%2Ffulltext%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-12-01T09%3A50%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22QZZX45WR%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Thakolwiboon%20et%20al.%22%2C%22parsedDate%22%3A%222025-09-23%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BThakolwiboon%2C%20Smathorn%2C%20Vyanka%20Redenbaugh%2C%20Bo%20Chen%2C%20Sage%20Hewitt%2C%20Shailee%20Shah%2C%20Itay%20Lotan%2C%20Michael%20Levy%2C%20et%20al.%20%26%23x201C%3BOutcomes%20After%20Acute%20Plasma%20Exchange%20for%20Myelin%20Oligodendrocyte%20Glycoprotein%20Antibody-Associated%20Disease.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%26lt%3B%5C%2Fi%26gt%3B%20105%2C%20no.%206%20%28September%2023%2C%202025%29%3A%20e213903.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000213903%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000213903%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcomes%20After%20Acute%20Plasma%20Exchange%20for%20Myelin%20Oligodendrocyte%20Glycoprotein%20Antibody-Associated%20Disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Smathorn%22%2C%22lastName%22%3A%22Thakolwiboon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vyanka%22%2C%22lastName%22%3A%22Redenbaugh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bo%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sage%22%2C%22lastName%22%3A%22Hewitt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shailee%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Itay%22%2C%22lastName%22%3A%22Lotan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Levy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mirasol%22%2C%22lastName%22%3A%22Forcadela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saif%22%2C%22lastName%22%3A%22Huda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Pique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Poullin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dimitrios%22%2C%22lastName%22%3A%22Champsas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%20V.%22%2C%22lastName%22%3A%22Danesh-Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Vasileiou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elias%20S.%22%2C%22lastName%22%3A%22Sotirchos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20B.%22%2C%22lastName%22%3A%22Davis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amanda%20D.%22%2C%22lastName%22%3A%22Henderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adi%22%2C%22lastName%22%3A%22Wilf-Yarkoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hadas%22%2C%22lastName%22%3A%22Stiebel-Kalish%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Bonelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%20C.%22%2C%22lastName%22%3A%22Arnold%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Boudot%20De%20La%20Motte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jiraporn%22%2C%22lastName%22%3A%22Jitprapaikulsan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heather%20E.%22%2C%22lastName%22%3A%22Moss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvia%20E.%22%2C%22lastName%22%3A%22Villarreal%20Navarro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yang%22%2C%22lastName%22%3A%22Mao-Draayer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Murli%22%2C%22lastName%22%3A%22Mishra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nisa%22%2C%22lastName%22%3A%22Vorasoot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Cacciaguerra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nanthaya%22%2C%22lastName%22%3A%22Tisavipat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deena%20A.%22%2C%22lastName%22%3A%22Tajfirouz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Mendelt%22%2C%22lastName%22%3A%22Tillema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastian%20A.%22%2C%22lastName%22%3A%22Lopez-Chiriboga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacqueline%22%2C%22lastName%22%3A%22Palace%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yael%22%2C%22lastName%22%3A%22Hacohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sean%20J.%22%2C%22lastName%22%3A%22Pittock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eoin%20P.%22%2C%22lastName%22%3A%22Flanagan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20J.%22%2C%22lastName%22%3A%22Chen%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Data%20on%20the%20plasma%20exchange%20%28PLEX%29%20in%20myelin%20oligodendrocyte%20glycoprotein%20antibody-associated%20disease%20%28MOGAD%29%20are%20limited.%20Herein%2C%20we%20evaluate%20outcomes%20after%20PLEX%20in%20MOGAD.%5CnMETHODS%3A%20This%20international%20multicenter%20retrospective%20cohort%20study%20included%20patients%20from%2018%20tertiary%20care%20centers%20in%206%20countries.%20Inclusion%20criteria%20included%20fulfillment%20of%20the%202023%20International%20MOGAD%20panel%20criteria%2C%20receipt%20of%20at%20least%203%20sessions%20of%20PLEX%2C%20and%20follow-up%20of%20%5Cu22653%20months%20after%20PLEX.%20Patients%20with%20coexisting%20neuroinflammatory%20disorders%20were%20excluded.%20We%20assessed%20the%20frequency%20of%20complete%20recovery%20%28CR%29%2C%20clinically%20significant%20improvement%20%28CSI%29%2C%20visual%20acuity%20%28VA%29%2C%20and%20Expanded%20Disability%20Status%20Scale%20%28EDSS%29.%20Logistic%20regression%20analyses%20were%20performed%20to%20identify%20predictors%20of%20CR%20and%20CSI.%5CnRESULTS%3A%20Of%20234%20patients%2C%20135%20%2858%25%29%20were%20female.%20The%20median%20%28interquartile%20range%20%5BIQR%5D%29%20age%20at%20attack%20was%2034%20%28IQR%2022-49%29%20years%2C%20and%2042%20%2817%25%29%20were%20children.%20In%20165%20of%20243%20%2868%25%29%2C%20the%20attack%20treated%20with%20PLEX%20was%20the%20first%20attack.%20Attack%20phenotypes%20included%20161%20optic%20neuritis%20%28235%20eyes%29%2C%2077%20myelitis%2C%2024%20acute%20disseminated%20encephalomyelitis%2C%2015%20brainstem%5C%2Fcerebellar%2C%203%20cerebral-cortical%20encephalitis%20attack%2C%20and%201%20cerebral%20polyfocal%20deficit-36%20with%20%26gt%3B1%20core%20phenotypes.%20A%20total%20of%20239%20%2899%25%29%20attacks%20were%20also%20treated%20with%20corticosteroids%20and%2032%20%2813%25%29%20with%20IV%20immunoglobulins.%20VA%20in%20optic%20neuritis%20improved%20from%2020%5C%2F400%20%2820%5C%2F70-hand%20motion%29%20to%2020%5C%2F20%20%2820%5C%2F20-20%5C%2F30%29%2C%20p%20%26lt%3B%200.001%2C%20and%20EDSS%20decreased%20from%20a%20median%20of%204.0%20%283.0-6.5%29%20to%201.0%20%280.0-2.5%29%2C%20p%20%26lt%3B%200.001.%20Of%20229%20attacks%20without%20subsequent%20attacks%20within%203%20months%2C%20100%20%2844%25%29%20achieved%20CR%20and%20213%20%2893%25%29%20CSI.%20The%20probability%20of%20CR%20was%20decreased%20with%20advanced%20age%20%28adjusted%20odd%20ratio%20%5B95%25%20CI%5D%200.97%20%5B0.96-0.99%5D%20per%20year%29%2C%20higher%20EDSS%20worsening%20from%20baseline%20%280.66%20%5B0.54-0.81%5D%20per%200.5%20increment%29%20and%20delayed%20PLEX%20%280.98%20%5B0.96-0.99%5D%20per%20day%29.%20Advanced%20age%20%280.97%20%5B0.96-0.99%5D%20per%20year%29%20and%20delayed%20PLEX%20%280.95%20%5B0.94-0.96%5D%20per%20day%29%20decreased%20the%20probability%20of%20CSI.%5CnDISCUSSION%3A%20We%20observed%20favorable%20outcomes%20after%20PLEX%20in%20MOGAD%20attacks.%20However%2C%20advanced%20age%20and%20delayed%20initiation%20of%20PLEX%20were%20associated%20with%20a%20reduced%20probability%20of%20improvement.%20The%20absence%20of%20a%20control%20group%20limits%20our%20ability%20to%20differentiate%20PLEX%20effects%20from%20spontaneous%20recovery%2C%20prior%20corticosteroid%20response%2C%20or%20long-term%20immunotherapy.%20Future%20prospective%20studies%20are%20needed%20to%20assess%20the%20impact%20of%20PLEX%20on%20improvement.%5CnCLASSIFICATION%20OF%20EVIDENCE%3A%20This%20study%20provides%20Class%20IV%20evidence%20that%20PLEX%20is%20associated%20with%20favorable%20clinical%20outcomes%20in%20patients%20with%20MOGAD.%22%2C%22date%22%3A%222025-09-23%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000213903%22%2C%22ISSN%22%3A%221526-632X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-09-01T08%3A42%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22P2YFJ85J%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Feys%20et%20al.%22%2C%22parsedDate%22%3A%222025-09-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFeys%2C%20Odile%2C%20Julia%20Makhalova%2C%20Thomas%20Manners%2C%20Jos%26%23xE9%3B-David%20Herrera-Garc%26%23xED%3Ba%2C%20Romain%20Carron%2C%20and%20Fabrice%20Bartolomei.%20%26%23x201C%3BRadiofrequency%20Thermocoagulation%20for%20the%20Treatment%20of%20Refractory%20Focal%20Status%20Epilepticus.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEpileptic%20Disorders%3A%20International%20Epilepsy%20Journal%20with%20Videotape%26lt%3B%5C%2Fi%26gt%3B%2C%20September%2010%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fepd2.70091%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fepd2.70091%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Radiofrequency%20thermocoagulation%20for%20the%20treatment%20of%20refractory%20focal%20status%20epilepticus%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Odile%22%2C%22lastName%22%3A%22Feys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Makhalova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Manners%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9-David%22%2C%22lastName%22%3A%22Herrera-Garc%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Carron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Bartolomei%22%7D%5D%2C%22abstractNote%22%3A%22This%20case%20study%20reports%20the%20first%20documented%20use%20of%20stereoelectroencephalography%20%28SEEG%29-guided%20radiofrequency%20thermocoagulation%20%28RFTC%29%20to%20treat%20refractory%20status%20epilepticus%20%28RSE%29.%20A%2033-year-old%20woman%20with%20drug-resistant%20epilepsy%20and%20recurrent%20RSE%20underwent%20SEEG%20to%20define%20her%20epileptogenic%20zone.%20A%20new%20RSE%20started%20shortly%20before%20and%20continued%20during%20the%20SEEG%20exploration%2C%20being%20unresponsive%20to%20multiple%20antiseizure%20medications%2C%20vagal%20nerve%20stimulation%2C%20and%20corticosteroid%20therapy.%20SEEG-signal%20quantification%20based%20on%20ictal%20biomarkers%2C%20that%20is%2C%20epileptogenicity%20index%20and%20connectivity%20epileptogenicity%20index%2C%20identified%20the%20epileptogenic%20zone%20network%20%28EZN%29%20within%20the%20mesial%20prefrontal%2C%20premotor%2C%20and%20parietal%20cortex%2C%20with%20major%20implication%20of%20the%20anterior-middle%20and%20posterior%20cingulate%20cortex.%20RFTC%20was%20performed%20on%20SEEG-identified%20targets%20within%20the%20EZN%20and%20resulted%20in%20rapid%20cessation%20of%20electroclinical%20seizure%20activity%20and%20full%20recovery%20from%20motor%20deficits.%20Seizure%20frequency%20remained%20reduced%20by%20over%2090%25%20at%204%20months%20post-procedure.%20This%20case%20highlights%20the%20potential%20of%20RFTC%20as%20a%20possible%20therapeutic%20option%20for%20RSE%20by%20directly%20disrupting%20critical%20network%20nodes%20responsible%20for%20seizure%20generation%20and%20propagation.%20The%20findings%20also%20suggest%20a%20broader%20role%20of%20SEEG%20not%20only%20for%20diagnostic%20purposes%20but%20also%20for%20the%20therapeutic%20management%20of%20refractory%20seizures%2C%20including%20status%20epilepticus.%22%2C%22date%22%3A%222025-09-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fepd2.70091%22%2C%22ISSN%22%3A%221950-6945%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RMECNPE%22%5D%2C%22dateModified%22%3A%222025-09-11T07%3A30%3A55Z%22%7D%7D%2C%7B%22key%22%3A%226L3SY3Y7%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gavoille%20et%20al.%22%2C%22parsedDate%22%3A%222025-09-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGavoille%2C%20Antoine%2C%20Mikail%20Nourredine%2C%20Fabien%20Rollot%2C%20Romain%20Casey%2C%20Guillaume%20Mathey%2C%20Anne%20Kerbrat%2C%20Jonathan%20Ciron%2C%20et%20al.%20%26%23x201C%3BTarget%20Trial%20Emulation%20to%20Replicate%20Randomised%20Clinical%20Trials%20Using%20Registry%20Data%20in%20Multiple%20Sclerosis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Neurology%2C%20Neurosurgery%2C%20and%20Psychiatry%26lt%3B%5C%2Fi%26gt%3B%2C%20September%204%2C%202025%2C%20jnnp-2025-336762.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2025-336762%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2025-336762%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Target%20trial%20emulation%20to%20replicate%20randomised%20clinical%20trials%20using%20registry%20data%20in%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Gavoille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikail%22%2C%22lastName%22%3A%22Nourredine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Kwiatkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David-Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al%20Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ines%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Sarov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Manchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maia%22%2C%22lastName%22%3A%22Tchikviladze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Rabilloud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Subtil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%5D%2C%22abstractNote%22%3A%22BackgroundTarget%20trial%20emulation%20%28TTE%29%20offers%20a%20formal%20framework%20for%20causal%20inference%20using%20observational%20data%2C%20but%20its%20validity%20must%20be%20evaluated%20in%20each%20research%20domain%20by%20replicating%20randomised%20clinical%20trials%20%28RCTs%29.%20We%20aimed%20to%20replicate%20eight%20RCTs%20evaluating%20the%20efficacy%20of%20disease-modifying%20therapies%20%28DMTs%29%20in%20multiple%20sclerosis%20%28MS%29%20using%20French%20registry%20data.%5CnMETHODS%3A%20This%20multicentre%2C%20retrospective%2C%20observational%20study%20was%20conducted%20using%20data%20extracted%20in%20December%202023%20from%20the%20Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%20%28OFSEP%29%20database.%20For%20each%20emulated%20trial%2C%20patients%20were%20included%20when%20they%20initiated%20one%20of%20the%20DMT%20evaluated%20in%20the%20corresponding%20RCT%20and%20met%20its%20inclusion%20criteria.%20Clinical%20outcomes%20were%20the%20annualised%20relapse%20rate%20and%203-month%20confirmed%20Expanded%20Disability%20Status%20Scale%20progression.%20Radiological%20outcomes%20were%20new%5C%2Fenlarged%20T2-lesions%20and%20new%20gadolinium-enhanced%20T1-lesions%20on%20a%20brain%20MRI.%20A%20targeted%20maximum%20likelihood%20estimator%20was%20used%20to%20estimate%20the%20treatment%20effect%20adjusted%20for%20confounding%20factors%20between%20groups%20and%20corrected%20for%20censoring%20and%20missing%20outcome%20assessment.%5CnRESULTS%3A%2014%5Cu2009111%20patients%20were%20included%20in%20eight%20emulated%20trials%3A%20ASSESS%20%28fingolimod%20vs%20glatiramer%20acetate%29%2C%20BEYOND%20%28interferon%20beta%20vs%20glatiramer%20acetate%29%2C%20CONFIRM%20%28dimethyl%20fumarate%20%28DMF%29%20vs%20glatiramer%20acetate%29%2C%20OPERA%20%28ocrelizumab%20vs%20interferon%20beta%29%2C%20REGARD%20%28interferon%20beta%20vs%20glatiramer%20acetate%29%2C%20RIFUND-MS%20%28rituximab%20vs%20DMF%29%2C%20TENERE%20%28teriflunomide%20vs%20interferon%20beta%29%20and%20TRANSFORMS%20%28fingolimod%20vs%20interferon%20beta%29.%20Treatment%20effects%20estimated%20in%20emulated%20trials%20were%20concordant%20with%20RCT%20findings%20in%20seven%20of%20eight%20trials%20for%20relapse%20rate%2C%20and%20in%20all%20six%20trials%20assessing%20disability%20progression.%20Radiological%20outcomes%20were%20more%20challenging%20to%20replicate%3B%20concordance%20was%20achieved%20in%20three%20of%20five%20trials%20for%20new%20T2-lesions%2C%20and%20one%20of%20four%20trials%20for%20new%20gadolinium-enhanced%20T1-lesions.%5CnCONCLUSION%3A%20The%20combined%20use%20of%20a%20TTE%20methodology%20and%20high-quality%20registry%20data%20is%20a%20valid%20tool%20to%20evaluate%20treatment%20effectiveness%20in%20MS.%22%2C%22date%22%3A%222025-09-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fjnnp-2025-336762%22%2C%22ISSN%22%3A%221468-330X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22MU4PAIR2%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Andikoetxea%20et%20al.%22%2C%22parsedDate%22%3A%222025-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAndikoetxea%2C%20Bego%26%23xF1%3Ba%20Garate%2C%20Antonio%20Mart%26%23xED%3Bn-Bastida%2C%20Marta%20Vidorreta%2C%20Mar%26%23xED%3Ba%20Cruz%20Rodr%26%23xED%3Bguez-Oroz%2C%20Lucas%20Soustelle%2C%20Thomas%20Troalen%2C%20and%20Maria%20A.%20Fern%26%23xE1%3Bndez-Seara.%20%26%23x201C%3BNeuromelanin%20Contrast%20Optimization%20and%20Improved%20Visualization%20of%20the%20Substantia%20Nigra%20in%20a%203D%20Gradient-Echo%20Sequence%20With%20Magnetization%20Transfer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNMR%20in%20Biomedicine%26lt%3B%5C%2Fi%26gt%3B%2038%2C%20no.%209%20%28September%202025%29%3A%20e70123.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fnbm.70123%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fnbm.70123%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Neuromelanin%20Contrast%20Optimization%20and%20Improved%20Visualization%20of%20the%20Substantia%20Nigra%20in%20a%203D%20Gradient-Echo%20Sequence%20With%20Magnetization%20Transfer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bego%5Cu00f1a%20Garate%22%2C%22lastName%22%3A%22Andikoetxea%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Mart%5Cu00edn-Bastida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marta%22%2C%22lastName%22%3A%22Vidorreta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20Cruz%22%2C%22lastName%22%3A%22Rodr%5Cu00edguez-Oroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucas%22%2C%22lastName%22%3A%22Soustelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Troalen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20A.%22%2C%22lastName%22%3A%22Fern%5Cu00e1ndez-Seara%22%7D%5D%2C%22abstractNote%22%3A%22Neuromelanin%20%28NM%29%20magnetic%20resonance%20imaging%20has%20been%20used%20to%20evaluate%20the%20loss%20of%20melanized%20neurons%20in%20the%20substantia%20nigra%2C%20the%20main%20characteristic%20of%20Parkinson%20disease%2C%20typically%20by%20measuring%20the%20contrast%20ratio%20%28CR%29%20between%20the%20NM-rich%20areas%20and%20the%20cerebral%20peduncles%20in%20the%20midbrain.%20Neuromelanin%20contrast%20can%20be%20generated%20by%20employing%20a%203D%20gradient-echo%20%28GRE%29%20sequence%20with%20magnetization%20transfer%20%28MT%29.%20In%20this%20work%2C%20we%20first%20evaluated%20the%20effect%20of%20the%20MT%20pulse%20frequency%20on%20the%20CR%20and%20contrast-to-noise%20ratio%20%28CNR%29%2C%20analyzing%20a%20large%20frequency%20range%20from%20500%20to%20100K%5Cu2009Hz.%20Secondly%2C%20the%20impact%20of%20the%203D%20GRE%20sequence%20flip%20angle%20%28FA%29%20was%20evaluated%20using%20angles%20from%205%5Cu00b0%20to%2040%5Cu00b0.%20Additionally%2C%20images%20were%20acquired%20both%20with%20and%20without%20MT%20for%20each%20FA%2C%20providing%20an%20opportunity%20to%20examine%20the%20effect%20of%20MT%20on%20tissue%20proton%20density%2C%20T1%2C%20and%20T2%2A%20values.%20Results%20showed%20that%20the%20highest%20CR%20and%20CNR%20were%20obtained%20for%20the%20lower%20MT%20frequencies%20%28500-2000%5Cu2009Hz%29%20and%20lower%20FAs%20%285%5Cu00b0-10%5Cu00b0%29.%20The%20lower%20FAs%20improved%20the%20visualization%20of%20the%20neuromelanin-rich%20area%20in%20the%20substantia%20nigra%20and%20facilitated%20delineating%20its%20volume.%20In%20addition%2C%20this%20work%20showed%20that%20the%20MT%20pulse%20decreased%20the%20T1%20and%20PD%20of%20the%20tissue.%20Furthermore%2C%20simulations%20supported%20the%20obtained%20in%5Cu00a0vivo%20results.%22%2C%22date%22%3A%222025-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fnbm.70123%22%2C%22ISSN%22%3A%221099-1492%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226GBQDAVI%22%2C%22M2AY8I5W%22%5D%2C%22dateModified%22%3A%222025-08-20T08%3A46%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22EBKNBNNG%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gavoille%20et%20al.%22%2C%22parsedDate%22%3A%222025-08-26%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGavoille%2C%20Antoine%2C%20Emmanuelle%20Leray%2C%20Romain%20Marignier%2C%20Fabien%20Rollot%2C%20Romain%20Casey%2C%20Guillaume%20Mathey%2C%20Laure%20Michel%2C%20et%20al.%20%26%23x201C%3BSex-Related%20Gap%20in%20the%20Use%20of%20Disease-Modifying%20Therapies%20in%20Multiple%20Sclerosis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%26lt%3B%5C%2Fi%26gt%3B%20105%2C%20no.%204%20%28August%2026%2C%202025%29%3A%20e213907.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000213907%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000213907%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sex-Related%20Gap%20in%20the%20Use%20of%20Disease-Modifying%20Therapies%20in%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Gavoille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Laure%22%2C%22lastName%22%3A%22Dubessy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al%20Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ines%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celine%22%2C%22lastName%22%3A%22Labeyrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Manchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maya%22%2C%22lastName%22%3A%22Tchikviladze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22OFSEP%20investigators%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20In%20women%20with%20multiple%20sclerosis%20%28MS%29%2C%20the%20therapeutic%20strategy%20may%20be%20influenced%20by%20the%20anticipation%20of%20future%20pregnancies%2C%20leading%20to%20underexposure%20to%20disease-modifying%20therapies%20%28DMTs%29%20and%20highly%20effective%20DMTs%20%28HEDMTs%29%20compared%20with%20men.%20We%20aimed%20to%20evaluate%20potential%20therapeutic%20inertia%20in%20women%20with%20MS%20and%20explore%20its%20causes.%5CnMETHODS%3A%20We%20performed%20a%20retrospective%20cohort%20study%20based%20on%20data%20extracted%20on%20June%202023%20from%20the%20Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%20for%20all%20patients%20with%20a%20relapsing-remitting%20MS%20onset%20between%2018%20and%2040%20years.%20The%20primary%20outcome%20was%20the%20annual%20probability%20of%20receiving%20a%20DMT%2C%20accounting%20for%20sex%2C%20disease%20severity%2C%20and%20pregnancy%5C%2Fpostpartum%20periods.%20Secondary%20outcomes%20were%20the%20annual%20probability%20of%20receiving%20a%20HEDMT%2C%20each%20DMT%20separately%2C%20and%20interaction%20of%20the%20effect%20of%20sex%20with%20calendar%20year%2C%20patient%20age%2C%20and%20disease%20duration.%20We%20used%20a%20longitudinal%20logistic%20model%20with%20generalized%20estimating%20equations%20and%20an%20inverse-probability-of-censoring%20weighting.%5CnRESULTS%3A%20We%20included%2022%2C657%20patients%20with%20MS%3B%2016%2C857%20%2874.4%25%29%20were%20female%2C%20mean%20%28SD%29%20age%20at%20onset%20was%2029.0%20%286.0%29%20years%2C%20and%20median%20%28interquartile%20range%29%20follow-up%20duration%20was%2011.6%20%286.6-17.3%29%20years.%20Women%20were%20significantly%20less%20likely%20to%20receive%20a%20DMT%20%28odds%20ratio%20%5BOR%5D%200.92%2C%2095%25%20CI%200.87-0.97%29%20or%20a%20HEDMT%20%28OR%200.80%2C%2095%25%20CI%200.74-0.86%29.%20This%20difference%20appeared%202%20years%20after%20disease%20onset%20for%20DMTs%20and%201%20year%20for%20HEDMTs%2C%20and%20did%20not%20differ%20significantly%20according%20to%20patient%26%23039%3Bs%20age.%20Teriflunomide%2C%20sphingosine-1-phosphate%20receptor%20modulators%2C%20and%20anti-CD20s%20were%20significantly%20underused%20in%20women%20throughout%20their%20entire%20period%20of%20availability%3B%20interferons%20%5Cu03b2%20%28IFN-%5Cu03b2%29%20and%20natalizumab%20were%20initially%20less%20used%20and%20then%20equally%20after%20some%20time%3B%20glatiramer%20acetate%20and%20fumarates%20were%20first%20used%20equally%2C%20then%20more%20frequently%20in%20women.%20The%20proportion%20of%20treated%20women%2C%20analyzed%20from%20the%20first%20childbirth%20of%205%2C268%20women%2C%20began%20to%20decline%2018%20months%20before%20childbirth%2C%20from%2042.6%25%20to%2027.9%25%20at%20the%20estimated%20time%20of%20conception.%5CnDISCUSSION%3A%20Women%20with%20MS%20were%20significantly%20less%20exposed%20to%20DMTs%20compared%20with%20men.%20Anticipation%20of%20pregnancy%20was%20probably%20an%20important%20factor%20underlying%20this%20difference%2C%20but%20also%20sex-specific%20therapeutic%20inertia.%20Neurologists%20and%20patients%20should%20be%20educated%20on%20the%20most%20recent%20recommendations%20on%20the%20use%20of%20DMTs%20in%20the%20context%20of%20pregnancy%20to%20avoid%20deleterious%20therapeutic%20inertia.%22%2C%22date%22%3A%222025-08-26%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000213907%22%2C%22ISSN%22%3A%221526-632X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22T4W95BS2%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Robin%20et%20al.%22%2C%22parsedDate%22%3A%222025-08-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRobin%2C%20Camille%2C%20Fabien%20Rollot%2C%20Mathilde%20Lefort%2C%20Romain%20Casey%2C%20Sandra%20Vukusic%2C%20Guillaume%20Mathey%2C%20Jonathan%20Ciron%2C%20et%20al.%20%26%23x201C%3BUse%20of%20Disease-Modifying%20Therapies%20in%20Patients%20With%20Late-Onset%20Multiple%20Sclerosis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%26lt%3B%5C%2Fi%26gt%3B%20105%2C%20no.%203%20%28August%2012%2C%202025%29%3A%20e213744.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000213744%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000213744%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Use%20of%20Disease-Modifying%20Therapies%20in%20Patients%20With%20Late-Onset%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Robin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Lefort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%20M.%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Kwiatkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ines%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Sarov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Manchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maya%22%2C%22lastName%22%3A%22Tchikviladze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Nifle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Edan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22as%20the%20OFSEP%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20The%20therapeutic%20strategy%20in%20patients%20with%20late-onset%20MS%20%28LOMS%29%20remains%20poorly%20defined.%20In%20this%20study%2C%20we%20aimed%20to%20evaluate%20both%20clinical%20and%20MRI%20outcomes%20between%202%20cohorts%20of%20patients%20with%20relapsing-remitting%20LOMS%20treated%20or%20not%20yet%20treated.%5CnMETHODS%3A%20Patients%20with%20relapsing-remitting%20MS%20were%20included%20for%20the%20analysis%20if%20disease%20onset%20occurred%20after%2055%20years%20and%20if%20they%20had%20at%20least%20one%20follow-up%20visit.%20The%20primary%20outcome%20was%20time%20to%20first%20relapse%20between%202%20matched%20groups%20of%20patients%20with%20LOMS%20%28treated%20and%20not%20yet%20treated%29.%20Secondary%20outcomes%20were%20as%20follows%3A%20%281%29%20time%20to%20first%20confirmed%20disability%20progression%20%28CDP%29%2C%20%282%29%20time%20to%20first%20progression%20independent%20of%20relapse%20activity%20%28PIRA%29%20event%2C%20%283%29%20time%20to%20secondary%20progression%20%28SPMS%29%2C%20%284%29%20time%20to%20first%20MRI%20activity%2C%20and%20%285%29%20serious%20infection%20incidence%20rates%20%28IIRs%29.%20For%20the%20comparative%20analyses%2C%20we%20adopted%20a%20time-dependent%20propensity%20score%20matching%20approach.%5CnRESULTS%3A%20A%20total%20of%20881%20patients%20fulfilled%20the%20inclusion%20criteria.%20The%20mean%20%28SD%29%20age%20at%20onset%20was%2059.9%20%284.43%29%20years.%20After%20applying%20propensity%20score%20matching%2C%20436%20patients%20were%20matched.%20The%20mean%20%28SD%29%20follow-up%20duration%20was%205.2%20%284.27%29%20years%20in%20the%20treated%20group%20and%205.0%20%283.86%29%20years%20in%20the%20not-yet-treated%20group.%20Mean%20%28SD%29%20time%20to%20first%20relapse%20was%20significantly%20longer%20in%20the%20treated%20group%20compared%20with%20the%20not-yet-treated%20group%20%287.0%20years%20%5B0.33%5D%20vs%205.4%20years%20%5B0.33%5D%3B%20p%20%3D%200.001%29.%20Mean%20%28SD%29%20time%20to%20first%20MRI%20activity%20was%20significantly%20longer%20in%20the%20treated%20group%20%285.9%20years%20%5B0.33%5D%20vs%205.0%20years%20%5B0.33%5D%3B%20p%20%3D%200.049%29.%20However%2C%20the%20mean%20time%20to%20CDP%2C%20PIRA%2C%20or%20SPMS%20was%20not%20different%20between%20the%202%20groups%20%28difference%20%3D%200.32%20years%3B%20p%20%3D%200.585%20for%20CDP%3B%20difference%20%3D%200.40%20years%3B%20p%20%3D%200.442%20for%20PIRA%3B%20difference%20%3D%20-0.02%20years%3B%20p%20%3D%200.952%20for%20SPMS%29.%20No%20increase%20in%20serious%20IIRs%20was%20observed%20with%20an%20incidence%20rate%20ratio%20of%200.38%20%2895%25%20CI%200.07-2.10%2C%20p%20%3D%200.265%29%20in%20the%20never-treated%20group%20compared%20with%20the%20treated%20one.%5CnDISCUSSION%3A%20This%20study%20demonstrates%20a%20beneficial%20effect%20of%20disease-modifying%20therapy%20%28DMT%29%20on%20disease%20activity%20in%20patients%20with%20LOMS%20but%20without%20significant%20impact%20on%20disability%20progression.%20Main%20limitations%20are%20linked%20to%20the%20challenge%20of%20data%20collection%20and%20to%20the%20baseline%20imbalances%20between%20the%202%20groups.%5CnCLASSIFICATION%20OF%20EVIDENCE%3A%20This%20study%20provides%20Class%20III%20evidence%20that%20in%20patients%20with%20LOMS%2C%20treatment%20with%20DMTs%20is%20associated%20with%20a%20longer%20time%20to%20first%20relapse%20compared%20with%20those%20not%20treated%20with%20DMTs.%22%2C%22date%22%3A%222025-08-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000213744%22%2C%22ISSN%22%3A%221526-632X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22F2BXABSJ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gavoille%20et%20al.%22%2C%22parsedDate%22%3A%222025-08-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGavoille%2C%20Antoine%2C%20Fabien%20Rollot%2C%20Romain%20Casey%2C%20Guillaume%20Mathey%2C%20Emmanuelle%20Le%20Page%2C%20Jonathan%20Ciron%2C%20J%26%23xE9%3Br%26%23xF4%3Bme%20De%20S%26%23xE8%3Bze%2C%20et%20al.%20%26%23x201C%3BTherapeutic%20Management%20During%20Pregnancy%20and%20Relapse%20Risk%20in%20Women%20With%20Multiple%20Sclerosis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJAMA%20Neurology%26lt%3B%5C%2Fi%26gt%3B%2C%20August%204%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamaneurol.2025.2550%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamaneurol.2025.2550%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Therapeutic%20Management%20During%20Pregnancy%20and%20Relapse%20Risk%20in%20Women%20With%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Gavoille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Kwiatkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David-Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Laure%22%2C%22lastName%22%3A%22Dubessy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al-Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22In%5Cu00e8s%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Sarov-Riviere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Nifle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Subtil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22OFSEP%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22IMPORTANCE%3A%20In%20women%20with%20multiple%20sclerosis%20%28MS%29%2C%20disease-modifying%20therapy%20%28DMT%29%20management%20during%20pregnancy%20might%20impact%20relapse%20risk.%5CnOBJECTIVE%3A%20To%20estimate%20the%20effect%20of%20DMT%20management%20during%20pregnancy%20on%20MS%20relapse%20rate%20and%20compare%20different%20therapeutic%20strategies.%5CnDESIGN%2C%20SETTING%2C%20AND%20PARTICIPANTS%3A%20This%20was%20a%20multicenter%20retrospective%20cohort%20study%20using%20data%20from%20January%201990%20to%20December%202023.%20Data%20were%20extracted%20in%20December%202023%20from%20the%20French%20MS%20registry.%20Among%2052%5Cu202f955%20women%20in%20the%20registry%2C%20we%20included%20pregnancies%20identified%20through%20childbirths%20in%20patients%20with%20relapsing-onset%20MS%20who%20were%20monitored%20for%20at%20least%2018%20months%20before%20delivery%20and%209%20months%20after.%20Pregnancies%20occurring%20less%20than%2018%20months%20apart%20or%20with%20missing%20month%20of%20birth%20were%20excluded.%5CnEXPOSURES%3A%20Mediation%20analysis%20was%20used%20to%20estimate%20the%20total%2C%20direct%2C%20and%20indirect%20%28mediated%20by%20DMT%20management%29%20effects%20of%20pregnancy.%20Different%20therapeutic%20strategies%20were%20compared%3A%20DMT%20interruption%2C%20switching%20to%20or%20maintaining%20interferon%20%5Cu03b2%20or%20glatiramer%20acetate%2C%20switching%20to%20or%20maintaining%20natalizumab%20until%20the%20third%20trimester%2C%20and%20switching%20to%20or%20maintaining%20intravenous%20anti-CD20%20and%20interrupting%20it%203%20months%20before%20conception.%5CnMAIN%20OUTCOMES%20AND%20MEASURES%3A%20The%20primary%20outcome%20was%20the%20annualized%20relapse%20rate%20%28ARR%29%20during%20the%20preconception%2C%20gestation%2C%20and%20postpartum%20periods.%20Within%20a%20causal%20inference%20framework%2C%20counterfactual%20ARRs%20were%20estimated%20using%20longitudinal%20g-computation%2C%20combining%20a%20random%20forest%20algorithm%20for%20predicting%20DMTs%2C%20and%20a%20mixed-effects%20Poisson%20model%20for%20relapses.%5CnRESULTS%3A%20We%20included%206341%20pregnancies%20occurring%20in%204998%20women%20%28mean%20%5BSD%5D%20age%20at%20conception%2C%2031.5%20%5B4.5%5D%20years%29.%20DMT%20management%20during%20pregnancy%20significantly%20increased%20ARR%20during%20gestation%20%28causal%20rate%20ratio%20%5BcRR%5D%2C%201.13%3B%2095%25%20CI%2C%201.06-1.22%29%20and%20postpartum%20%28cRR%2C%201.08%3B%2095%25%20CI%2C%201.01-1.16%29%20periods.%20This%20led%20to%20a%20deleterious%20total%20effect%20of%20pregnancy%20on%20ARR%2C%20particularly%20in%20women%20receiving%20natalizumab%20before%20pregnancy%20with%20prolonged%20interruption%20%28ie%2C%20interruption%20before%20the%20second%20trimester%20or%20resumption%20more%20than%203%20months%20after%20delivery%3B%20cRR%2C%202.18%3B%2095%25%20CI%2C%201.76-2.69%29%2C%20and%20in%20women%20receiving%20fingolimod%20%28cRR%2C%202.15%3B%2095%25%20CI%2C%201.60-2.93%29.%20Compared%20to%20DMT%20interruption%2C%20anti-CD20%20strategy%20was%20the%20most%20effective%20%28cRR%2C%200.38%3B%2095%25%20CI%2C%200.25-0.52%29%2C%20followed%20by%20the%20natalizumab%20strategy%20with%20short%20interruption%20%28cRR%2C%200.80%3B%2095%25%20CI%2C%200.71-0.90%29%2C%20whereas%20interferon%20%5Cu03b2%20%28cRR%2C%200.93%3B%2095%25%20CI%2C%200.86-0.99%29%20and%20glatiramer%20acetate%20strategies%20%28cRR%2C%200.91%3B%2095%25%20CI%2C%200.84-0.99%29%20were%20less%20effective.%5CnCONCLUSION%3A%20In%20this%20study%2C%20DMT%20management%20during%20pregnancy%20significantly%20increased%20relapse%20risk%2C%20particularly%20in%20patients%20receiving%20natalizumab%20with%20prolonged%20interruption%20or%20fingolimod.%20The%20strategy%20based%20on%20the%20use%20of%20anti-CD20%20before%20pregnancy%20was%20the%20most%20effective%20to%20mitigate%20this%20risk.%22%2C%22date%22%3A%222025-08-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1001%5C%2Fjamaneurol.2025.2550%22%2C%22ISSN%22%3A%222168-6157%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22WE66JXHA%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nimje%20et%20al.%22%2C%22parsedDate%22%3A%222025-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BNimje%2C%20Swetali%2C%20Thierry%20Arti%26%23xE8%3Bres%2C%20Maxime%20Guye%2C%20and%20Ludovic%20de%20Rochefort.%20%26%23x201C%3BInsights%20on%20Scan-Specific%20Deep-Learning%20Strategies%20for%20Brain%20MRI%20Parallel%20Imaging%20Reconstruction.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNMR%20in%20Biomedicine%26lt%3B%5C%2Fi%26gt%3B%2038%2C%20no.%208%20%28August%202025%29%3A%20e70079.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fnbm.70079%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fnbm.70079%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Insights%20on%20Scan-Specific%20Deep-Learning%20Strategies%20for%20Brain%20MRI%20Parallel%20Imaging%20Reconstruction%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Swetali%22%2C%22lastName%22%3A%22Nimje%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Arti%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludovic%22%2C%22lastName%22%3A%22de%20Rochefort%22%7D%5D%2C%22abstractNote%22%3A%22Scan-specific%20deep%20learning%20strategies%20have%20been%20proposed%20for%20parallel%20imaging%20reconstruction%20in%20which%20auto-calibrated%20signals%20%28ACS%29%20are%20used%20for%20training.%20Here%2C%20we%20introduce%20methods%20to%20objectively%20optimize%20architecture%20and%20training%20details.%20In%20addition%2C%20we%20introduce%20a%20new%20metric%20to%20better%20characterize%20the%20quality%20of%20the%20reconstructed%20images.%20Various%20brain%20MRI%20situations%20are%20considered.%20The%20evaluated%20models%20encompass%20single-layer%20and%20three-layer%20residual%20CNN%20architectures%20with%20real%20and%20complex%20convolutions.%20Hyperparameters%20such%20as%20the%20level%20of%20linearity%20in%20leaky%20activation%20functions%2C%20loss%20function%2C%20kernel%20sizes%20and%20depths%20are%20optimized%20using%20grid-search%20with%20K-fold%20cross%20validation.%20The%20performances%20regarding%20ACS%20reference%20size%20and%20mode%20are%20also%20evaluated.%20An%20innovative%20COrrelation-Based%20Residual%20Artifact%20Index%20%28COBRAI%29%20quantifying%20the%20level%20of%20structured%20residual%20artifacts%20is%20proposed.%20Qualitative%20and%20quantitative%20comparisons%20are%20performed%20both%20on%20the%20FastMRI%20and%20in-house%20multi-contrasts%202D%20data.%20The%20proposed%20objective%20grid-search%20strategy%20based%20on%20ACS%20successfully%20provided%20optimized%20hyperparameters%2C%20retrospectively%20validated%20by%20enhanced%20image%20quality%20metrics.%20Notably%2C%20it%20is%20shown%20that%20nonlinearities%20produce%20structured%20residual%20artifacts%2C%20and%20that%2C%20among%20the%20models%20tested%2C%20a%20three-layer%20residual%20linear%20CNN%20with%20complex%20implementation%20and%20a%20reduced%20number%20of%20parameters%20is%20more%20robust%2C%20particularly%20providing%20less%20structured%20artifacts%20with%20less%20training%20data%2C%20leading%20to%20larger%20acceleration%20rates.%20Deep-learning%20MRI%20parallel%20image%20reconstruction%20in%20the%20scan-specific%20approach%20can%20be%20optimized%20using%20grid-search%20with%20K-fold%20cross%20validation.%20It%20was%20successfully%20applied%20in%20various%202D%20brain%20MRI%20situations.%20The%20quantification%20of%20structured%20residual%20artifacts%20with%20COBRAI%20is%20a%20useful%20complementary%20characterization%20to%20state-of-the-art%20metrics%2C%20and%20it%20can%20be%20used%20to%20drive%20model%20selection.%22%2C%22date%22%3A%222025-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fnbm.70079%22%2C%22ISSN%22%3A%221099-1492%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22DNKN89WD%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22BQ9SSM9N%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Attia%20et%20al.%22%2C%22parsedDate%22%3A%222025-07-22%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAttia%2C%20R.%2C%20N.%20Stolowy%2C%20R.%20Fitoussi%2C%20and%20T.%20David.%20%26%23x201C%3BSevere%20Corneal%20Flattening%20in%20Bilateral%20Cornea%20Plana.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20Francais%20D%26%23x2019%3Bophtalmologie%26lt%3B%5C%2Fi%26gt%3B%2048%2C%20no.%207%20%28July%2022%2C%202025%29%3A%20104587.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jfo.2025.104587%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jfo.2025.104587%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Severe%20corneal%20flattening%20in%20bilateral%20cornea%20plana%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Attia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Stolowy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Fitoussi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22David%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222025-07-22%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jfo.2025.104587%22%2C%22ISSN%22%3A%221773-0597%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-08-06T08%3A34%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22R632UBY8%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22K%5Cu00fcstner%20et%20al.%22%2C%22parsedDate%22%3A%222025-06-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BK%26%23xFC%3Bstner%2C%20Thomas%2C%20Roy%20Haast%2C%20Nikos%20Priovoulos%2C%20Patricia%20Clement%2C%20and%20Daniel%20Pinto%20Dos%20Santos.%20%26%23x201C%3BESMRMB%202025%20Focus%20Topic%3A%20Cycle%20of%20Quality-from%20Concept%20to%20Clinical%20and%20Scientific%20Impact.%26%23x201D%3B%20%26lt%3Bi%26gt%3BMagma%20%28New%20York%2C%20N.Y.%29%26lt%3B%5C%2Fi%26gt%3B%2C%20June%2014%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10334-025-01272-0%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10334-025-01272-0%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22ESMRMB%202025%20focus%20topic%3A%20cycle%20of%20quality-from%20concept%20to%20clinical%20and%20scientific%20impact%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22K%5Cu00fcstner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roy%22%2C%22lastName%22%3A%22Haast%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nikos%22%2C%22lastName%22%3A%22Priovoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Clement%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20Pinto%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222025-06-14%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10334-025-01272-0%22%2C%22ISSN%22%3A%221352-8661%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22FBQIKF54%22%5D%2C%22dateModified%22%3A%222025-06-16T08%3A00%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22ZFVS4C2I%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mostame%20et%20al.%22%2C%22parsedDate%22%3A%222025-06-13%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMostame%2C%20Parham%2C%20Jonathan%20Wirsich%2C%20Thomas%20Alderson%2C%20Ben%20Ridley%2C%20Anne-Lise%20Giraud%2C%20David%20W.%20Carmichael%2C%20Serge%20Vulliemoz%2C%20Maxime%20Guye%2C%20Louis%20Lemieux%2C%20and%20Sepideh%20Sadaghiani.%20%26%23x201C%3BA%20Multiplex%20of%20Connectome%20Trajectories%20Enables%20Several%20Connectivity%20Patterns%20in%20Parallel.%26%23x201D%3B%20%26lt%3Bi%26gt%3BeLife%26lt%3B%5C%2Fi%26gt%3B%2013%20%28June%2013%2C%202025%29%3A%20RP98777.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7554%5C%2FeLife.98777%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7554%5C%2FeLife.98777%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20multiplex%20of%20connectome%20trajectories%20enables%20several%20connectivity%20patterns%20in%20parallel%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Parham%22%2C%22lastName%22%3A%22Mostame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Wirsich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Alderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ben%22%2C%22lastName%22%3A%22Ridley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Lise%22%2C%22lastName%22%3A%22Giraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20W.%22%2C%22lastName%22%3A%22Carmichael%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Vulliemoz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Lemieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sepideh%22%2C%22lastName%22%3A%22Sadaghiani%22%7D%5D%2C%22abstractNote%22%3A%22Complex%20brain%20function%20comprises%20a%20multitude%20of%20neural%20operations%20in%20parallel%20and%20often%20at%20different%20speeds.%20Each%20of%20these%20operations%20is%20carried%20out%20across%20a%20network%20of%20distributed%20brain%20regions.%20How%20multiple%20distributed%20processes%20are%20facilitated%20in%20parallel%20is%20largely%20unknown.%20We%20postulate%20that%20such%20processing%20relies%20on%20a%20multiplex%20of%20dynamic%20network%20patterns%20emerging%20in%20parallel%20but%20from%20different%20functional%20connectivity%20%28FC%29%20timescales.%20Given%20the%20dominance%20of%20inherently%20slow%20fMRI%20in%20network%20science%2C%20it%20is%20unknown%20whether%20the%20brain%20leverages%20such%20multi-timescale%20network%20dynamics.%20We%20studied%20FC%20dynamics%20concurrently%20across%20a%20breadth%20of%20timescales%20%28from%20infraslow%20to%20%5Cu03b3-range%29%20in%20rare%2C%20simultaneously%20recorded%20intracranial%20EEG%20and%20fMRI%20in%20humans%2C%20and%20source-localized%20scalp%20EEG-fMRI%20data%20in%20humans.%20We%20examined%20spatial%20and%20temporal%20convergence%20of%20connectome%20trajectories%20across%20timescales.%20%26%23039%3BSpatial%20convergence%26%23039%3B%20refers%20to%20spatially%20similar%20EEG%20and%20fMRI%20connectome%20patterns%2C%20while%20%26%23039%3Btemporal%20convergence%26%23039%3B%20signifies%20the%20more%20specific%20case%20of%20spatial%20convergence%20at%20corresponding%20timepoints%20in%20EEG%20and%20fMRI.%20We%20observed%20spatial%20convergence%20but%20temporal%20divergence%20across%20FC%20timescales%3B%20connectome%20states%20%28recurrent%20FC%20patterns%29%20with%20partial%20spatial%20similarity%20were%20found%20in%20fMRI%20and%20all%20EEG%20frequency%20bands%2C%20but%20these%20occurred%20asynchronously%20across%20FC%20timescales.%20Our%20findings%20suggest%20that%20hemodynamic%20and%20frequency-specific%20electrophysiological%20signals%2C%20while%20involving%20similar%20large-scale%20networks%2C%20represent%20functionally%20distinct%20connectome%20trajectories%20that%20operate%20at%20different%20FC%20speeds%20and%20in%20parallel.%20This%20multiplex%20is%20poised%20to%20enable%20concurrent%20connectivity%20across%20multiple%20sets%20of%20brain%20regions%20independently.%22%2C%22date%22%3A%222025-06-13%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.7554%5C%2FeLife.98777%22%2C%22ISSN%22%3A%222050-084X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22HVJZKIZG%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22WIPJYKQS%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Uher%20et%20al.%22%2C%22parsedDate%22%3A%222025-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BUher%2C%20Daniel%2C%20Gerhard%20S.%20Drenthen%2C%20Christianne%20M.%20Hoeberigs%2C%20Rick%20H.%20G.%20J.%20van%20Lanen%2C%20Albert%20J.%20Colon%2C%20Roy%20A.%20M.%20Haast%2C%20Vivianne%20H.%20J.%20M.%20van%20Kranen-Mastenbroek%2C%20et%20al.%20%26%23x201C%3BThe%20Role%20of%20Ultra-High%20Field%20MRI%20and%20Image%20Processing%20in%20the%20Presurgical%20Workup%20in%20MRI-Negative%20Focal%20Epilepsy%3A%20A%20Validated%207T%20MRI%20Case%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEpilepsy%20%26amp%3B%20Behavior%20Reports%26lt%3B%5C%2Fi%26gt%3B%2030%20%28June%202025%29%3A%20100761.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ebr.2025.100761%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ebr.2025.100761%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20role%20of%20ultra-high%20field%20MRI%20and%20image%20processing%20in%20the%20presurgical%20workup%20in%20MRI-negative%20focal%20epilepsy%3A%20A%20validated%207T%20MRI%20case%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Uher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerhard%20S.%22%2C%22lastName%22%3A%22Drenthen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christianne%20M.%22%2C%22lastName%22%3A%22Hoeberigs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rick%20H.%20G.%20J.%22%2C%22lastName%22%3A%22van%20Lanen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%20J.%22%2C%22lastName%22%3A%22Colon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roy%20A.%20M.%22%2C%22lastName%22%3A%22Haast%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vivianne%20H.%20J.%20M.%22%2C%22lastName%22%3A%22van%20Kranen-Mastenbroek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guido%22%2C%22lastName%22%3A%22Widman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20A.%20M.%22%2C%22lastName%22%3A%22Hofman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%20G.%22%2C%22lastName%22%3A%22Wagner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20C.%22%2C%22lastName%22%3A%22Beckervordersandforth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacobus%20F.%20A.%22%2C%22lastName%22%3A%22Jansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olaf%20E.%20M.%20G.%22%2C%22lastName%22%3A%22Schijns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Walter%20H.%22%2C%22lastName%22%3A%22Backes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22ACE%20study%20group%22%7D%5D%2C%22abstractNote%22%3A%22This%20case%20study%20demonstrates%20the%20value%20of%20combined%207%5Cu00a0T%20structural%20and%20functional%20MRI%20in%20the%20presurgical%20workup%20of%20a%2024-year-old%20male%20with%20drug-resistant%20focal%20epilepsy%20who%20was%20initially%20considered%20MRI-negative%20on%20clinical%203%5Cu00a0T%20MRI.%20The%20patient%20underwent%20extensive%20presurgical%20workup%20with%207%5Cu00a0T%20MRI%2C%20magnetoencephalography%2C%20stereo-electroencephalography%2C%20and%20resection%20of%20the%20suspected%20right%20frontal%20epileptogenic%20zone.%20Histopathology%20showed%20focal%20cortical%20dysplasia%20%28FCD%29%20type%20IIb.%20The%20patient%20remained%2011%5Cu00a0months%20after%20surgery%20seizure-free.%20Retrospective%20analysis%20revealed%20that%20both%20structural%20and%20functional%207%5Cu00a0T%20MRI%20showed%20abnormalities%20within%20the%20resected%20area.%20Morphometric%20Analysis%20Program%20%28MAP18%29%20detected%20abnormalities%20on%20both%203%5Cu00a0T%20and%207%5Cu00a0T%20images.%20However%2C%20abnormalities%20were%20more%20conspicuous%20on%207%5Cu00a0T.%20Resting-state%20functional%20MRI%20metrics%2C%20particularly%20regional%20homogeneity%20and%20fractional%20amplitude%20of%20low-frequency%20fluctuations%2C%20demonstrated%20significantly%20increased%20values%20in%20both%20a%20MAP18-defined%20region%20of%20interest%20and%20the%20entire%20resected%20area%20compared%20to%20a%20healthy%20control%20group%20%28p%5Cu00a0%26lt%3B%5Cu00a00.05%29.%20However%2C%20extensive%20unspecific%20abnormalities%20were%20also%20observed%20outside%20the%20resected%20region%2C%20highlighting%20the%20importance%20of%20a%20multimodal%20approach.%20This%20case%20study%20illustrates%20that%20advanced%20image%20processing%20of%20ultra-high%20field%20structural%20and%20resting-state%20functional%20MRI%20scans%20may%20enhance%20the%20detection%20of%20subtle%20epileptogenic%20lesions%20in%20presurgical%20evaluation%2C%20potentially%20improving%20post-operative%20seizure%20outcome%20and%20associated%20quality%20of%20life.%22%2C%22date%22%3A%222025-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ebr.2025.100761%22%2C%22ISSN%22%3A%222589-9864%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22FBQIKF54%22%5D%2C%22dateModified%22%3A%222025-04-03T15%3A09%3A13Z%22%7D%7D%2C%7B%22key%22%3A%222BXMTS7B%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Alonso-Ortiz%20et%20al.%22%2C%22parsedDate%22%3A%222025-05-20%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAlonso-Ortiz%2C%20Eva%2C%20Daniel%20Papp%2C%20Robert%20L.%20Barry%2C%20Kyota%20Po%26%23xEB%3Bti%2C%20Alan%20C.%20Seifert%2C%20Kyle%20M.%20Gilbert%2C%20Nibardo%20Lopez-Rios%2C%20et%20al.%20%26%23x201C%3BMulti-Center%20Benchmarking%20of%20Cervical%20Spinal%20Cord%20RF%20Coils%20for%207%26%23x2009%3BT%20MRI%3A%20A%20Traveling%20Spines%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BMagnetic%20Resonance%20in%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2C%20May%2020%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmrm.30551%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmrm.30551%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Multi-center%20benchmarking%20of%20cervical%20spinal%20cord%20RF%20coils%20for%207%5Cu2009T%20MRI%3A%20A%20traveling%20spines%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Alonso-Ortiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Papp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20L.%22%2C%22lastName%22%3A%22Barry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kyota%22%2C%22lastName%22%3A%22Po%5Cu00ebti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alan%20C.%22%2C%22lastName%22%3A%22Seifert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kyle%20M.%22%2C%22lastName%22%3A%22Gilbert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nibardo%22%2C%22lastName%22%3A%22Lopez-Rios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Paska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Falk%22%2C%22lastName%22%3A%22Eippert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nikolaus%22%2C%22lastName%22%3A%22Weiskopf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Beghini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%20N.%22%2C%22lastName%22%3A%22Graedel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Trampel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20F.%22%2C%22lastName%22%3A%22Callaghan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%20S.%22%2C%22lastName%22%3A%22Aigner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Freund%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maryam%22%2C%22lastName%22%3A%22Seif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lien%22%2C%22lastName%22%3A%22Destruel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Callot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johanna%22%2C%22lastName%22%3A%22Vannesjo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Cohen-Adad%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20The%20depth%20within%20the%20body%2C%20small%20diameter%2C%20long%20length%2C%20and%20varying%20tissue%20surrounding%20the%20spinal%20cord%20impose%20specific%20considerations%20when%20designing%20RF%20coils.%20The%20optimal%20coil%20configuration%20for%207%5Cu2009T%20cervical%20spinal%20cord%20MRI%20is%20unknown%20and%20currently%20there%20are%20very%20few%20coil%20options.%20The%20purpose%20of%20this%20work%20was%20%281%29%20to%20establish%20a%20quality%20control%20protocol%20for%20evaluating%207%5Cu2009T%20cervical%20spinal%20cord%20coils%2C%20and%20%282%29%20to%20use%20that%20protocol%20to%20evaluate%20the%20performance%20of%20four%20different%20coil%20designs.%5CnMETHODS%3A%20Three%20healthy%20volunteers%20and%20a%20custom%20anthropomorphic%20phantom%20%28the%20traveling%20spines%20cohort%29%20were%20scanned%20at%20seven%207%5Cu2009T%20imaging%20centers%20using%20a%20common%20protocol%20and%20each%20center%26%23039%3Bs%20specific%20cervical%20spinal%20cord%20coil.%20Four%20different%20coil%20designs%20were%20tested%20%28two%20in-house%2C%20one%20Rapid%20Biomedical%2C%20and%20one%20MRI.TOOLS%20design%29.%5CnRESULTS%3A%20The%20Rapid%20Biomedical%20coil%20was%20found%20to%20have%20the%20highest%20%20%20B%201%20%2B%20%20%24%24%20%7B%5C%5Cmathrm%7BB%7D%7D_1%5E%7B%2B%7D%20%24%24%20%20efficiency%2C%20whereas%20one%20of%20the%20in-house%20designs%20%28NeuroPoly%20Lab%29%20had%20the%20highest%20SNR%20and%20the%20largest%20spinal%20cord%20coverage.%20The%20MRI.TOOLS%20coil%20had%20the%20most%20uniform%20%20%20B%201%20%2B%20%20%24%24%20%7B%5C%5Cmathrm%7BB%7D%7D_1%5E%7B%2B%7D%20%24%24%20%20profile%20along%20the%20cervical%20spinal%20cord%3B%20however%2C%20it%20was%20limited%20in%20its%20ability%20to%20provide%20the%20requested%20flip%20angles%20%28especially%20for%20larger%20individuals%29.%20The%20latter%20was%20also%20the%20case%20for%20the%20second%20in-house%20coil%20%28MSSM%29.%5CnCONCLUSION%3A%20The%20results%20of%20this%20study%20serve%20as%20a%20guide%20for%20the%20spinal%20cord%20MRI%20community%20in%20selecting%20the%20most%20suitable%20coil%20based%20on%20specific%20requirements%20and%20offer%20a%20standardized%20protocol%20for%20assessing%20future%20coils.%22%2C%22date%22%3A%222025-05-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fmrm.30551%22%2C%22ISSN%22%3A%221522-2594%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22ZFC2Q648%22%2C%22R8ARNQR7%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22DNR3BIPC%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mourre%20et%20al.%22%2C%22parsedDate%22%3A%222025-05-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMourre%2C%20H%26%23xE9%3Bl%26%23xE8%3Bne%2C%20Julia%20Makhalova%2C%20Lisa%20Soncin%2C%20Elodie%20Garnier%2C%20Hugo%20Dary%2C%20Arnaud%20Le%20Troter%2C%20Roy%20A.%20M.%20Haast%2C%20et%20al.%20%26%23x201C%3BNuclei-Specific%20Amygdala%20Enlargement%20Is%20Linked%20to%20Psychiatric%20Comorbidities%20in%20Drug-Resistant%20Focal%20Epilepsy.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnals%20of%20Clinical%20and%20Translational%20Neurology%26lt%3B%5C%2Fi%26gt%3B%2C%20May%2019%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Facn3.70071%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Facn3.70071%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Nuclei-Specific%20Amygdala%20Enlargement%20Is%20Linked%20to%20Psychiatric%20Comorbidities%20in%20Drug-Resistant%20Focal%20Epilepsy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Mourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Makhalova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Soncin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Garnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Dary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Le%20Troter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roy%20A.%20M.%22%2C%22lastName%22%3A%22Haast%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Testud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Arthuis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%20Medina%22%2C%22lastName%22%3A%22Villalon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanislas%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Pizzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22B%5Cu00e9nar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Bartolomei%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20Amygdala%20enlargement%20has%20been%20the%20subject%20of%20controversial%20studies%20regarding%20its%20significance%20in%20terms%20of%20pathogenicity%20both%20in%20epilepsy%20and%20in%20psychiatric%20comorbidities%20such%20as%20anxiety%2C%20depression%2C%20and%20post-traumatic%20stress%20disorder.%20However%2C%20no%20causal%20link%20has%20been%20established%20in%20either%20direction%2C%20and%20the%20role%20of%20distinct%20amygdala%20nuclei%20remains%20unknown.%20We%20investigated%20volumetric%20changes%20of%20the%20amygdala%20and%20its%20nine%20main%20nuclei%20and%20their%20associations%20with%20psychiatric%20comorbidities%20in%20patients%20with%20drug-resistant%20focal%20epilepsy.%5CnMETHODS%3A%20Eighty-seven%20adult%20patients%20with%20drug-resistant%20focal%20epilepsy%2C%20available%207%5Cu2009T%20MRI%2C%20and%20completed%20standardized%20psychiatric%20assessments%20were%20included.%20Whole%20amygdala%20and%20nuclei%20volumes%20were%20quantified%20and%20compared%20to%20healthy%20controls.%20Correlations%20between%20the%20amygdala%20or%20nuclei%20volumes%20and%20psychiatric%20scores%20were%20analyzed%2C%20as%20well%20as%20the%20prevalence%20and%20severity%20of%20each%20comorbidity%20depending%20on%20the%20presence%20of%20enlargement.%5CnRESULTS%3A%20Amygdala%20enlargement%20was%20present%20in%2041%25%20of%20patients%2C%20with%20bilateral%20enlargement%20observed%20in%2030%25%20of%20these%20cases%2C%20while%20atrophy%20was%20noted%20in%202%25.%20Bilateral%20enlargement%20correlated%20with%20higher%20posttraumatic%20stress%20disorder%20and%20depression%20scores.%20Central%20nucleus%20enlargement%20was%20associated%20with%20a%20greater%20prevalence%20of%20depression%20and%20more%20severe%20anxiety.%20Bilateral%20enlargement%20of%20distinct%20nuclei%20in%20the%20basolateral%20group%20was%20linked%20to%20more%20severe%20depression%20or%20posttraumatic%20stress%20disorder.%5CnINTERPRETATION%3A%20These%20findings%20suggest%20that%20bilateral%20amygdala%20enlargement%2C%20particularly%20in%20specific%20nuclei%2C%20may%20serve%20as%20a%20morphological%20marker%20of%20psychiatric%20comorbidities%20in%20epilepsy.%20Further%20research%20is%20needed%20to%20explore%20the%20specific%20roles%20of%20amygdala%20nuclei%20in%20psycho-epileptogenesis.%22%2C%22date%22%3A%222025-05-19%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Facn3.70071%22%2C%22ISSN%22%3A%222328-9503%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22UP3H3ICX%22%2C%225P5FWCR9%22%2C%22XTA6KS7L%22%2C%22FBQIKF54%22%5D%2C%22dateModified%22%3A%222025-05-27T08%3A14%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22KE4GQ8UH%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marignier%20et%20al.%22%2C%22parsedDate%22%3A%222025-05-16%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMarignier%2C%20Romain%2C%20Javier%20Villacieros-%26%23xC1%3Blvarez%2C%20Carmen%20Espejo%2C%20Georgin%20Arrambide%2C%20Nicol%26%23xE1%3Bs%20Fissolo%2C%20Luc%26%23xED%3Ba%20Guti%26%23xE9%3Brrez%2C%20Alessandro%20Dinoto%2C%20et%20al.%20%26%23x201C%3BAssessment%20of%20Neuronal%20and%20Glial%20Serum%20Biomarkers%20in%20Myelin%20Oligodendrocyte%20Glycoprotein%20Antibody-Associated%20Disease%3A%20The%20MULTIMOGAD%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Neurology%2C%20Neurosurgery%2C%20and%20Psychiatry%26lt%3B%5C%2Fi%26gt%3B%2C%20May%2016%2C%202025%2C%20jnnp-2024-335137.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2024-335137%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2024-335137%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Assessment%20of%20neuronal%20and%20glial%20serum%20biomarkers%20in%20myelin%20oligodendrocyte%20glycoprotein%20antibody-associated%20disease%3A%20the%20MULTIMOGAD%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javier%22%2C%22lastName%22%3A%22Villacieros-%5Cu00c1lvarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carmen%22%2C%22lastName%22%3A%22Espejo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georgin%22%2C%22lastName%22%3A%22Arrambide%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicol%5Cu00e1s%22%2C%22lastName%22%3A%22Fissolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%5Cu00eda%22%2C%22lastName%22%3A%22Guti%5Cu00e9rrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandro%22%2C%22lastName%22%3A%22Dinoto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Mulero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Rubio-Flores%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%22%2C%22lastName%22%3A%22Nieto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carmen%22%2C%22lastName%22%3A%22Alcal%5Cu00e1%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20E.%22%2C%22lastName%22%3A%22Meca-Lallana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%22%2C%22lastName%22%3A%22Mart%5Cu00ednez-Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Mill%5Cu00e1n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rapha%5Cu00ebl%22%2C%22lastName%22%3A%22Bernard-Valnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22In%5Cu00e9s%22%2C%22lastName%22%3A%22Gonz%5Cu00e1lez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aida%22%2C%22lastName%22%3A%22Orv%5Cu00edz%20Garc%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%22%2C%22lastName%22%3A%22Tellez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Navarro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Presas-Rodr%5Cu00edguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%5Cu00eda%22%2C%22lastName%22%3A%22Romero-Pinel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sergio%22%2C%22lastName%22%3A%22Mart%5Cu00ednez-Y%5Cu00e9lamos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Pablo%22%2C%22lastName%22%3A%22Cuello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%20Maria%22%2C%22lastName%22%3A%22Alonso%20Torres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%22%2C%22lastName%22%3A%22Pi%5Cu00f1ar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gary%22%2C%22lastName%22%3A%22%5Cu00c1lvarez%20Bravo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lakhdar%22%2C%22lastName%22%3A%22Benyahya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Trouillet-Assant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Dyon-Tafani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Froment%20Tilikete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Kerschen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alex%22%2C%22lastName%22%3A%22Rovira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Auger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Montalban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%22%2C%22lastName%22%3A%22Tintore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Mariotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Cobo-Calvo%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Serum%20neurofilament%20light%20chain%20%28sNfL%29%20and%20serum%20glial%20fibrillary%20acidic%20protein%20%28sGFAP%29%20have%20emerged%20as%20important%20biomarkers%20in%20multiple%20sclerosis%20%28MS%29%20and%20aquaporin-4%20seropositive%20neuromyelitis%20optica%20spectrum%20disorder%20%28AQP4-NMOSD%29.%20However%2C%20their%20interest%20in%20myelin%20oligodendrocyte%20glycoprotein%20antibody-associated%20disease%20%28MOGAD%29%20remains%20unclear.%20Our%20aim%20was%20to%20characterise%20sNfL%20and%20sGFAP%20profile%20and%20analyse%20their%20usefulness%20in%20predicting%20relapses%20and%20disability%20in%20MOGAD.%5CnMETHODS%3A%20Retrospective%20study%20of%20adult%20MOGAD%20patients%20with%20serum%20samples%20collected%20at%20baseline%20%28%5Cu22643%20months%20from%20disease%20onset%29%20and%20follow-up%20%28%26gt%3B6%20months%20from%20baseline%20sample%29.%20sNfL%20and%20sGFAP%20were%20analysed%20using%20Simoa%20HD-1%2C%20and%20values%20were%20compared%20across%20time-points.%20The%20association%20between%20biomarkers%20and%20clinical%20variables%20and%20their%20predictive%20value%20for%20disability%20and%20relapses%20were%20analysed.%5CnRESULTS%3A%20Eighty-nine%20MOGAD%20patients%20were%20included.%20Baseline%20sNfL%20and%20sGFAP%20values%20were%20high%20at%20baseline%20and%20decreased%20over%20time%20%28p%26lt%3B0.001%2C%20p%3D0.027%2C%20respectively%29.%20sNfL%20and%20sGFAP%20values%20were%20associated%20with%20Expanded%20Disability%20Status%20Scale%20%28EDSS%29%20at%20attacks%20%28%5Cu03b2%200.15%20%280.06%3B%200.25%29%2C%20p%3D0.002%3B%20%5Cu03b2%200.14%20%280.07%3B%200.21%29%2C%20p%26lt%3B0.001%2C%20respectively%29%20and%20were%20lower%20in%20optic%20neuritis%20presentations%20%28%5Cu03b2%20-0.69%20%28-1.18%3B%20-0.19%29%2C%20p%3D0.007%3B%20%5Cu03b2%20-0.42%20%28-0.76%3B%20-0.08%29%2C%20p%3D0.016%29.%20Biomarker%20deltas%5B%5Cu0394%5D%20%28baseline%20values%20-%20second%20samples%20values%29%20were%20associated%20with%20%5Cu0394EDSS%20%28initial%20EDSS%20-%20final%20EDSS%29%20%28%5Cu0394sNfL%20%5Cu03b2%200.52%20%280.01%3B%201.04%29%2C%20p%3D0.046%3B%20%5Cu0394sGFAP%20%5Cu03b2%201.07%20%280.38%3B%201.75%29%2C%20p%3D0.003%29.%20Finally%2C%20sNfL%20values%20independently%20predicted%20the%20risk%20of%20relapses%20%28HR%202.06%20%281.41%3B%203.01%29%2C%20p%26lt%3B0.001%29.%5CnCONCLUSIONS%3A%20Our%20results%20on%20sNfL%20and%20sGFAP%20suggest%20initial%20neuro-axonal%20and%20astrocytic%20damage%20in%20MOGAD%20and%20the%20utility%20of%20these%20biomarkers%20at%20onset%20and%20follow-up%20in%20predicting%20clinical%20recovery%20and%20relapses.%22%2C%22date%22%3A%222025-05-16%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fjnnp-2024-335137%22%2C%22ISSN%22%3A%221468-330X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22JITMD4XG%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Demortiere%20et%20al.%22%2C%22parsedDate%22%3A%222025-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDemortiere%2C%20Sarah%2C%20Natacha%20Stolowy%2C%20Marine%20Perriguey%2C%20Clemence%20Boutiere%2C%20Audrey%20Rico%2C%20Frederic%20Hilezian%2C%20Blaise-Roger%20Ndjomo-Ndjomo%2C%20et%20al.%20%26%23x201C%3BDiagnostic%20Utility%20of%20Kappa%20Free%20Light%20Chain%20Index%20in%20Adults%20With%20Inaugural%20Optic%20Neuritis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2012%2C%20no.%203%20%28May%202025%29%3A%20e200386.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200386%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200386%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnostic%20Utility%20of%20Kappa%20Free%20Light%20Chain%20Index%20in%20Adults%20With%20Inaugural%20Optic%20Neuritis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Stolowy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Blaise-Roger%22%2C%22lastName%22%3A%22Ndjomo-Ndjomo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Boucraut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20A%20simple%2C%20quick%2C%20and%20reproducible%20procedure%20for%20distinguishing%20multiple%20sclerosis%20%28MS%29%2C%20myelin%20oligodendrocyte%20glycoprotein%20antibody-associated%20disease%20%28MOGAD%29%2C%20and%20neuromyelitis%20optica%20spectrum%20disorder%20%28NMOSD%29%20at%20inaugural%20optic%20neuritis%20%28ION%29%20could%20be%20highly%20valuable%20in%20guiding%20early%20management.%5CnMETHODS%3A%20We%20included%20all%20adults%20admitted%20to%20the%20MS%20center%20of%20Marseille%20for%20ION%20between%20March%202016%20and%20April%202024%2C%20with%20CSF%20analysis%20including%20the%20kappa%20free%20light%20chain%20%28K-FLC%29%20index.%20Receiver%20operating%20characteristic%20curves%20were%20used%20to%20measure%20the%20diagnostic%20ability%20of%20the%20K-FLC%20index.%5CnRESULTS%3A%20Two%20hundred%20twenty-seven%20adults%20were%20admitted%20for%20ION%3B%20210%20%2893%25%29%20had%20a%20K-FLC%20index%20measurement.%20MS%20was%20diagnosed%20in%2084%20%2840%25%29%3B%20clinically%20isolated%20syndrome%20suggestive%20of%20MS%20in%2077%20%2836.5%25%29%2C%20including%2020%20with%20future%20conversion%20to%20MS%20%28CISwc%29%3B%20MOGAD%20in%2026%20%2812.5%25%29%3B%20NMOSD%20in%2013%20%286%25%29%3B%20and%20other%20inflammatory%20disorders%20in%2010%20%285%25%29.%20A%20K-FLC%20index%20%5Cu22656.7%20differentiated%20MS%5C%2FCISwc%20from%20other%20diagnoses%20with%20specificity%2086%25%20and%20sensitivity%2095%25%20%28area%20under%20the%20curve%20%5BAUC%5D%200.94%29.%20A%20K-FLC%20index%20%26lt%3B4.9%20differentiated%20MOGAD%20from%20other%20diagnoses%20with%20specificity%2063%25%20and%20sensitivity%2092%25%20%28AUC%200.78%29%20and%20MOGAD%20from%20MS%5C%2FCISwc%20with%20specificity%2096%25%20and%20sensitivity%2092%25%20%28AUC%200.97%29.%20Among%20all%20patients%2C%2093%20%2844%25%29%20had%20a%20K-FLC%20index%20%26lt%3B4.9%3A%2024%20of%20these%20%2826%25%29%20had%20MOGAD%20and%205%20%285.5%25%29%20MS%5C%2FCISwc.%20Among%20the%20remaining%20patients%20with%20a%20K-FLC%20index%20%5Cu22654.9%20%28n%20%3D%20117%29%2C%202%20%281.7%25%29%20had%20MOGAD%20%28K-FLC%20index%20of%207.9%20and%2016.2%29%20and%2099%20%2885%25%29%20MS%5C%2FCISwc.%20Among%20patients%20with%20normal%20MRI%20%28n%20%3D%2096%29%2C%2073%20%2876%25%29%20had%20a%20K-FLC%20index%20%26lt%3B4.9%3A%2022%20of%20these%20%2830%25%29%20had%20MOGAD%2C%20and%20none%20showed%20conversion%20to%20MS.%20Among%20the%20remaining%20patients%20with%20a%20K-FLC%20index%20%5Cu22654.9%20%28n%20%3D%2023%29%2C%202%20%288.5%25%29%20had%20MOGAD%20and%207%20%2830.5%25%29%20showed%20conversion%20to%20MS.%20The%20K-FLC%20index%20did%20not%20differentiate%20NMOSD%20from%20other%20diagnoses%20and%20only%20moderately%20differentiated%20NMO%20from%20MS%5C%2FCISwc%20%28AUC%200.80%29.%5CnDISCUSSION%3A%20The%20K-FLC%20index%20is%20an%20accessible%20biomarker%20to%20guide%20early%20diagnosis%20in%20patients%20with%20ION.%20The%20probability%20of%20MOGAD%20in%20patients%20with%20ION%20and%20a%20K-FLC%20index%20%5Cu22654.9%20is%20low%20even%20in%20case%20of%20normal%20brain%5C%2Fspinal%20cord%20MRI.%5CnCLASSIFICATION%20OF%20EVIDENCE%3A%20This%20study%20provides%20Class%20II%20evidence%20that%20for%20patients%20with%20ION%2C%20the%20K-FLC%20index%20can%20distinguish%20between%20MS%5C%2FCISwc%20and%20MOGAD.%22%2C%22date%22%3A%222025-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200386%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%5D%2C%22dateModified%22%3A%222025-12-01T09%3A50%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22XVGGM5PL%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cohen%20et%20al.%22%2C%22parsedDate%22%3A%222025-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCohen%2C%20Mikael%2C%20Fabien%20Rollot%2C%20Marc%20Debouverie%2C%20H%26%23xE9%3Bl%26%23xE8%3Bne%20Zephir%2C%20Sandra%20Vukusic%2C%20J%26%23xE9%3Brome%20De%20Seze%2C%20Pierre%20Labauge%2C%20et%20al.%20%26%23x201C%3BSecondary%20Progression%20Activity%20Monitoring%20in%20MS%20despite%20an%20Early%20Highly%20Active%20Treatment%20the%20SPAM%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Neurology%26lt%3B%5C%2Fi%26gt%3B%2032%2C%20no.%205%20%28May%202025%29%3A%20e16583.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.16583%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.16583%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Secondary%20progression%20activity%20monitoring%20in%20MS%20despite%20an%20early%20highly%20active%20treatment%20the%20SPAM%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Debouverie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9rome%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cassandre%22%2C%22lastName%22%3A%22Landes-Chateau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydiane%22%2C%22lastName%22%3A%22Mondot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Levraut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al%20Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Cabre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Philippe%22%2C%22lastName%22%3A%22Neau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mickael%22%2C%22lastName%22%3A%22Zedet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22In%5Cu00e8s%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Haifa%20Ben%22%2C%22lastName%22%3A%22Nasr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dalia%20Dimitri%22%2C%22lastName%22%3A%22Boulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Philippe%22%2C%22lastName%22%3A%22Camdessanche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Coustans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Nifle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Brassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22OFSEP%20and%20SFSEP%20study%20groups%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Real-world%20data%20suggest%20that%20the%20early%20use%20of%20highly%20active%20therapies%20%28HAT%29%20may%20reduce%20the%20risk%20of%20transition%20to%20secondary%20progressive%20MS%20%28SPMS%29.%20However%2C%20current%20knowledge%20about%20predictive%20factors%20of%20outcomes%20needs%20to%20be%20improved.%20The%20primary%20objective%20of%20this%20study%20was%20to%20determine%20factors%20associated%20with%20the%20occurrence%20of%20SPMS%20in%20patients%20treated%20early%20after%20MS%20onset%20with%20an%20HAT.%5CnMETHODS%3A%20Retrospective%2C%20multicentric%20study%20based%20on%20the%20French%20MS%20database.%20Patients%20who%20initiated%20a%20HAT%20within%205%5Cu2009years%20after%20MS%20onset%2C%20EDSS%20%5Cu2a7d4%2C%20and%20had%20a%20follow-up%20%26gt%3B5%5Cu2009years%20were%20included.%20The%20association%20of%20each%20covariate%20at%20baseline%20with%20time%20to%20the%20occurrence%20of%20SPMS%20was%20quantified%20by%20hazard%20ratios%20%28HRs%29%20in%20unadjusted%20and%20adjusted%20Cox%20proportional%20hazards%20models.%5CnRESULTS%3A%20Two%20thousand%20two%20hundred%20and%20thirty-seven%20patients%20were%20included%20in%20the%20analysis%3A%20mean%20age%2031.6%5Cu2009years%2C%20female%5C%2Fmale%20sex%20ratio%202.3%2C%20and%20median%20EDSS%202.0.%20The%20estimated%20probability%20of%20reaching%20SPMS%2C%20progression%20independent%20of%20relapse%20activity%20%28PIRA%29%20and%20progression%20independent%20of%20activity%20%28PIA%29%20at%2010%5Cu2009years%20was%208%25%2C%2022%25%2C%20and%2011%25%2C%20respectively.%20After%20adjustment%2C%20we%20found%20that%20female%20patients%20%28HR%200.64%2C%20p%5Cu2009%3D%5Cu20090.036%29%20had%20a%20lower%20risk%20of%20developing%20SPMS.%20Older%20age%2C%20EDSS%20%26gt%3B0%20%28HR%207.44%2C%20p%5Cu2009%26lt%3B%5Cu20090.001%29%2C%20and%20oral%20versus%20intravenous%20HAT%20%28HR%201.97%2C%20p%5Cu2009%3D%5Cu20090.003%29%20were%20significantly%20associated%20with%20an%20increased%20SPMS%20risk.%20Early%20PIRA%20and%20PIA%20predicted%20conversion%20to%20SPMS.%5CnCONCLUSIONS%3A%20Early%20HAT%20use%20resulted%20in%20a%20low%20risk%20of%20developing%20SPMS%20over%2010%5Cu2009years.%20Introducing%20the%20HAT%20before%20any%20residual%20disability%20was%20associated%20with%20a%20lower%20risk%20of%20progression.%22%2C%22date%22%3A%222025-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fene.16583%22%2C%22ISSN%22%3A%221468-1331%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22YCW6SA77%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cotinat%20et%20al.%22%2C%22parsedDate%22%3A%222025-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCotinat%2C%20Ma%26%23xEB%3Bva%2C%20No%26%23xEB%3Blle%20Messaoudi%2C%20Emmanuelle%20Robinet%2C%20Laurent%20Suissa%2C%20Emilie%20Doche%2C%20Maxime%20Guye%2C%20Bertrand%20Audoin%2C%20Laurent%20Bensoussan%2C%20Jean-Philippe%20Ranjeva%2C%20and%20Wafaa%20Zaaraoui.%20%26%23x201C%3BDynamics%20of%20Ionic%20and%20Cytotoxic%20Edema%20During%20Acute%20and%20Subacute%20Stages%20of%20Patients%20With%20Ischemic%20Stroke%3A%20Complementarity%20of%2023Na%20MRI%20and%20Diffusion%20MRI.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNMR%20in%20Biomedicine%26lt%3B%5C%2Fi%26gt%3B%2038%2C%20no.%205%20%28May%202025%29%3A%20e70028.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fnbm.70028%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fnbm.70028%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dynamics%20of%20Ionic%20and%20Cytotoxic%20Edema%20During%20Acute%20and%20Subacute%20Stages%20of%20Patients%20With%20Ischemic%20Stroke%3A%20Complementarity%20of%2023Na%20MRI%20and%20Diffusion%20MRI%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ma%5Cu00ebva%22%2C%22lastName%22%3A%22Cotinat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00eblle%22%2C%22lastName%22%3A%22Messaoudi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Robinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Suissa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Doche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Bensoussan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%5D%2C%22abstractNote%22%3A%22Cerebral%20imaging%20is%20crucial%20in%20the%20diagnosis%20and%20treatment%20algorithm%20of%20acute%20stroke%20to%20determine%20salvageable%20brain%20tissue.%20While%20diffusion%20MRI%20is%20commonly%20used%20to%20define%20the%20ischemic%20core%2C%20it%20cannot%20reliably%20distinguish%20irreversibly%20damaged%20from%20salvageable%20tissue.%20We%20investigated%20the%20added%20value%20of%2023Na%20MRI%20to%20define%20irreversible%20necrotic%20tissue%20after%20a%20stroke.%20Fifteen%20patients%20with%20acute%20stroke%20involving%20medial%20cerebral%20artery%20occlusion%20were%20longitudinally%20explored%20with%20conventional%20and%2023Na%20MRI%20within%2024%5Cu2009h%2C%2070%5Cu2009h%20following%20stroke%20and%20at%203%5Cu2009months%20to%20characterize%20the%20necrotic%20area.%20Time-courses%20of%20sodium%20accumulations%20were%20observed%20within%20regions%20presenting%20with%20or%20spared%20by%20cytotoxic%5C%2Fionic%20edema%20and%20converting%20or%20not%20to%20necrosis.%20Dynamics%20of%20sodium%20accumulations%20were%20very%20different%20across%20subjects.%20At%20the%20group%20level%2C%20time-courses%20of%20sodium%20signal%20in%20cytotoxic%20edema%20showed%20a%20non-linear%20increase%20with%20an%20upper%20asymptote%20of%2059%5Cu2009%5Cu00b1%5Cu20096%25%25%20relative%20to%20the%20contralateral%20hemisphere.%20Regions%20with%20a%20larger%20early%20increase%20in%2023Na%20signal%20%28ionic%20edema%29%20showed%20a%20non-linear%20accumulation%20during%20the%20first%2070%5Cu2009h%20and%20were%20associated%20with%20subsequent%20necrosis%20at%20month%203.%20Some%20of%20the%20regions%20with%20no%20ionic%20edema%20during%20the%20first%2070%5Cu2009h%20became%20necrotic%20at%20month%203%2C%20showing%20that%20pejorative%20pathophysiological%20processes%20could%20worsen%20after%2070%5Cu2009h%20following%20attack.%20Final%20necrotic%20volume%20was%20well%20predicted%20by%20the%20cytotoxic%20volume%20%28ADC%20decrease%29%20during%20the%20first%2024%5Cu2009h%2C%20and%20by%20the%20volume%20of%20ionic%20edema%20during%20the%20subacute%20period%20%2825-70%5Cu2009h%29%20following%20attack.%20The%20regions%20showing%20ionic%20edema%20showed%20a%20non-linear%20increase%20of%2023Na%20signal%20during%20the%20first%2070%5Cu2009h%2C%20with%20larger%20sodium%20accumulations%20in%20regions%20converting%20to%20necrosis%20at%20month%203.%20It%20may%20be%20of%20interest%20to%20consider%20the%20role%20of%20ionic%20edema%20imaging%20in%20the%2070%5Cu2009h%20after%20stroke%20and%20reperfusion%2C%20with%20a%20view%20to%20better%20understand%20stroke%20pathophysiology.%20Sodium%20MRI%20could%20add%20complementary%20information%20about%20the%20fate%20of%20cell%20necrosis%20within%20low%20ADC%20signal%20regions.%22%2C%22date%22%3A%222025-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fnbm.70028%22%2C%22ISSN%22%3A%221099-1492%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22UP3H3ICX%22%2C%22P66W67T8%22%2C%226KPLZTET%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22NW8ZZ25N%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dollomaja%20et%20al.%22%2C%22parsedDate%22%3A%222025-04-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDollomaja%2C%20Borana%2C%20Huifang%20E.%20Wang%2C%20Maxime%20Guye%2C%20Julia%20Makhalova%2C%20Fabrice%20Bartolomei%2C%20and%20Viktor%20K.%20Jirsa.%20%26%23x201C%3BVirtual%20Epilepsy%20Patient%20Cohort%3A%20Generation%20and%20Evaluation.%26%23x201D%3B%20%26lt%3Bi%26gt%3BPLoS%20Computational%20Biology%26lt%3B%5C%2Fi%26gt%3B%2021%2C%20no.%204%20%28April%2011%2C%202025%29%3A%20e1012911.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pcbi.1012911%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pcbi.1012911%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Virtual%20epilepsy%20patient%20cohort%3A%20Generation%20and%20evaluation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Borana%22%2C%22lastName%22%3A%22Dollomaja%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Huifang%20E.%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Makhalova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Bartolomei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Viktor%20K.%22%2C%22lastName%22%3A%22Jirsa%22%7D%5D%2C%22abstractNote%22%3A%22Epilepsy%20is%20a%20prevalent%20brain%20disorder%2C%20characterized%20by%20sudden%2C%20abnormal%20brain%20activity%2C%20making%20it%20difficult%20to%20live%20with.%20One-third%20of%20people%20with%20epilepsy%20do%20not%20respond%20to%20anti-epileptic%20drugs.%20Drug-resistant%20epilepsy%20is%20treated%20with%20brain%20surgery.%20Successful%20surgical%20treatment%20relies%20on%20identifying%20brain%20regions%20responsible%20for%20seizure%20onset%2C%20known%20as%20epileptogenic%20zones%20%28EZ%29.%20Despite%20various%20methods%20for%20EZ%20estimation%2C%20evaluating%20their%20efficacy%20remains%20challenging%20due%20to%20a%20lack%20of%20ground%20truth%20for%20empirical%20data.%20To%20address%20this%2C%20we%20generated%20and%20evaluated%20a%20cohort%20of%2030%20virtual%20epilepsy%20patients%2C%20using%20patient-specific%20anatomical%20and%20functional%20data%20from%2030%20real%20drug-resistant%20epilepsy%20patients.%20This%20personalized%20modeling%2C%20based%20on%20the%20patient%26%23039%3Bs%20brain%20data%2C%20is%20called%20a%20virtual%20brain%20twin.%20For%20each%20virtual%20patient%2C%20we%20provided%20data%20that%20included%20anatomically%20parcellated%20brain%20regions%2C%20structural%20connectivity%2C%20reconstructed%20intracranial%20electrodes%2C%20simulated%20brain%20activity%20at%20both%20the%20brain%20region%20and%20electrode%20levels%2C%20and%20key%20parameters%20of%20the%20virtual%20brain%20twin.%20These%20key%20parameters%2C%20which%20include%20the%20EZ%20hypothesis%2C%20serve%20as%20the%20ground-truth%20for%20simulated%20brain%20activity.%20For%20each%20virtual%20brain%20twin%2C%20we%20generated%20synthetic%20spontaneous%20seizures%2C%20stimulation-induced%20seizures%20and%20interictal%20activity.%20We%20systematically%20evaluated%20these%20simulated%20brain%20signals%20by%20quantitatively%20comparing%20them%20against%20their%20corresponding%20empirical%20intracranial%20recordings.%20Simulated%20signals%20based%20on%20patient-specific%20EZ%20captured%20spatio-temporal%20seizure%20generation%20and%20propagation.%20Through%20in-silico%20exploration%20of%20stimulation%20parameters%2C%20we%20also%20demonstrated%20the%20role%20of%20patient-specific%20stimulation%20location%20and%20amplitude%20in%20reproducing%20empirically%20stimulated%20seizures.%20The%20virtual%20epileptic%20cohort%20is%20openly%20available%2C%20and%20can%20be%20directly%20used%20to%20systematically%20evaluate%20methods%20for%20the%20estimation%20of%20EZ%20or%20source%20localization%20using%20ground%20truth%20EZ%20parameters%20and%20source%20signals.%22%2C%22date%22%3A%222025-04-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pcbi.1012911%22%2C%22ISSN%22%3A%221553-7358%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22XTA6KS7L%22%2C%229RMECNPE%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22WXTRWDEL%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cotinat%20et%20al.%22%2C%22parsedDate%22%3A%222025-04-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCotinat%2C%20Ma%26%23xEB%3Bva%2C%20Emmanuelle%20Robinet%2C%20No%26%23xEB%3Blle%20Messaoudi%2C%20Laurent%20Suissa%2C%20Emilie%20Doche%2C%20Maxime%20Guye%2C%20Laurent%20Bensoussan%2C%20Wafaa%20Zaaraoui%2C%20and%20Jean-Philippe%20Ranjeva.%20%26%23x201C%3BAdded%20Value%20of%20Sodium%20MR%20Imaging%20and%20Proton%20MR%20Spectroscopy%20to%20Conventional%20MR%20Imaging%20for%20a%20Better%20Characterization%20of%20the%20Ischemic%20Stroke%3A%20A%20Narrative%20Review.%26%23x201D%3B%20%26lt%3Bi%26gt%3BMagnetic%20Resonance%20in%20Medical%20Sciences%3A%20MRMS%3A%20An%20Official%20Journal%20of%20Japan%20Society%20of%20Magnetic%20Resonance%20in%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2C%20April%209%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2463%5C%2Fmrms.rev.2025-0002%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2463%5C%2Fmrms.rev.2025-0002%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Added%20Value%20of%20Sodium%20MR%20Imaging%20and%20Proton%20MR%20Spectroscopy%20to%20Conventional%20MR%20Imaging%20for%20a%20Better%20Characterization%20of%20the%20Ischemic%20Stroke%3A%20A%20Narrative%20Review%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ma%5Cu00ebva%22%2C%22lastName%22%3A%22Cotinat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Robinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00eblle%22%2C%22lastName%22%3A%22Messaoudi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Suissa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Doche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Bensoussan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%5D%2C%22abstractNote%22%3A%22Stroke%20is%20a%20major%20cause%20of%20disability%20and%20death%20in%20adults%20worldwide.%20In%20clinical%20setting%2C%20time%20efficient%20MRI%20protocols%20including%20diffusion%20weighted%20images%2C%20fluid%20attenuated%20inversion%20recovery%2C%20fast%20T2%2A-weighted%20images%20and%20MR%20angiography%20aim%20to%20establish%20ischemic%20stroke%20diagnosis%2C%20visualize%20vessel%20occlusion%20and%20determine%20the%20extent%20of%20ischemia%20damage%20distinguishing%20between%20the%20salvageable%20ischemic%20penumbra%20and%20the%20infarct%20core.%20Thus%2C%20MRI%20plays%20a%20pivotal%20role%20in%20diagnosis%2C%20treatment%20decision-making%2C%20and%20prognostic%20assessment%2C%20although%20prediction%20based%20on%20these%20elements%20remains%20limited%20and%20can%20be%20improved.%20We%20reviewed%20the%20added-values%20of%20alternative%20MRI%20methods%20such%20as%20sodium%2823Na%29%20MRI%20and%201H%20MR%20spectroscopic%20imaging%20that%20open%20new%20temporal%20and%20pathophysiological%20windows%20on%20ionic%20dys-homeostasis%20and%20metabolism%20alteration%20in%20the%20context%20of%20ischemic%20stroke%20and%20reperfusion.%20Insights%20on%20the%20timeline%20of%20the%20cellular%20events%20accessible%20using%20these%20alternative%20methods%20and%20perspectives%20to%20improve%20clinical%20outcome%20prediction%20of%20ischemic%20stroke%20patients%20are%20discussed.%22%2C%22date%22%3A%222025-04-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.2463%5C%2Fmrms.rev.2025-0002%22%2C%22ISSN%22%3A%221880-2206%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22UP3H3ICX%22%2C%22HVJZKIZG%22%2C%22P66W67T8%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22NCYFCF6W%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hong%20et%20al.%22%2C%22parsedDate%22%3A%222025-04-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHong%2C%20J%26%23xE9%3Br%26%23xE9%3Bmy%2C%20Malo%20Gaubert%2C%20Mathilde%20Lefort%2C%20Jean%20Christophe%20Ferr%26%23xE9%3B%2C%20Emmanuelle%20Le%20Page%2C%20Laure%20Michel%2C%20Pierre%20Labauge%2C%20et%20al.%20%26%23x201C%3BLimited%20Added%20Value%20of%20Systematic%20Spinal%20Cord%20MRI%20vs%20Brain%20MRI%20Alone%20to%20Classify%20Patients%20with%20MS%20as%20Active%20or%20Inactive%20during%20Follow-Up.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Neurology%26lt%3B%5C%2Fi%26gt%3B%20272%2C%20no.%204%20%28April%205%2C%202025%29%3A%20316.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00415-025-13068-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00415-025-13068-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Limited%20added%20value%20of%20systematic%20spinal%20cord%20MRI%20vs%20brain%20MRI%20alone%20to%20classify%20patients%20with%20MS%20as%20active%20or%20inactive%20during%20follow-up%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00e9my%22%2C%22lastName%22%3A%22Hong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malo%22%2C%22lastName%22%3A%22Gaubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Lefort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Christophe%22%2C%22lastName%22%3A%22Ferr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22de%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Durand-Dubief%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Cotton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Edan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elise%22%2C%22lastName%22%3A%22Bannier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Comb%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20utility%20of%20systematic%20spinal%20cord%20%28SC%29%20MRI%20for%20monitoring%20disease%20activity%20after%20a%20multiple%20sclerosis%20%28MS%29%20diagnosis%20remains%20a%20topic%20of%20debate.%5CnOBJECTIVES%3A%20To%20evaluate%20the%20frequency%20of%20disease%20activity%20when%20considering%20brain%20MRI%20alone%20versus%20both%20brain%20and%20SC%20MRI%20and%20to%20identify%20factors%20associated%20with%20the%20occurrence%20of%20new%20SC%20lesions.%5CnMETHODS%3A%20We%20conducted%20a%20retrospective%20analysis%20of%20clinical%20and%20imaging%20data%20prospectively%20collected%20over%205%5Cu00a0years%20as%20part%20of%20the%20EMISEP%20cohort%20study.%20A%20total%20of%20221%20intervals%20%28with%20both%20brain%20and%20spinal%20cord%20MRI%20scans%20available%20at%202%20consecutive%20time-points%29%20from%2068%20patients%20were%20analysed.%20For%20each%20interval%2C%20brain%20%283D%20Fluid-Attenuated%20Inversion%20Recovery%20%28FLAIR%2C%20axial%20T2%20and%20axial%20PD%29%20and%20SC%20MRI%20%28sagittal%20T2%20and%20phase-sensitive%20inversion%20recovery%2C%20axial%20T2%2Aw%20and%203D%20T1%29%20were%20reviewed%20to%20detect%20new%20lesions.%20Each%20interval%20was%20classified%20as%20symptomatic%20%28with%20relapse%29%20or%20asymptomatic.%20The%20baseline%20brain%20and%20SC%20lesion%20numbers%20were%20computed.%5CnRESULTS%3A%20SC%20MRI%20activity%20without%20clinical%20relapse%20and%5C%2For%20brain%20MRI%20activity%20was%20rare%20%284%20out%20of%20221%20intervals%2C%202%25%29.%20The%20occurrence%20of%20a%20new%20SC%20lesion%20was%20associated%20with%20the%20number%20of%20brain%20lesions%20at%20baseline%20%28OR%20%3D%5Cu20091.002%20%5B1.000%3B%201.0004%5D%2C%20p%5Cu2009%3D%200.015%29%20and%20the%20occurrence%20of%20a%20new%20brain%20lesion%20during%20the%20interval%20%28OR%20%3D%5Cu20091.170%20%5B1.041%3B%201.314%5D%2C%20p%5Cu2009%3D%200.009%29%2C%20but%20not%20with%20the%20baseline%20SC%20lesion%20number%20%28p%5Cu2009%3D%200.6%29.%5CnCONCLUSION%3A%20These%20findings%20support%20the%20current%20guidelines%20recommending%20routine%20disease%20monitoring%20with%20brain%20MRI%20alone%2C%20even%20in%20patients%20with%20a%20high%20SC%20lesion%20load.%22%2C%22date%22%3A%222025-04-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00415-025-13068-2%22%2C%22ISSN%22%3A%221432-1459%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22T6U3CK9C%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lod%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222025-04-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLod%26%23xE9%3B%2C%20Baptiste%2C%20Burhan%20Rashid%20Hussein%2C%20C%26%23xE9%3Bdric%20Meur%26%23xE9%3Be%2C%20Ricky%20Walsh%2C%20Malo%20Gaubert%2C%20Nicolas%20Lassalle%2C%20Guilhem%20Courbon%2C%20et%20al.%20%26%23x201C%3BEvaluation%20of%20a%20Deep%20Learning%20Segmentation%20Tool%20to%20Help%20Detect%20Spinal%20Cord%20Lesions%20from%20Combined%20T2%20and%20STIR%20Acquisitions%20in%20People%20with%20Multiple%20Sclerosis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Radiology%26lt%3B%5C%2Fi%26gt%3B%2C%20April%204%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00330-025-11541-0%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00330-025-11541-0%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20a%20deep%20learning%20segmentation%20tool%20to%20help%20detect%20spinal%20cord%20lesions%20from%20combined%20T2%20and%20STIR%20acquisitions%20in%20people%20with%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Baptiste%22%2C%22lastName%22%3A%22Lod%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Burhan%20Rashid%22%2C%22lastName%22%3A%22Hussein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Meur%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ricky%22%2C%22lastName%22%3A%22Walsh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malo%22%2C%22lastName%22%3A%22Gaubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Lassalle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guilhem%22%2C%22lastName%22%3A%22Courbon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agathe%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeanne%22%2C%22lastName%22%3A%22Le%20Bars%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Durand-Dubief%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Outteryck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9ment%22%2C%22lastName%22%3A%22Mehier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Poulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Cathelineau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Hong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Criton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Motillon-Alonso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Augustin%22%2C%22lastName%22%3A%22Lecler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9rique%22%2C%22lastName%22%3A%22Charbonneau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Duron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Bani-Sadr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Delpierre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Ferr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Edan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Cotton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Galassi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Comb%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20develop%20a%20deep%20learning%20%28DL%29%20model%20for%20the%20detection%20of%20spinal%20cord%20%28SC%29%20multiple%20sclerosis%20%28MS%29%20lesions%20from%20both%20sagittal%20T2%20and%20short%20tau%20inversion%20recovery%20%28STIR%29%20sequences%20and%20to%20investigate%20whether%20such%20a%20model%20could%20improve%20the%20performance%20of%20clinicians%20in%20detecting%20SC%20lesions.%5CnMATERIALS%20AND%20METHODS%3A%20A%20DL%20tool%20was%20developed%20based%20on%20SC%20sagittal%20T2%20and%20STIR%20acquisitions%20from%20the%20imaging%20database%20of%20the%20French%20MS%20registry%20%28OFSEP%29%2C%20including%20retrospective%20data%20from%2040%20different%20scanners.%20A%20multi-reader%20study%20based%20on%20retrospective%20data%20was%20performed%20between%20December%202023%20and%20June%202024%20to%20compare%20the%20performance%20of%2020%20clinicians%20in%20interpreting%20upper%20and%20lower%20SC%20acquisitions%20with%20and%20without%20the%20use%20of%20the%20tool.%20A%20ground%20truth%20was%20established%20by%20three%20experts.%20Sensitivity%2C%20precision%2C%20and%20inter-reader%20variability%20were%20evaluated.%5CnRESULTS%3A%20We%20included%2050%20patients%20%2839%20females%2C%20median%20age%3A%2041%20years%20%5Brange%3A%2015-67%5D%29%20with%20SC%20MRI%20acquired%20between%20February%202017%20and%20December%202022.%20When%20reading%20with%20the%20tool%2C%20the%20clinicians%26%23039%3B%20mean%20sensitivity%20to%20detect%20SC%20lesions%20improved%20%28from%2074.3%25%20%5B95%25%20CI%5Cu2009%3D%5Cu200967.8-80.6%25%5D%20to%2079.2%25%20%5B95%25%20CI%3A%2073.5-85.0%25%5D%3B%20p%5Cu2009%26lt%3B%5Cu20090.0001%29%2C%20with%20no%20evidence%20of%20difference%20in%20the%20mean%20precision%3A%20%2869.0%25%20%5B95%25%20CI%3A%2062.8-75.2%25%5D%20vs%2070.1%25%20%5B95%25%20CI%3A%2064.3-75.9%25%5D%3B%20p%5Cu2009%3D%5Cu20090.08%29.%20Inter-reader%20variability%20in%20lesion%20detection%20was%20slightly%20improved%20with%20the%20tool%20%28Light%26%23039%3Bs%20kappa%5Cu2009%3D%200.55%20vs%200.60%29%2C%20but%20without%20statistical%20difference%20%28p%5Cu2009%3D%5Cu20090.056%29.%5CnCONCLUSION%3A%20The%20use%20of%20an%20automatic%20tool%20can%20help%20clinicians%20detect%20SC%20lesions%20in%20pwMS%20by%20increasing%20their%20sensitivity.%5CnKEY%20POINTS%3A%20Question%20No%20tool%20to%20help%20detect%20MS%20SC%20lesions%20is%20used%20in%20clinical%20practice%20despite%20their%20frequency%20and%20prognostic%20value.%20Findings%20This%20DL-based%20tool%20led%20to%20improvement%20in%20clinicians%26%23039%3B%20sensitivity%20in%20detecting%20SC%20lesions%20from%20both%20sagittal%20T2%20and%20STIR%20sequences%2C%20without%20decreasing%20precision.%20Clinical%20relevance%20Our%20study%20indicated%20the%20potential%20of%20a%20DL-based%20tool%20to%20assist%20clinicians%20in%20the%20challenging%20task%20of%20detecting%20SC%20lesions%20in%20people%20with%20MS%20on%20a%20combination%20of%20sequences%20commonly%20acquired%20in%20clinical%20practice.%22%2C%22date%22%3A%222025-04-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00330-025-11541-0%22%2C%22ISSN%22%3A%221432-1084%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22T5DYS4X8%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Piazzola%20et%20al.%22%2C%22parsedDate%22%3A%222025-04-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPiazzola%2C%20Cecilia%2C%20Thomas%20Graillon%2C%20Nadine%20Girard%2C%20Henry%20Dufour%2C%20Thierry%20Brue%2C%20and%20Frederic%20Castinetti.%20%26%23x201C%3BDesmopressin%20Is%20a%20Safe%20and%20Effective%20Secretagogue%20to%20Replace%20Corticotropin-Releasing%20Hormone%20in%20Petrosal%20Sinus%20Sampling.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnales%20d%26%23x2019%3BEndocrinologie%26lt%3B%5C%2Fi%26gt%3B%2086%2C%20no.%202%20%28April%201%2C%202025%29%3A%20101678.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ando.2024.101678%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ando.2024.101678%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Desmopressin%20is%20a%20safe%20and%20effective%20secretagogue%20to%20replace%20corticotropin-releasing%20hormone%20in%20petrosal%20sinus%20sampling%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cecilia%22%2C%22lastName%22%3A%22Piazzola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Graillon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Girard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henry%22%2C%22lastName%22%3A%22Dufour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Brue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Castinetti%22%7D%5D%2C%22abstractNote%22%3A%22Purpose%5CnBilateral%20inferior%20petrosal%20sinus%20sampling%20%28BIPSS%29%20with%20corticotropin-releasing%20hormone%20%28CRH%29%20was%20the%20gold%20standard%20for%20distinguishing%20Cushing%20disease%20%28CD%29%20from%20ectopic%20ACTH%20secretion%20%28EAS%29.%20CRH%2C%20however%2C%20is%20no%20longer%20available.%5CnObjective%5CnTo%20assess%20the%20reliability%20of%20BIPSS%20with%20desmopressin%20to%20differentiate%20CD%20from%20EAS.%5CnMethods%5CnA%20retrospective%20study%20included%20patients%20who%20underwent%20BIPSS%20with%20desmopressin%20for%20ACTH-dependent%20hypercortisolism%2C%20with%20the%20whole%20diagnostic%20procedure%20in%20a%20single%20center.%5CnResults%5CnFifty-eight%20patients%20with%20confirmed%20etiological%20diagnosis%20were%20included%3A%2051%20CD%2C%207%20EAS.%20Forty-three%20CD%20patients%20%2884.3%25%29%20had%20post-stimulation%20ratio%20%5Cu22652%20before%20stimulation%20and%206%20of%20the%20other%208%20%2875%25%29%20had%20a%20ratio%20%5Cu22653.%20All%20EAS%20patients%20were%20correctly%20diagnosed%20before%20and%20after%20stimulation.%20Sensitivity%20was%2084.3%25%20before%20stimulation%20and%2092.2%25%20combining%20pre-%20and%20post-stimulation%20results%3B%20specificity%20reached%20100%25.%20A%20ROC%20curve%20established%20optimal%20thresholds%20at%201.4%20before%20stimulation%20and%201.7%20after.%5CnConclusion%5CnDesmopressin%20is%20a%20good%20substitute%20for%20CRH%2C%20correcting%20diagnosis%20compared%20to%20baseline%20BIPSS%20in%2012%25%20of%20cases.%22%2C%22date%22%3A%222025-04-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ando.2024.101678%22%2C%22ISSN%22%3A%220003-4266%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0003426624007613%22%2C%22collections%22%3A%5B%22W98NEAUQ%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A12Z%22%7D%7D%2C%7B%22key%22%3A%2222FKLIQY%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bartolomei%20et%20al.%22%2C%22parsedDate%22%3A%222025-03-29%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBartolomei%2C%20F.%2C%20J.%20Makhalova%2C%20J.%20Benoit%2C%20and%20S.%20Lagarde.%20%26%23x201C%3BThe%20Different%20Subtypes%20of%20Temporal%20Lobe%20Seizures%20Networks.%26%23x201D%3B%20%26lt%3Bi%26gt%3BRevue%20Neurologique%26lt%3B%5C%2Fi%26gt%3B%2C%20March%2029%2C%202025%2C%20S0035-3787%2825%2900485-0.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.neurol.2025.03.004%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.neurol.2025.03.004%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20different%20subtypes%20of%20temporal%20lobe%20seizures%20networks%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Bartolomei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Makhalova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Benoit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Lagarde%22%7D%5D%2C%22abstractNote%22%3A%22Temporal%20lobe%20epilepsies%20%28TLEs%29%20are%20among%20the%20forms%20of%20epilepsy%20most%20frequently%20encountered%20in%20surgical%20evaluations%2C%20characterized%20by%20a%20wide%20range%20of%20anatomical%2C%20functional%2C%20and%20electroclinical%20subtypes.%20Traditional%20classifications%2C%20such%20as%20mesial%20and%20lateral%20TLE%2C%20have%20been%20broadened%20by%20advances%20in%20stereoelectroencephalography%20%28SEEG%29%2C%20revealing%20more%20complex%20forms%20such%20as%20mesio-lateral%20and%20temporal-plus%20seizures.%20These%20findings%20support%20the%20concept%20of%20epileptogenic%20networks%2C%20emphasizing%20interconnected%20regions%20rather%20than%20isolated%20focal%20areas%20in%20the%20genesis%20of%20seizures.%20Quantitative%20tools%2C%20such%20as%20the%20epileptogenicity%20index%20%28EI%29%2C%20are%20improving%20the%20accuracy%20of%20SEEG%20interpretation%2C%20which%20is%20closely%20correlated%20with%20surgical%20results.%20Temporal-plus%20epilepsies%2C%20in%20particular%2C%20require%20full%20SEEG%20exploration%20due%20to%20their%20broader%20involvement%20in%20the%20network%2C%20necessitating%20tailored%20surgical%20approaches.%20A%20better%20understanding%20of%20TLEs%20subtypes%20and%20epileptogenic%20networks%20is%20an%20essential%20basis%20for%20advancing%20minimally%20invasive%20surgical%20techniques%2C%20including%20laser%20interstitial%20thermal%20therapy%20%28LITT%29%20and%20neuromodulation.%20These%20methods%20rely%20on%20the%20precise%20localization%20of%20epileptogenic%20networks.%20This%20network-based%20framework%20represents%20an%20important%20step%20towards%20optimizing%20surgical%20outcomes%20and%20advancing%20personalized%20epilepsy%20care.%22%2C%22date%22%3A%222025-03-29%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.neurol.2025.03.004%22%2C%22ISSN%22%3A%220035-3787%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RMECNPE%22%5D%2C%22dateModified%22%3A%222025-04-01T09%3A34%3A42Z%22%7D%7D%2C%7B%22key%22%3A%224ELVJV2L%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Barrit%20et%20al.%22%2C%22parsedDate%22%3A%222025-03-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBarrit%2C%20Sami%2C%20Nathan%20Torcida%2C%20Aurelien%20Mazeraud%2C%20Sebastien%20Boulogne%2C%20Jeanne%20Benoit%2C%20Timoth%26%23xE9%3Be%20Carette%2C%20Thibault%20Carron%2C%20et%20al.%20%26%23x201C%3BSpecialized%20Large%20Language%20Model%20Outperforms%20Neurologists%20at%20Complex%20Diagnosis%20in%20Blinded%20Case-Based%20Evaluation.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBrain%20Sciences%26lt%3B%5C%2Fi%26gt%3B%2015%2C%20no.%204%20%28March%2027%2C%202025%29%3A%20347.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fbrainsci15040347%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fbrainsci15040347%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Specialized%20Large%20Language%20Model%20Outperforms%20Neurologists%20at%20Complex%20Diagnosis%20in%20Blinded%20Case-Based%20Evaluation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sami%22%2C%22lastName%22%3A%22Barrit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathan%22%2C%22lastName%22%3A%22Torcida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelien%22%2C%22lastName%22%3A%22Mazeraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastien%22%2C%22lastName%22%3A%22Boulogne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeanne%22%2C%22lastName%22%3A%22Benoit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timoth%5Cu00e9e%22%2C%22lastName%22%3A%22Carette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Carron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertil%22%2C%22lastName%22%3A%22Delsaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Diab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Kermorvant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sofia%22%2C%22lastName%22%3A%22Maldonado%20Slootjes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Redon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Robin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sofiene%22%2C%22lastName%22%3A%22Hadidane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Harlay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vito%22%2C%22lastName%22%3A%22Tota%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tanguy%22%2C%22lastName%22%3A%22Madec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Niset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mejdeddine%22%2C%22lastName%22%3A%22Al%20Barajraji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20R.%22%2C%22lastName%22%3A%22Madsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%22%2C%22lastName%22%3A%22El%20Hadwe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Massager%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanislas%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Carron%22%7D%5D%2C%22abstractNote%22%3A%22Background%5C%2FObjectives%3A%20Artificial%20intelligence%20%28AI%29%2C%20particularly%20large%20language%20models%20%28LLMs%29%2C%20has%20demonstrated%20versatility%20in%20various%20applications%20but%20faces%20challenges%20in%20specialized%20domains%20like%20neurology.%20This%20study%20evaluates%20a%20specialized%20LLM%26%23039%3Bs%20capability%20and%20trustworthiness%20in%20complex%20neurological%20diagnosis%2C%20comparing%20its%20performance%20to%20neurologists%20in%20simulated%20clinical%20settings.%20Methods%3A%20We%20deployed%20GPT-4%20Turbo%20%28OpenAI%2C%20San%20Francisco%2C%20CA%2C%20US%29%20through%20Neura%20%28Sciense%2C%20New%20York%2C%20NY%2C%20US%29%2C%20an%20AI%20infrastructure%20with%20a%20dual-database%20architecture%20integrating%20%26quot%3Blong-term%20memory%26quot%3B%20and%20%26quot%3Bshort-term%20memory%26quot%3B%20components%20on%20a%20curated%20neurological%20corpus.%20Five%20representative%20clinical%20scenarios%20were%20presented%20to%2013%20neurologists%20and%20the%20AI%20system.%20Participants%20formulated%20differential%20diagnoses%20based%20on%20initial%20presentations%2C%20followed%20by%20definitive%20diagnoses%20after%20receiving%20conclusive%20clinical%20information.%20Two%20senior%20academic%20neurologists%20blindly%20evaluated%20all%20responses%2C%20while%20an%20independent%20investigator%20assessed%20the%20verifiability%20of%20AI-generated%20information.%20Results%3A%20AI%20achieved%20a%20significantly%20higher%20normalized%20score%20%2886.17%25%29%20compared%20to%20neurologists%20%2855.11%25%2C%20p%20%26lt%3B%200.001%29.%20For%20differential%20diagnosis%20questions%2C%20AI%20scored%2085%25%20versus%2046.15%25%20for%20neurologists%2C%20and%20for%20final%20diagnosis%2C%2088.24%25%20versus%2070.93%25.%20AI%20obtained%2015%20maximum%20scores%20in%20its%2020%20evaluations%20and%20responded%20in%20under%2030%20s%20compared%20to%20neurologists%26%23039%3B%20average%20of%209%20min.%20All%20AI-provided%20references%20were%20classified%20as%20relevant%20with%20no%20hallucinatory%20content%20detected.%20Conclusions%3A%20A%20specialized%20LLM%20demonstrated%20superior%20diagnostic%20performance%20compared%20to%20practicing%20neurologists%20across%20complex%20clinical%20challenges.%20This%20indicates%20that%20appropriately%20harnessed%20LLMs%20with%20curated%20knowledge%20bases%20can%20achieve%20domain-specific%20relevance%20in%20complex%20clinical%20disciplines%2C%20suggesting%20potential%20for%20AI%20as%20a%20time-efficient%20asset%20in%20clinical%20practice.%22%2C%22date%22%3A%222025-03-27%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fbrainsci15040347%22%2C%22ISSN%22%3A%222076-3425%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22NRCIS67N%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Roger%20et%20al.%22%2C%22parsedDate%22%3A%222025-03-20%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRoger%2C%20Coleen%2C%20Adele%20Lasbleiz%2C%20Hugo%20Dary%2C%20Lauriane%20Pini%2C%20Patricia%20Ancel%2C%20Anezka%20Kovarova%2C%20Marie-Pierre%20Ranjeva%2C%20et%20al.%20%26%23x201C%3BStructural%20Alterations%20of%20Individual%20Hypothalamic%20Nuclei%20in%20Young%20Females%20with%20Obesity%20and%20Anorexia%20Nervosa%3A%20An%20in%20Vivo%207-T%20MRI%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20American%20Journal%20of%20Clinical%20Nutrition%26lt%3B%5C%2Fi%26gt%3B%2C%20March%2020%2C%202025%2C%20S0002-9165%2825%2900071-1.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ajcnut.2025.02.003%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ajcnut.2025.02.003%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Structural%20alterations%20of%20individual%20hypothalamic%20nuclei%20in%20young%20females%20with%20obesity%20and%20anorexia%20nervosa%3A%20an%20in%20vivo%207-T%20MRI%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Coleen%22%2C%22lastName%22%3A%22Roger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adele%22%2C%22lastName%22%3A%22Lasbleiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Dary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauriane%22%2C%22lastName%22%3A%22Pini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Ancel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anezka%22%2C%22lastName%22%3A%22Kovarova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrice%22%2C%22lastName%22%3A%22Darmon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benedicte%22%2C%22lastName%22%3A%22Gaborit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yu%22%2C%22lastName%22%3A%22Fu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20J.%22%2C%22lastName%22%3A%22Cozzone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Dutour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20hypothalamus%20%28HT%29%20plays%20a%20crucial%20role%20in%20regulating%20eating%20behaviors.%20Disruptions%20in%20its%20function%20have%20been%20linked%20to%20the%20development%20of%20weight-related%20disorders.%20Nevertheless%2C%20its%20characterization%20remains%20a%20challenge.%5CnOBJECTIVES%3A%20We%20assessed%20the%20structural%20alterations%20of%20individual%20HT%20nuclei%20related%20to%20eating%20behaviors%20in%20patients%20with%20weight-related%20disorders%2C%20and%20their%20association%20with%20body%20mass%20index%20%28BMI%29%20and%20severity%20of%20eating%20disorders.%5CnMETHODS%3A%20Forty-four%20young%20females%20with%20normal%20weight%20%28HC%2C%20n%20%3D%2021%29%2C%20restrictive%20anorexia%20nervosa%20%28AN%2C%20n%20%3D%2013%29%2C%20and%20living%20with%20obesity%20%28OB%2C%20n%20%3D%2010%29%20were%20explored%20in%20vivo%20using%207-T%20high-resolution%20%280.6%20mm%20isotropic%20voxel%29%20T1%20quantitative%20magnetic%20resonance%20imaging%20%28MRI%29.%20Volumes%20and%20quantitative%20T1%20values%20of%20individual%20HT%20nuclei%20were%20compared%20after%20whole-brain%20normalization%20using%20nonparametric%20tests%20%28corrected%20for%20multiple%20comparisons%20for%20groups%20and%20regions%29.%20We%20investigated%20the%20parameters%20associated%20with%20BMI%20and%20eating%20disorders%2C%20such%20as%20MRI%20parameters%20of%20HT%20nuclei%2C%20ghrelin%20and%20leptin%20levels%2C%20depression%2C%20and%20anxiety%20using%20multivariate%20nonlinear%20partial%20least%20square%20%28NIPALS%29.%5CnRESULTS%3A%20Both%20AN%20and%20OB%20showed%20higher%20volumes%20of%20HT%20relative%20to%20HC%20%28Zscores%3A%200.78%20%5Cu00b1%201.06%3B%201.43%20%5Cu00b1%201.51%29.%20AN%20showed%20significantly%20higher%20volumes%20and%20T1%20values%20of%20the%20right%20paraventricular%20nucleus%20%28PaVN%29%20%28volume%20Zscore%3A%201.82%20%5Cu00b1%201.45%3B%20T1%20Zscore%3A%203.76%20%5Cu00b1%204.67%29%2C%20and%20higher%20T1%20values%20of%20the%20left%20PaVN%20%28Zscore%3A%202.25%20%5Cu00b1%202.37%29%20and%20right%20periventricular%20nuclei%20%28Zscore%3A%203.73%20%5Cu00b1%204.81%29.%20NIPALS%20models%20showed%20that%20lower%20BMI%20in%20AN%20was%20associated%20with%20structural%20alterations%20of%20the%20bilateral%20PaVN%2C%20right%20anterior%20commissure%2C%20and%20left%20fornix%20%28FX%29.%20Higher%20BMI%20in%20OB%20was%20associated%20with%20structural%20alterations%20within%20the%20right%20PaVN%2C%20bilateral%20FX%2C%20left%20posterior%20hypothalamic%20nucleus%2C%20right%20lateral%20HT%2C%20and%20right%20anterior%20hypothalamic%20area.%20Finally%2C%20the%20severity%20of%20eating%20disorders%20was%20associated%20with%20larger%20structural%20alterations%20within%20the%20bilateral%20PaVN%2C%20bilateral%20arcuate%20hypothalamic%20nuclei%2C%20right%20bed%20nucleus%20of%20stria%20terminalis%2C%20left%20medial%20preoptic%20nucleus%2C%20and%20right%20tubero-mammillary%20hypothalamic%20nucleus.%5CnCONCLUSIONS%3A%20Weight-related%20disorders%20are%20associated%20with%20significant%20micro%20and%20macrostructural%20alterations%20in%20HT%20nuclei%20involved%20in%20eating%20behaviors.%22%2C%22date%22%3A%222025-03-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ajcnut.2025.02.003%22%2C%22ISSN%22%3A%221938-3207%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22UP3H3ICX%22%2C%224ZGX55W3%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22BDR4Y4EI%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Testud%20et%20al.%22%2C%22parsedDate%22%3A%222025-03-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BTestud%2C%20Benoit%2C%20Aur%26%23xE9%3Blien%20Destruel%2C%20Thomas%20Troalen%2C%20Jean-Philippe%20Ranjeva%2C%20and%20Maxime%20Guye.%20%26%23x201C%3BReview%20of%207T%20MRI%20Imaging%20of%20Pituitary%20Microadenomas%3A%20Are%20We%20There%20Yet%3F%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeuroradiology%26lt%3B%5C%2Fi%26gt%3B%2C%20March%208%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00234-025-03554-9%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00234-025-03554-9%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Review%20of%207T%20MRI%20imaging%20of%20pituitary%20microadenomas%3A%20are%20we%20there%20yet%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Testud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lien%22%2C%22lastName%22%3A%22Destruel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Troalen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%207T%20MRI%20imaging%20of%20the%20pituitary%20gland%20is%20an%20emerging%20technique.%20The%20purpose%20of%20this%20article%20is%20to%20review%20the%20current%20status%20of%20the%207T%20MRI%20of%20the%20pituitary%20gland%2C%20particularly%20in%20the%20context%20of%20pituitary%20microadenoma%20pathology.%20We%20will%20discuss%20technical%20challenges%20and%20parallel%20transmission%20opportunities.%5CnMETHODS%3A%20Follow-up%20study%20selection%20and%20data%20extraction%20were%20performed%20following%20PRISMA%20guidelines.%20We%20focused%20on%20diagnostic%20performance%20and%20acquisition%20protocols.%20Inclusion%20criteria%20were%3A%20MRI%20imaging%20studies%20of%20pituitary%20adenoma%20at%207T.%20Exclusion%20criteria%20were%3A%20Case%20reports%20and%20reviews%3B%20studies%20which%20did%20not%20report%20MRI%20protocols%3B%20surgical%20planning%20studies%3B%20studies%20focusing%20exclusively%20on%20macroadenomas%20for%20which%20ultra-high%20magnetic%20field%20imaging%20is%20less%20decisive%20than%20microadenomas%20in%20clinical%20practice.%5CnRESULTS%3A%20Six%20studies%20were%20included.%207T%20MRI%20outperformed%201.5%20or%203T%20MRI%20for%20the%20detection%20of%20microadenomas.%20Acquisition%20protocols%20employed%20were%20heterogeneous%2C%20with%20two-dimensional%20T2-w%20and%20T1-w%20turbo%20spin-echo%20sequences%2C%20three-dimensional%20T1-w%20isotropic%20spin-echo%20and%20gradient-echo%20sequences%20%28resolution%3A%200.6%20and%200.8%5Cu00a0mm%29%2C%20and%20dynamic%20contrast-enhanced%20T1-w%20sequences.%5CnCONCLUSION%3A%207T%20MRI%20is%20a%20promising%20tool%20for%20overcoming%20the%20difficulties%20encountered%20by%20conventional%20MRI%2C%20particularly%20in%20the%20case%20of%20Cushing%20disease.%20However%2C%20there%20is%20insufficient%20data%20to%20precisely%20define%20an%20optimal%20protocol%20yet.%22%2C%22date%22%3A%222025-03-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00234-025-03554-9%22%2C%22ISSN%22%3A%221432-1920%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22UP3H3ICX%22%2C%22XTA6KS7L%22%2C%22PCMV2W5C%22%2C%22R8ARNQR7%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22MYHUPB9W%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Schilling%20et%20al.%22%2C%22parsedDate%22%3A%222025-03-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSchilling%2C%20Kurt%20G.%2C%20Francesco%20Grussu%2C%20Andrada%20Ianus%2C%20Brian%20Hansen%2C%20Amy%20F.%20D.%20Howard%2C%20Rachel%20L.%20C.%20Barrett%2C%20Manisha%20Aggarwal%2C%20et%20al.%20%26%23x201C%3BConsiderations%20and%20Recommendations%20from%20the%20ISMRM%20Diffusion%20Study%20Group%20for%20Preclinical%20Diffusion%20MRI%3A%20Part%202-Ex%20Vivo%20Imaging%3A%20Added%20Value%20and%20Acquisition.%26%23x201D%3B%20%26lt%3Bi%26gt%3BMagnetic%20Resonance%20in%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2C%20March%204%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmrm.30435%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmrm.30435%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Considerations%20and%20recommendations%20from%20the%20ISMRM%20diffusion%20study%20group%20for%20preclinical%20diffusion%20MRI%3A%20Part%202-Ex%20vivo%20imaging%3A%20Added%20value%20and%20acquisition%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kurt%20G.%22%2C%22lastName%22%3A%22Schilling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Grussu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrada%22%2C%22lastName%22%3A%22Ianus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Hansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20F.%20D.%22%2C%22lastName%22%3A%22Howard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%20L.%20C.%22%2C%22lastName%22%3A%22Barrett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manisha%22%2C%22lastName%22%3A%22Aggarwal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stijn%22%2C%22lastName%22%3A%22Michielse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatima%22%2C%22lastName%22%3A%22Nasrallah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Warda%22%2C%22lastName%22%3A%22Syeda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nian%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jelle%22%2C%22lastName%22%3A%22Veraart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alard%22%2C%22lastName%22%3A%22Roebroeck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20F.%22%2C%22lastName%22%3A%22Bagdasarian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cornelius%22%2C%22lastName%22%3A%22Eichner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Farshid%22%2C%22lastName%22%3A%22Sepehrband%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Zimmermann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucas%22%2C%22lastName%22%3A%22Soustelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christien%22%2C%22lastName%22%3A%22Bowman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%20C.%22%2C%22lastName%22%3A%22Tendler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreea%22%2C%22lastName%22%3A%22Hertanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ben%22%2C%22lastName%22%3A%22Jeurissen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marleen%22%2C%22lastName%22%3A%22Verhoye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucio%22%2C%22lastName%22%3A%22Frydman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yohan%22%2C%22lastName%22%3A%22van%20de%20Looij%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Hike%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeff%20F.%22%2C%22lastName%22%3A%22Dunn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karla%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bennett%20A.%22%2C%22lastName%22%3A%22Landman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Noam%22%2C%22lastName%22%3A%22Shemesh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22McKinnon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shawna%22%2C%22lastName%22%3A%22Farquharson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flavio%22%2C%22lastName%22%3A%22Dell%27Acqua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlo%22%2C%22lastName%22%3A%22Pierpaoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivana%22%2C%22lastName%22%3A%22Drobnjak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Leemans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%20D.%22%2C%22lastName%22%3A%22Harkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Descoteaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Duan%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hao%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%20D.%22%2C%22lastName%22%3A%22Santin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%20C.%22%2C%22lastName%22%3A%22Grant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andre%22%2C%22lastName%22%3A%22Obenaus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gene%20S.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dan%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Le%20Bihan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%20J.%22%2C%22lastName%22%3A%22Blackband%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luisa%22%2C%22lastName%22%3A%22Ciobanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Els%22%2C%22lastName%22%3A%22Fieremans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruiliang%22%2C%22lastName%22%3A%22Bai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Trygve%20B.%22%2C%22lastName%22%3A%22Leergaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jiangyang%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tim%20B.%22%2C%22lastName%22%3A%22Dyrby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20Allan%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Cohen-Adad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20D.%22%2C%22lastName%22%3A%22Budde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ileana%20O.%22%2C%22lastName%22%3A%22Jelescu%22%7D%5D%2C%22abstractNote%22%3A%22The%20value%20of%20preclinical%20diffusion%20MRI%20%28dMRI%29%20is%20substantial.%20While%20dMRI%20enables%20in%20vivo%20non-invasive%20characterization%20of%20tissue%2C%20ex%20vivo%5Cu00a0dMRI%20is%20increasingly%20being%20used%20to%20probe%20tissue%20microstructure%20and%20brain%20connectivity.%20Ex%20vivo%20dMRI%20has%20several%20experimental%20advantages%20including%20higher%20SNR%20and%20spatial%20resolution%20compared%20to%20in%20vivo%20studies%2C%20and%20enabling%20more%20advanced%20diffusion%20contrasts%20for%20improved%20microstructure%20and%20connectivity%20characterization.%20Another%20major%20advantage%20of%20ex%20vivo%20dMRI%20is%20the%20direct%20comparison%20with%20histological%20data%2C%20as%20a%20crucial%20methodological%20validation.%20However%2C%20there%20are%20a%20number%20of%20considerations%20that%20must%20be%20made%20when%20performing%20ex%20vivo%20experiments.%20The%20steps%20from%20tissue%20preparation%2C%20image%20acquisition%20and%20processing%2C%20and%20interpretation%20of%20results%20are%20complex%2C%20with%20many%20decisions%20that%20not%20only%20differ%20dramatically%20from%20in%20vivo%20imaging%20of%20small%20animals%2C%20but%20ultimately%20affect%20what%20questions%20can%20be%20answered%20using%20the%20data.%20This%20work%20represents%20%26quot%3BPart%202%26quot%3B%20of%20a%20three-part%20series%20of%20recommendations%20and%20considerations%20for%20preclinical%20dMRI.%20We%20describe%20best%20practices%20for%20dMRI%20of%20ex%20vivo%20tissue%2C%20with%20a%20focus%20on%20the%20value%20that%20ex%20vivo%20imaging%20adds%20to%20the%20field%20of%20dMRI%20and%20considerations%20in%20ex%20vivo%20image%20acquisition.%20We%20first%20give%20general%20considerations%20and%20foundational%20knowledge%20that%20must%20be%20considered%20when%20designing%20experiments.%20We%20briefly%20describe%20differences%20in%20specimens%20and%20models%20and%20discuss%20why%20some%20may%20be%20more%20or%20less%20appropriate%20for%20different%20studies.%20We%20then%20give%20guidelines%20for%20ex%20vivo%20protocols%2C%20including%20tissue%20fixation%2C%20sample%20preparation%2C%20and%20MR%20scanning.%20In%20each%20section%2C%20we%20attempt%20to%20provide%20guidelines%20and%20recommendations%2C%20but%20also%20highlight%20areas%20for%20which%20no%20guidelines%20exist%20%28and%20why%29%2C%20and%20where%20future%20work%20should%20lie.%20An%20overarching%20goal%20herein%20is%20to%20enhance%20the%20rigor%20and%20reproducibility%20of%20ex%20vivo%20dMRI%20acquisitions%20and%20analyses%2C%20and%20thereby%20advance%20biomedical%20knowledge.%22%2C%22date%22%3A%222025-03-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fmrm.30435%22%2C%22ISSN%22%3A%221522-2594%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22YXS7B6S7%22%2C%22M2AY8I5W%22%5D%2C%22dateModified%22%3A%222025-03-11T08%3A47%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22J9GHBINL%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guttieres%20et%20al.%22%2C%22parsedDate%22%3A%222025-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuttieres%2C%20Laura%2C%20Lea%20Vannelli%2C%20Sarah%20Demortiere%2C%20Marine%20Perriguey%2C%20Maya%20Elziere%2C%20Pierre%20Durozard%2C%20Clemence%20Boutiere%2C%20et%20al.%20%26%23x201C%3BFluorescein%20Angiography%20as%20a%20Surrogate%20Marker%20of%20Disease%20Activity%20in%20Susac%20Syndrome.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2012%2C%20no.%202%20%28March%202025%29%3A%20e200379.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200379%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200379%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Fluorescein%20Angiography%20as%20a%20Surrogate%20Marker%20of%20Disease%20Activity%20in%20Susac%20Syndrome%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Guttieres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lea%22%2C%22lastName%22%3A%22Vannelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maya%22%2C%22lastName%22%3A%22Elziere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Stolowy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20To%20evaluate%20the%20sensitivity%20of%20fluorescein%20angiography%20%28FA%29%20in%20detecting%20disease%20activity%20in%20Susac%20syndrome.%5CnMETHODS%3A%20We%20conducted%20a%20blinded%20analysis%20of%20all%20FA%2C%20brain%20MRI%2C%20and%20audiogram%20examinations%20performed%20throughout%20the%20follow-up%20of%20patients%20with%20Susac%20syndrome.%5CnRESULTS%3A%20A%20total%20of%2079%20FA%20examinations%2C%2085%20brain%20MRI%20scans%2C%20and%2049%20audiograms%20were%20analyzed%20from%209%20patients%20followed%20for%20a%20mean%20%28SD%29%20period%20of%206%20%284%29%20years.%20Disease%20activity%20was%20detected%20in%2041.5%25%20of%20FA%20examinations%2C%2010.5%25%20of%20MRI%20scans%2C%20and%2025%25%20of%20audiograms%20%28FA%20vs%20MRI%2C%20p%20%26lt%3B%200.0001%3B%20FA%20vs%20audiogram%2C%20p%20%3D%200.06%3B%20audiogram%20vs%20MRI%2C%20p%20%26lt%3B%200.05%29.%20Within%203%20months%20of%20clinical%20relapses%2C%20activity%20was%20observed%20in%2057%25%2C%2024%25%2C%20and%2027%25%20of%20FA%2C%20MRI%2C%20and%20audiogram%20examinations%2C%20respectively%20%28FA%20vs%20MRI%2C%20p%20%26lt%3B%200.05%3B%20FA%20vs%20audiogram%2C%20p%20%3D%200.09%3B%20audiogram%20vs%20MRI%2C%20p%20%3D%201%29.%20Quantitative%20analysis%20of%20FA%20showed%20a%20mean%20%28SD%29%20of%202.5%20%282.5%29%20leakages%20%28both%20eyes%29%20during%20relapses%20compared%20with%201.2%20%281.4%29%20during%20remission%20%28p%20%26lt%3B%200.05%29.%5CnDISCUSSION%3A%20FA%2C%20particularly%20arterial%20leakage%2C%20demonstrated%20the%20highest%20sensitivity%20in%20detecting%20disease%20activity%20and%20may%20be%20a%20valuable%20tool%20for%20treatment%20management%20in%20Susac%20syndrome.%20Future%20studies%20with%20larger%20samples%20should%20aim%20to%20identify%20the%20optimal%20threshold%20of%20FA%20changes%20associated%20with%20an%20increased%20risk%20of%20relapse.%22%2C%22date%22%3A%222025-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200379%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%5D%2C%22dateModified%22%3A%222025-12-01T09%3A50%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22PR8HZX9E%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Villacieros-%5Cu00c1lvarez%20et%20al.%22%2C%22parsedDate%22%3A%222025-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVillacieros-%26%23xC1%3Blvarez%2C%20Javier%2C%20Carmen%20Espejo%2C%20Georgina%20Arrambide%2C%20Alessandro%20Dinoto%2C%20Patricia%20Mulero%2C%20Laura%20Rubio-Flores%2C%20Pablo%20Nieto%2C%20et%20al.%20%26%23x201C%3BProfile%20and%20Usefulness%20of%20Serum%20Cytokines%20to%20Predict%20Prognosis%20in%20Myelin%20Oligodendrocyte%20Glycoprotein%20Antibody-Associated%20Disease.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2012%2C%20no.%202%20%28March%202025%29%3A%20e200362.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200362%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200362%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Profile%20and%20Usefulness%20of%20Serum%20Cytokines%20to%20Predict%20Prognosis%20in%20Myelin%20Oligodendrocyte%20Glycoprotein%20Antibody-Associated%20Disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javier%22%2C%22lastName%22%3A%22Villacieros-%5Cu00c1lvarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carmen%22%2C%22lastName%22%3A%22Espejo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georgina%22%2C%22lastName%22%3A%22Arrambide%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandro%22%2C%22lastName%22%3A%22Dinoto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Mulero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Rubio-Flores%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%22%2C%22lastName%22%3A%22Nieto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carmen%22%2C%22lastName%22%3A%22Alcal%5Cu00e1%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20E.%22%2C%22lastName%22%3A%22Meca-Lallana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Millan-Pascual%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%22%2C%22lastName%22%3A%22Mart%5Cu00ednez-Garc%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raphael%22%2C%22lastName%22%3A%22Bernard-Valnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22In%5Cu00e9s%22%2C%22lastName%22%3A%22Gonz%5Cu00e1lez-Su%5Cu00e1rez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%5Cu00edda%22%2C%22lastName%22%3A%22Orviz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%22%2C%22lastName%22%3A%22T%5Cu00e9llez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Navarro%20Cant%5Cu00f3%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Presas-Rodr%5Cu00edguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sergio%22%2C%22lastName%22%3A%22Mart%5Cu00ednez-Y%5Cu00e9lamos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Pablo%22%2C%22lastName%22%3A%22Cuello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%22%2C%22lastName%22%3A%22Alonso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%22%2C%22lastName%22%3A%22Pi%5Cu00f1ar%20Morales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gary%22%2C%22lastName%22%3A%22%5Cu00c1lvarez%20Bravo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lakhdar%22%2C%22lastName%22%3A%22Benyahya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Trouillet-Assant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Dyon-Tafan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Froment%20Tilikete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Kerschen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c0lex%22%2C%22lastName%22%3A%22Rovira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Auger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Montalban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%22%2C%22lastName%22%3A%22Tintore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Mariotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Cobo-Calvo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20To%20characterize%20the%20serum%20cytokine%20profile%20in%20myelin%20oligodendrocyte%20glycoprotein%20antibody-associated%20disease%20%28MOGAD%29%20at%20onset%20and%20during%20follow-up%20and%20assess%20their%20utility%20for%20predicting%20relapses%20and%20disability.%5CnMETHODS%3A%20This%20retrospective%20multicentric%20cohort%20study%20included%20patients%20aged%2016%20years%20and%20older%20meeting%20MOGAD%202023%20criteria%2C%20with%20serum%20samples%20collected%20at%20baseline%20%28%5Cu22643%20months%20from%20disease%20onset%29%20and%20follow-up%20%28%5Cu22656%20months%20from%20the%20baseline%29%2C%20and%20age-matched%20and%20time%20to%20sampling-matched%20patients%20with%20multiple%20sclerosis%20%28MS%29.%20Eleven%20cytokines%20were%20assessed%20using%20the%20ELLA%20system.%20Data%20comparisons%20and%20statistical%20analyses%20between%20cytokine%20levels%20and%20clinical%20outcomes%20were%20performed.%5CnRESULTS%3A%20Eighty-eight%20patients%20with%20MOGAD%20and%2032%20patients%20with%20MS%20were%20included.%20Patients%20with%20MOGAD%20showed%20higher%20IL6%20%28p%20%3D%200.036%29%2C%20IL8%20%28p%20%3D%200.012%29%2C%20and%20IL18%20%28p%20%3D%200.026%29%20baseline%20levels%20compared%20with%20those%20with%20MS%2C%20in%20non-optic%20neuritis%20%28ON%29%20presentations.%20BAFF%20values%20increased%20over%20time%2C%20especially%20in%20patients%20with%20MOGAD%20treated%20with%20anti-CD20%20%28p%20%3D%200.002%29.%20Baseline%20BAFF%2C%20CXCL10%2C%20IL10%2C%20and%20IL8%20levels%20correlated%20with%20disease%20severity%20at%20MOGAD%20onset%20%28all%20p%20%26lt%3B%200.05%29.%20Finally%2C%20higher%20baseline%20BAFF%20levels%20predicted%20lower%20risk%20of%20relapses%20%28hazard%20ratio%200.41%20%5B0.19%3B%200.89%5D%2C%20p%20%3D%200.024%29.%5CnDISCUSSION%3A%20This%20study%20suggests%20a%20proinflammatory%20Th17-dominant%20profile%20in%20non-ON%20MOGAD%20patients%2C%20with%20a%20novel%20finding%20of%20a%20potential%20protective%20role%20of%20BAFF%20on%20relapses.%20These%20results%20shed%20new%20light%20on%20the%20pathogenesis%20of%20MOGAD%2C%20potentially%20guiding%20therapeutic%20decisions.%22%2C%22date%22%3A%222025-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200362%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22ZA2SCPEV%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mainguy%20et%20al.%22%2C%22parsedDate%22%3A%222025-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMainguy%2C%20Marie%2C%20Romain%20Casey%2C%20Sandra%20Vukusic%2C%20Christine%20Lebrun-Frenay%2C%20Eric%20Berger%2C%20Anne%20Kerbrat%2C%20Abdullatif%20Al%20Khedr%2C%20et%20al.%20%26%23x201C%3BAssessing%20the%20Risk%20of%20Relapse%20After%20In%20Vitro%20Fertilization%20in%20Women%20With%20Multiple%20Sclerosis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2012%2C%20no.%202%20%28March%202025%29%3A%20e200371.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200371%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200371%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Assessing%20the%20Risk%20of%20Relapse%20After%20In%20Vitro%20Fertilization%20in%20Women%20With%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Mainguy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al%20Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ines%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%20M.%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Manchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Sarov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Older%20studies%20reported%20an%20increased%20risk%20of%20relapse%20after%20in%20vitro%20fertilization%20%28IVF%29%20in%20women%20with%20multiple%20sclerosis%20%28MS%29%2C%20which%20has%20not%20been%20confirmed%20by%20more%20recent%20works.%20All%20these%20studies%20had%20several%20limitations%2C%20such%20as%20small%20sample%20sizes%2C%20absence%20of%20a%20control%20population%2C%20or%20lack%20of%20neurologic%20validation%20of%20the%20relapses.%20The%20aim%20of%20this%20study%20was%20to%20determine%20the%20risk%20of%20relapse%20after%20IVF%20in%20women%20with%20MS.%5CnMETHODS%3A%20This%20retrospective%20cohort%20study%20included%20all%20women%20with%20MS%20who%20underwent%20IVF%20between%202009%20and%202019%20and%20a%20control%20group%20of%20women%20with%20MS%20who%20did%20not%20undergo%20IVF%20matched%20on%20age%2C%20MS%20duration%2C%20number%20of%20relapses%2C%20and%20MS-specific%20treatments%20in%20the%20previous%20year.%20Data%20on%20MS%20%28disease%20duration%2C%20treatments%2C%20and%20relapses%29%20were%20from%20the%20French%20MS%20Registry%20%28OFSEP%29%2C%20whereas%20data%20on%20IVF%20%28number%20of%20procedures%2C%20stimulation%20protocol%20type%2C%20and%20outcomes%29%20were%20from%20the%20French%20national%20health%20insurance%20database.%20For%20this%2C%20the%202%20databases%20were%20linked%20by%20indirect%20matching.%5CnRESULTS%3A%20In%20total%2C%20115%20women%20with%20MS%20underwent%20199%20IVF%20procedures%20%28mean%20age%20at%20first%20IVF%3A%2033.9%20%5Cu00b1%204.0%20years%3B%2045.2%25%20had%20%5Cu22652%20IVF%20procedures%29%2C%20and%20175%20IVFs%20%2888.0%25%29%20could%20be%20matched%20to%20specific%20patients.%20The%20risk%20of%20relapse%20in%20the%203%20months%20after%20index%20date%20was%20the%20same%20in%20both%20IVF%20group%20and%20control%20group%20%280.06%20relapse%20per%20patient-year%29%2C%20as%20confirmed%20also%20by%20the%20before-after%20analysis%20in%20the%20IVF%20group%20%280.06%20vs%200.08%29.%5CnDISCUSSION%3A%20This%20study%2C%20using%20a%2010-year%20clinical%20and%20administrative%20dataset%2C%20did%20not%20find%20any%20increased%20risk%20of%20relapse%20after%20IVF.%20The%20maintenance%20of%20disease-modifying%20therapies%20until%20IVF%20was%20a%20determining%20factor%20in%20reducing%20the%20risk%20of%20relapse.%22%2C%22date%22%3A%222025-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200371%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22LK9RGRCC%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Schilling%20et%20al.%22%2C%22parsedDate%22%3A%222025-02-26%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSchilling%2C%20Kurt%20G.%2C%20Amy%20F.%20D.%20Howard%2C%20Francesco%20Grussu%2C%20Andrada%20Ianus%2C%20Brian%20Hansen%2C%20Rachel%20L.%20C.%20Barrett%2C%20Manisha%20Aggarwal%2C%20et%20al.%20%26%23x201C%3BConsiderations%20and%20Recommendations%20from%20the%20ISMRM%20Diffusion%20Study%20Group%20for%20Preclinical%20Diffusion%20MRI%3A%20Part%203-Ex%20Vivo%20Imaging%3A%20Data%20Processing%2C%20Comparisons%20with%20Microscopy%2C%20and%20Tractography.%26%23x201D%3B%20%26lt%3Bi%26gt%3BMagnetic%20Resonance%20in%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2C%20February%2026%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmrm.30424%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmrm.30424%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Considerations%20and%20recommendations%20from%20the%20ISMRM%20Diffusion%20Study%20Group%20for%20preclinical%20diffusion%20MRI%3A%20Part%203-Ex%20vivo%20imaging%3A%20Data%20processing%2C%20comparisons%20with%20microscopy%2C%20and%20tractography%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kurt%20G.%22%2C%22lastName%22%3A%22Schilling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20F.%20D.%22%2C%22lastName%22%3A%22Howard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Grussu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrada%22%2C%22lastName%22%3A%22Ianus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Hansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%20L.%20C.%22%2C%22lastName%22%3A%22Barrett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manisha%22%2C%22lastName%22%3A%22Aggarwal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stijn%22%2C%22lastName%22%3A%22Michielse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatima%22%2C%22lastName%22%3A%22Nasrallah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Warda%22%2C%22lastName%22%3A%22Syeda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nian%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jelle%22%2C%22lastName%22%3A%22Veraart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alard%22%2C%22lastName%22%3A%22Roebroeck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20F.%22%2C%22lastName%22%3A%22Bagdasarian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cornelius%22%2C%22lastName%22%3A%22Eichner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Farshid%22%2C%22lastName%22%3A%22Sepehrband%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Zimmermann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucas%22%2C%22lastName%22%3A%22Soustelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christien%22%2C%22lastName%22%3A%22Bowman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%20C.%22%2C%22lastName%22%3A%22Tendler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreea%22%2C%22lastName%22%3A%22Hertanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ben%22%2C%22lastName%22%3A%22Jeurissen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marleen%22%2C%22lastName%22%3A%22Verhoye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucio%22%2C%22lastName%22%3A%22Frydman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yohan%22%2C%22lastName%22%3A%22van%20de%20Looij%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Hike%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeff%20F.%22%2C%22lastName%22%3A%22Dunn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karla%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bennett%20A.%22%2C%22lastName%22%3A%22Landman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Noam%22%2C%22lastName%22%3A%22Shemesh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22McKinnon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shawna%22%2C%22lastName%22%3A%22Farquharson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flavio%22%2C%22lastName%22%3A%22Dell%27Acqua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlo%22%2C%22lastName%22%3A%22Pierpaoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivana%22%2C%22lastName%22%3A%22Drobnjak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Leemans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%20D.%22%2C%22lastName%22%3A%22Harkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Descoteaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Duan%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hao%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%20D.%22%2C%22lastName%22%3A%22Santin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%20C.%22%2C%22lastName%22%3A%22Grant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andre%22%2C%22lastName%22%3A%22Obenaus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gene%20S.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dan%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Le%20Bihan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%20J.%22%2C%22lastName%22%3A%22Blackband%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luisa%22%2C%22lastName%22%3A%22Ciobanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Els%22%2C%22lastName%22%3A%22Fieremans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruiliang%22%2C%22lastName%22%3A%22Bai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Trygve%20B.%22%2C%22lastName%22%3A%22Leergaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jiangyang%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tim%20B.%22%2C%22lastName%22%3A%22Dyrby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20Allan%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Cohen-Adad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20D.%22%2C%22lastName%22%3A%22Budde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ileana%20O.%22%2C%22lastName%22%3A%22Jelescu%22%7D%5D%2C%22abstractNote%22%3A%22Preclinical%20diffusion%20MRI%20%28dMRI%29%20has%20proven%20value%20in%20methods%20development%20and%20validation%2C%20characterizing%20the%20biological%20basis%20of%20diffusion%20phenomena%2C%20and%20comparative%20anatomy.%20While%20dMRI%20enables%20in%20vivo%20non-invasive%20characterization%20of%20tissue%2C%20ex%20vivo%20dMRI%20is%20increasingly%20being%20used%20to%20probe%20tissue%20microstructure%20and%20brain%20connectivity.%20Ex%20vivo%20dMRI%20has%20several%20experimental%20advantages%20that%20facilitate%20high%20spatial%20resolution%20and%20high%20SNR%20images%2C%20cutting-edge%20diffusion%20contrasts%2C%20and%20direct%20comparison%20with%20histological%20data%20as%20a%20methodological%20validation.%20However%2C%20there%20are%20a%20number%20of%20considerations%20that%20must%20be%20made%20when%20performing%20ex%20vivo%20experiments.%20The%20steps%20from%20tissue%20preparation%2C%20image%20acquisition%20and%20processing%2C%20and%20interpretation%20of%20results%20are%20complex%2C%20with%20many%20decisions%20that%20not%20only%20differ%20dramatically%20from%20in%20vivo%20imaging%20of%20small%20animals%2C%20but%20ultimately%20affect%20what%20questions%20can%20be%20answered%20using%20the%20data.%20This%20work%20concludes%20a%20three-part%20series%20of%20recommendations%20and%20considerations%20for%20preclinical%20dMRI.%20Herein%2C%20we%20describe%20best%20practices%20for%20dMRI%20of%20ex%20vivo%20tissue%2C%20with%20a%20focus%20on%20image%20pre-processing%2C%20data%20processing%2C%20and%20comparisons%20with%20microscopy.%20In%20each%20section%2C%20we%20attempt%20to%20provide%20guidelines%20and%20recommendations%20but%20also%20highlight%20areas%20for%20which%20no%20guidelines%20exist%20%28and%20why%29%2C%20and%20where%20future%20work%20should%20lie.%20We%20end%20by%20providing%20guidelines%20on%20code%20sharing%20and%20data%20sharing%20and%20point%20toward%20open-source%20software%20and%20databases%20specific%20to%20small%20animal%20and%20ex%20vivo%20imaging.%22%2C%22date%22%3A%222025-02-26%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fmrm.30424%22%2C%22ISSN%22%3A%221522-2594%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22YXS7B6S7%22%2C%22M2AY8I5W%22%5D%2C%22dateModified%22%3A%222025-03-11T08%3A47%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22AYCBN44T%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jelescu%20et%20al.%22%2C%22parsedDate%22%3A%222025-02-26%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BJelescu%2C%20Ileana%20O.%2C%20Francesco%20Grussu%2C%20Andrada%20Ianus%2C%20Brian%20Hansen%2C%20Rachel%20L.%20C.%20Barrett%2C%20Manisha%20Aggarwal%2C%20Stijn%20Michielse%2C%20et%20al.%20%26%23x201C%3BConsiderations%20and%20Recommendations%20from%20the%20ISMRM%20Diffusion%20Study%20Group%20for%20Preclinical%20Diffusion%20MRI%3A%20Part%201%3A%20In%20Vivo%20Small-Animal%20Imaging.%26%23x201D%3B%20%26lt%3Bi%26gt%3BMagnetic%20Resonance%20in%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2C%20February%2026%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmrm.30429%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmrm.30429%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Considerations%20and%20recommendations%20from%20the%20ISMRM%20diffusion%20study%20group%20for%20preclinical%20diffusion%20MRI%3A%20Part%201%3A%20In%20vivo%20small-animal%20imaging%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ileana%20O.%22%2C%22lastName%22%3A%22Jelescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Grussu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrada%22%2C%22lastName%22%3A%22Ianus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Hansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%20L.%20C.%22%2C%22lastName%22%3A%22Barrett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manisha%22%2C%22lastName%22%3A%22Aggarwal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stijn%22%2C%22lastName%22%3A%22Michielse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatima%22%2C%22lastName%22%3A%22Nasrallah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Warda%22%2C%22lastName%22%3A%22Syeda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nian%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jelle%22%2C%22lastName%22%3A%22Veraart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alard%22%2C%22lastName%22%3A%22Roebroeck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20F.%22%2C%22lastName%22%3A%22Bagdasarian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cornelius%22%2C%22lastName%22%3A%22Eichner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Farshid%22%2C%22lastName%22%3A%22Sepehrband%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Zimmermann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucas%22%2C%22lastName%22%3A%22Soustelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christien%22%2C%22lastName%22%3A%22Bowman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%20C.%22%2C%22lastName%22%3A%22Tendler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreea%22%2C%22lastName%22%3A%22Hertanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ben%22%2C%22lastName%22%3A%22Jeurissen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marleen%22%2C%22lastName%22%3A%22Verhoye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucio%22%2C%22lastName%22%3A%22Frydman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yohan%22%2C%22lastName%22%3A%22van%20de%20Looij%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Hike%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeff%20F.%22%2C%22lastName%22%3A%22Dunn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karla%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bennett%20A.%22%2C%22lastName%22%3A%22Landman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Noam%22%2C%22lastName%22%3A%22Shemesh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22McKinnon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shawna%22%2C%22lastName%22%3A%22Farquharson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flavio%22%2C%22lastName%22%3A%22Dell%27Acqua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlo%22%2C%22lastName%22%3A%22Pierpaoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivana%22%2C%22lastName%22%3A%22Drobnjak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Leemans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%20D.%22%2C%22lastName%22%3A%22Harkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Descoteaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Duan%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hao%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%20D.%22%2C%22lastName%22%3A%22Santin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%20C.%22%2C%22lastName%22%3A%22Grant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andre%22%2C%22lastName%22%3A%22Obenaus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gene%20S.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dan%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Le%20Bihan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%20J.%22%2C%22lastName%22%3A%22Blackband%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luisa%22%2C%22lastName%22%3A%22Ciobanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Els%22%2C%22lastName%22%3A%22Fieremans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruiliang%22%2C%22lastName%22%3A%22Bai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Trygve%20B.%22%2C%22lastName%22%3A%22Leergaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jiangyang%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tim%20B.%22%2C%22lastName%22%3A%22Dyrby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20Allan%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Cohen-Adad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20D.%22%2C%22lastName%22%3A%22Budde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kurt%20G.%22%2C%22lastName%22%3A%22Schilling%22%7D%5D%2C%22abstractNote%22%3A%22Small-animal%20diffusion%20MRI%20%28dMRI%29%20has%20been%20used%20for%20methodological%20development%20and%20validation%2C%20characterizing%20the%20biological%20basis%20of%20diffusion%20phenomena%2C%20and%20comparative%20anatomy.%20The%20steps%20from%20animal%20setup%20and%20monitoring%2C%20to%20acquisition%2C%20analysis%2C%20and%20interpretation%20are%20complex%2C%20with%20many%20decisions%20that%20may%20ultimately%20affect%20what%20questions%20can%20be%20answered%20using%20the%20resultant%20data.%20This%20work%20aims%20to%20present%20selected%20considerations%20and%20recommendations%20from%20the%20diffusion%20community%20on%20best%20practices%20for%20preclinical%20dMRI%20of%20in%20vivo%20animals.%20We%20describe%20the%20general%20considerations%20and%20foundational%20knowledge%20that%20must%20be%20considered%20when%20designing%20experiments.%20We%20briefly%20describe%20differences%20in%20animal%20species%20and%20disease%20models%20and%20discuss%20why%20some%20may%20be%20more%20or%20less%20appropriate%20for%20different%20studies.%20We%2C%20then%2C%20give%20recommendations%20for%20in%20vivo%20acquisition%20protocols%2C%20including%20decisions%20on%20hardware%2C%20animal%20preparation%2C%20and%20imaging%20sequences%2C%20followed%20by%20advice%20for%20data%20processing%20including%20preprocessing%2C%20model-fitting%2C%20and%20tractography.%20Finally%2C%20we%20provide%20an%20online%20resource%20that%20lists%20publicly%20available%20preclinical%20dMRI%20datasets%20and%20software%20packages%20to%20promote%20responsible%20and%20reproducible%20research.%20In%20each%20section%2C%20we%20attempt%20to%20provide%20guides%20and%20recommendations%2C%20but%20also%20highlight%20areas%20for%20which%20no%20guidelines%20exist%20%28and%20why%29%2C%20and%20where%20future%20work%20should%20focus.%20Although%20we%20mainly%20cover%20the%20central%20nervous%20system%20%28on%20which%20most%20preclinical%20dMRI%20studies%20are%20focused%29%2C%20we%20also%20provide%2C%20where%20possible%20and%20applicable%2C%20recommendations%20for%20other%20organs%20of%20interest.%20An%20overarching%20goal%20is%20to%20enhance%20the%20rigor%20and%20reproducibility%20of%20small%20animal%20dMRI%20acquisitions%20and%20analyses%2C%20and%20thereby%20advance%20biomedical%20knowledge.%22%2C%22date%22%3A%222025-02-26%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fmrm.30429%22%2C%22ISSN%22%3A%221522-2594%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22YXS7B6S7%22%2C%22M2AY8I5W%22%5D%2C%22dateModified%22%3A%222025-03-11T08%3A47%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22MKSZ2T58%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22de%20S%5Cu00e8ze%20et%20al.%22%2C%22parsedDate%22%3A%222025-02-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BS%26%23xE8%3Bze%2C%20J%26%23xE9%3Br%26%23xF4%3Bme%20de%2C%20Pierre%20Labauge%2C%20Roland%20Liblau%2C%20Mikel%20Martinez%2C%20Thibault%20Moreau%2C%20Laurent%20Suchet%2C%20Patrick%20Vermersch%2C%20et%20al.%20%26%23x201C%3BLymphoTEC%3A%20A%20Retrospective%20Real-World%20Study%20on%20Lymphocyte%20Reconstitution%20After%20Lymphopenia%20in%20Patients%20with%20Multiple%20Sclerosis%20Treated%20with%20Dimethyl%20Fumarate%20in%20France.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAdvances%20in%20Therapy%26lt%3B%5C%2Fi%26gt%3B%2C%20February%2019%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs12325-024-03092-5%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs12325-024-03092-5%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22LymphoTEC%3A%20a%20Retrospective%20Real-World%20Study%20on%20Lymphocyte%20Reconstitution%20After%20Lymphopenia%20in%20Patients%20with%20Multiple%20Sclerosis%20Treated%20with%20Dimethyl%20Fumarate%20in%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22de%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roland%22%2C%22lastName%22%3A%22Liblau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikel%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Suchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Vermersch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Giannesini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22In%5Cu00e8s%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Labeyrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Neau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%22%2C%22lastName%22%3A%22Dobay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hanyue%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Seth%22%2C%22lastName%22%3A%22Levin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marilyn%22%2C%22lastName%22%3A%22Gros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marta%22%2C%22lastName%22%3A%22Ruiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Dimethyl%20fumarate%20%28DMF%29%20has%20demonstrated%20a%20favorable%20benefit-risk%20profile%20in%20patients%20with%20relapsing-remitting%20multiple%20sclerosis%20%28RRMS%29.%20Some%20patients%20may%20develop%20lymphopenia%20on%20DMF%3B%20therefore%2C%20LymphoTEC%20evaluated%20absolute%20lymphocyte%20count%20%28ALC%29%20reconstitution%20after%20DMF%20discontinuation.%5CnMETHODS%3A%20LymphoTEC%20was%20a%20retrospective%2C%20multicenter%20study%20of%20patients%20with%20RRMS%20in%20the%20Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%20registry.%20Times%20to%20ALC%20reconstitution%20and%20lymphopenia%20were%20estimated%20by%20the%20Kaplan-Meier%20method.%20Univariate%20and%20multivariate%20analyses%20evaluated%20factors%20associated%20with%20ALC%20reconstitution%20after%20DMF%20discontinuation%20or%20lymphopenia%20after%20DMF%20initiation.%20Patients%20treated%20with%20DMF%20for%5Cu00a0%5Cu2265%5Cu00a03%5Cu00a0months%20with%5Cu00a0%5Cu2265%5Cu00a01%20ALC%20in%20the%206%5Cu00a0months%20before%5C%2Fclose%20to%20DMF%20initiation%20and%5Cu00a0%5Cu2265%5Cu00a01%20ALC%20during%20treatment%20were%20included.%5CnRESULTS%3A%20Overall%2C%201429%20RRMS%20patients%20were%20included%3B%20356%20patients%20developed%20lymphopenia%2C%20of%20whom%20183%20discontinued%20DMF.%20Overall%2C%20ALC%20decreased%20by%2033%25%20over%20the%20first%20year%20and%20plateaued%20thereafter.%20The%20probability%20of%20developing%20lymphopenia%20was%2018.2%25%20after%201%5Cu00a0year.%20In%20patients%20with%20lymphopenia%2C%20median%20times%20to%20ALC%20reconstitution%20after%20DMF%20discontinuation%20were%203.8%5Cu00a0months%20overall%2C%204.0%5Cu00a0months%20for%20Grade%201%20lymphopenia%2C%203.0%5Cu00a0months%20for%20Grade%202%2C%20and%209.7%5Cu00a0months%20for%20Grade%203.%20At%2012%5Cu00a0months%2C%2083.0%25%20had%20reconstituted%20ALC.%20In%20DMF%20discontinuers%2C%20median%20time%20to%20discontinuation%20was%201.2%5Cu00a0years.%20There%20was%20no%20increased%20risk%20of%20serious%20or%20opportunistic%20infections%20in%20patients%20with%20lymphopenia.%20No%20cases%20of%20progressive%20multifocal%20leukoencephalopathy%20were%20reported.%20First%20ALC%20reconstitution%20after%20DMF%20discontinuation%20was%20associated%20with%20diabetes%2C%20DMF%20duration%2C%20DMF%20duration%20before%20lymphopenia%2C%20and%20DMF%20duration%20after%20lymphopenia%3B%20first%20lymphopenia%20after%20DMF%20initiation%20was%20associated%20with%20age%20and%20ALC%20at%20DMF%20initiation.%5CnCONCLUSION%3A%20LymphoTEC%20confirms%20previous%20reports%20on%20DMF-induced%20lymphopenia%3B%20the%20benefit-risk%20profile%20of%20DMF%20remains%20favorable.%20Most%20cases%20of%20lymphopenia%20were%20not%20severe%20and%20ALC%20reconstitution%20typically%20occurred%20within%204%5Cu00a0months%20of%20DMF%20discontinuation.%20Patients%20with%20shorter%20and%20milder%20lymphopenia%20had%20faster%20ALC%20reconstitution.%5CnTRIAL%20REGISTRATION%3A%20ClinicalTrials.gov%20NCT04756687.%22%2C%22date%22%3A%222025-02-19%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs12325-024-03092-5%22%2C%22ISSN%22%3A%221865-8652%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22DPH3URT3%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Stolowy%20et%20al.%22%2C%22parsedDate%22%3A%222025-02-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BStolowy%2C%20Natacha%2C%20Lilija%20Gutmann%2C%20Margareta%20L%26%23xFC%3Bpke%2C%20Thierry%20David%2C%20Michael%20Dorr%2C%20Christina%20Mayer%2C%20Christoph%20Heesen%2C%20et%20al.%20%26%23x201C%3BOCT-Based%20Retina%20Assessment%20Reflects%20Visual%20Impairment%20in%20Multiple%20Sclerosis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInvestigative%20Ophthalmology%20%26amp%3B%20Visual%20Science%26lt%3B%5C%2Fi%26gt%3B%2066%2C%20no.%202%20%28February%203%2C%202025%29%3A%2039.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1167%5C%2Fiovs.66.2.39%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1167%5C%2Fiovs.66.2.39%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22OCT-Based%20Retina%20Assessment%20Reflects%20Visual%20Impairment%20in%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Stolowy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lilija%22%2C%22lastName%22%3A%22Gutmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margareta%22%2C%22lastName%22%3A%22L%5Cu00fcpke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22David%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Dorr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christina%22%2C%22lastName%22%3A%22Mayer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Heesen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederike%20Cosima%22%2C%22lastName%22%3A%22Oertel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ting-Yi%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Friedemann%22%2C%22lastName%22%3A%22Paul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hanna%20Gwendolyn%22%2C%22lastName%22%3A%22Zimmermann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20To%20explore%20the%20relationship%20between%20visual%20performance%20and%20retinal%20morphology%20as%20assessed%20by%20optical%20coherence%20tomography%20%28OCT%29%2C%20and%20the%20ability%20of%20OCT%20to%20reflect%20visual%20impairment%20in%20people%20with%20multiple%20sclerosis%20%28PwMS%29%20compared%20with%20healthy%20controls%20%28HC%29.%5CnMETHODS%3A%20We%20gathered%20data%20from%20two%20neurology%20referral%20centers%20on%20PwMS%20and%20HC.%20Neurological%20and%20ophthalmological%20assessments%2C%20including%20OCT%2C%20high-contrast%20visual%20acuity%20%28HCVA%29%20and%20low-contrast%20visual%20acuity%20%28LCVA%29%2C%20area%20under%20the%20log%20contrast%20sensitivity%20function%20%28AULCSF%29%2C%20and%20vision-related%20quality%20of%20life%20%28National%20Eye%20Institute%20Visual%20Function%20Questionnaire%29%2C%20were%20conducted%20between%202018%20and%202020%2C%20with%20follow-up%20at%201%5Cu00a0year.%5CnRESULTS%3A%20A%20total%20of%20137%20PwMS%20%28271%20eyes%29%20and%20118%20HC%20%28236%20eyes%29%20were%20available%20for%20analysis.%20The%20peripapillary%20retinal%20nerve%20fiber%20layer%20%28pRNFL%29%20and%20the%20macular%20ganglion%20cell%20layer%20and%20inner%20plexiform%20layer%20volume%20%28mGCIPL%29%20volume%20were%20both%20reduced%20in%20PwMS%20%2892%5Cu00a0%5Cu00b5m%20in%20PwMS%20vs%2098%5Cu00a0%5Cu00b5m%20in%20HC%20%5BP%5Cu00a0%26lt%3B%5Cu00a00.001%5D%2C%200.55%20mm3%20vs%200.62%20mm3%20%5BP%5Cu00a0%26lt%3B%5Cu00a00.001%5D%2C%20respectively%29.%20A%20cutoff%20effect%20for%20visual%20impairment%20was%20observed%20in%20PwMS%20when%20pRNFL%20fell%20below%2068.8%5Cu00a0%5Cu00b5m%20%28HCVA%29%2C%2071.4%5Cu00a0%5Cu00b5m%20%28LCVA%29%2C%20and%2072.6%5Cu00a0%5Cu00b5m%20%28AULCSF%29.%20Using%20mixed%20effects%20models%2C%20the%20mGCIPL%20volume%20emerged%20as%20the%20variable%20most%20strongly%20associated%20with%20the%20AULCSF%20%28P%5Cu00a0%26lt%3B%5Cu00a00.001%29.%20The%20AULCSF%20showed%20the%20strongest%20correlation%20with%20both%20pRNFL%20and%20mGCIPL%20%28P%5Cu00a0%26lt%3B%5Cu00a00.001%29%2C%20with%20optic%20neuritis%20being%20a%20significant%20contributing%20factor%20%28P%5Cu00a0%26lt%3B%5Cu00a00.001%29.%5CnCONCLUSIONS%3A%20AULCSF%20outperformed%20standard%20HCVA%20and%20LCVA%2C%20closely%20reflecting%20retinal%20atrophy.%20mGCIPL%20loss%20showed%20stronger%20associations%20with%20vision%20tests%20and%20detected%20neurodegeneration%20without%20the%20cutoff%20effect%20seen%20in%20pRNFL%2C%20making%20it%20the%20best%20marker%20for%20neuronal%20atrophy.%22%2C%22date%22%3A%222025-02-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1167%5C%2Fiovs.66.2.39%22%2C%22ISSN%22%3A%221552-5783%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229L2KHJ5X%22%5D%2C%22dateModified%22%3A%222025-03-18T16%3A32%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22CGL276QZ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lebret%20et%20al.%22%2C%22parsedDate%22%3A%222025-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLebret%2C%20Anna%2C%20Sabina%20Frese%2C%20Simon%20L%26%23xE9%3Bvy%2C%20Armin%20Curt%2C%20Virginie%20Callot%2C%20Patrick%20Freund%2C%20and%20Maryam%20Seif.%20%26%23x201C%3BSpinal%20Cord%20Blood%20Perfusion%20Deficit%20Is%20Associated%20with%20Clinical%20Impairment%20after%20Spinal%20Cord%20Injury.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Neurotrauma%26lt%3B%5C%2Fi%26gt%3B%2042%2C%20no.%203%26%23x2013%3B4%20%28February%202025%29%3A%20280%26%23x2013%3B91.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fneu.2024.0267%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fneu.2024.0267%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Spinal%20Cord%20Blood%20Perfusion%20Deficit%20is%20Associated%20with%20Clinical%20Impairment%20after%20Spinal%20Cord%20Injury%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Lebret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabina%22%2C%22lastName%22%3A%22Frese%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22L%5Cu00e9vy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armin%22%2C%22lastName%22%3A%22Curt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Callot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Freund%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maryam%22%2C%22lastName%22%3A%22Seif%22%7D%5D%2C%22abstractNote%22%3A%22Spinal%20cord%20injury%20%28SCI%29%20results%20in%20intramedullary%20microvasculature%20disruption%20and%20blood%20perfusion%20deficit%20at%20and%20remote%20from%20the%20injury%20site.%20However%2C%20the%20relationship%20between%20remote%20vascular%20impairment%20and%20functional%20recovery%20remains%20understudied.%20We%20characterized%20perfusion%20impairment%20in%5Cu00a0vivo%2C%20rostral%20to%20the%20injury%2C%20using%20magnetic%20resonance%20imaging%20%28MRI%29%2C%20and%20investigated%20its%20association%20with%20lesion%20extent%20and%20impairment%20following%20SCI.%20Twenty-one%20patients%20with%20chronic%20cervical%20SCI%20and%2039%20healthy%20controls%20%28HC%29%20underwent%20a%20high-resolution%20MRI%20protocol%2C%20including%20intravoxel%20incoherent%20motion%20%28IVIM%29%20and%20T2%2A-weighted%20MRI%20covering%20C1%5Cu2013C3%20cervical%20levels%2C%20as%20well%20as%20T2-weighted%20MRI%20to%20determine%20lesion%20volumes.%20IVIM%20matrices%20%28i.e.%2C%20blood%20volume%20fraction%2C%20velocity%2C%20flow%20indices%2C%20and%20diffusion%29%20and%20cord%20structural%20characteristics%20were%20calculated%20to%20assess%20perfusion%20changes%20and%20cervical%20cord%20atrophy%2C%20respectively.%20Patients%20with%20SCI%20additionally%20underwent%20a%20standard%20clinical%20examination%20protocol%20to%20assess%20functional%20impairment.%20Correlation%20analysis%20was%20used%20to%20investigate%20associations%20between%20IVIM%20parameters%20with%20lesion%20volume%20and%20sensorimotor%20dysfunction.%20Cervical%20cord%20white%20and%20gray%20matter%20were%20atrophied%20%2827.60%25%20and%2021.10%25%2C%20p%20%26lt%3B%200.0001%2C%20respectively%29%20above%20the%20cervical%20cord%20injury%2C%20accompanied%20by%20a%20lower%20blood%20volume%20fraction%20%28%5Cu221222.05%25%2C%20p%20%26lt%3B%200.001%29%20and%20a%20higher%20blood%20velocity-related%20index%20%28%2B38.72%25%2C%20p%20%26lt%3B%200.0001%29%20in%20patients%20with%20SCI%20compared%20with%20HC.%20Crucially%2C%20gray%20matter%20remote%20perfusion%20deficit%20correlated%20with%20larger%20lesion%20volumes%20and%20clinical%20impairment.%20This%20study%20shows%20clinically%20eloquent%20perfusion%20deficit%20rostral%20to%20a%20SCI%2C%20its%20magnitude%20driven%20by%20injury%20severity.%20These%20findings%20indicate%20trauma-induced%20widespread%20microvascular%20alterations%20beyond%20the%20injury%20site.%20Perfusion%20MRI%20matrices%20in%20the%20spinal%20cord%20hold%20promise%20as%20biomarkers%20for%20monitoring%20treatment%20effects%20and%20dynamic%20changes%20in%20microvasculature%20integrity%20following%20SCI.%22%2C%22date%22%3A%222025-02%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1089%5C%2Fneu.2024.0267%22%2C%22ISSN%22%3A%220897-7151%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.liebertpub.com%5C%2Fdoi%5C%2F10.1089%5C%2Fneu.2024.0267%22%2C%22collections%22%3A%5B%22ZFC2Q648%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22TU28B94B%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cho%20et%20al.%22%2C%22parsedDate%22%3A%222025-01-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCho%2C%20Soomi%2C%20Julia%20Makhalova%2C%20Samuel%20Medina%20Villalon%2C%20Nathalie%20Villeneuve%2C%20Agnes%20Tr%26%23xE9%3Bbuchon%2C%20Manel%20Krouma%2C%20Didier%20Scavarda%2C%20et%20al.%20%26%23x201C%3BStereoelectroencephalographic%20Exploration%20and%20Surgical%20Outcome%20in%20Lennox-Gastaut%20Syndrome.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEpilepsia%26lt%3B%5C%2Fi%26gt%3B%2C%20January%2027%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fepi.18283%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fepi.18283%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Stereoelectroencephalographic%20exploration%20and%20surgical%20outcome%20in%20Lennox-Gastaut%20syndrome%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soomi%22%2C%22lastName%22%3A%22Cho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Makhalova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Medina%20Villalon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Villeneuve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agnes%22%2C%22lastName%22%3A%22Tr%5Cu00e9buchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manel%22%2C%22lastName%22%3A%22Krouma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Scavarda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22L%5Cu00e9pine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Milh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Carron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Bonini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9raldine%22%2C%22lastName%22%3A%22Daquin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Aubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanislas%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Pizzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Bartolomei%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20Lennox-Gastaut%20syndrome%20%28LGS%29%20is%20typically%20characterized%20by%20drug-resistant%20epilepsy%20and%20subsequent%20cognitive%20deterioration.%20Surgery%20is%20a%20rare%20but%20viable%20option%20for%20the%20control%20of%20seizures%20in%20a%20subset%20of%20patients%20with%20LGS.%20This%20study%20aimed%20to%20describe%20the%20organization%20of%20the%20epileptogenic%20zone%20network%20%28EZN%29%20in%20patients%20with%20LGS%20using%20stereoelectroencephalography%20%28SEEG%29%20and%20to%20report%20the%20outcome%20of%20post-SEEG%20treatment.%5CnMETHODS%3A%20A%20quantitative%20SEEG%20signal%20analysis%20was%20conducted%20in%2014%20consecutive%20patients%20with%20LGS%2C%20in%20whom%20a%20potentially%20localized%20EZN%20was%20suggested%20based%20on%20a%20comprehensive%20noninvasive%20evaluation.%20The%20EZN%20and%20the%20irritative%20zone%20network%20were%20identified%20using%20relevant%20biomarkers%20during%20ictal%20%28epileptogenicity%20index%20and%20connectivity%20epileptogenicity%20index%29%20and%20interictal%20%28spikes%20and%20high-frequency%20oscillations%29%20recordings.%20The%20applied%20post-SEEG%20treatments%20were%20assessed%2C%20including%20SEEG-guided%20radiofrequency%20thermocoagulation%20%28RF-TC%29%2C%20surgery%2C%20and%20neurostimulation.%5CnRESULTS%3A%20The%20seizure%20onset%20patterns%20showed%20some%20specificity%20by%20seizure%20type%2C%20with%2084%25%20of%20tonic%20seizures%20involving%20low-voltage%20fast%20activity.%20The%20EZN%20of%20patients%20with%20LGS%20was%20often%2C%20but%20not%20always%2C%20complex%20and%20extensive%2C%20involving%20two%20or%20more%20lobes%20%2879%25%29%20and%20both%20hemispheres%20%2864%25%29.%20The%20lateral%20neocortical%20structures%2C%20particularly%20the%20lateral%20premotor%20and%20dorsolateral%20prefrontal%20cortices%2C%20were%20identified%20as%20being%20most%20frequently%20involved%20in%20the%20EZN.%20Among%20the%20explored%20subcortical%20structures%2C%20only%20the%20pulvinar%2C%20central-lateral%20thalamic%20nucleus%2C%20and%20hypothalamic%20hamartoma%20belonged%20to%20the%20EZN.%20Twelve%20patients%20%2886%25%29%20underwent%20SEEG-guided%20RF-TC%2C%20with%2050%25%20experiencing%20a%20%26gt%3B50%25%20reduction%20in%20baseline%20seizure%20frequency.%20Four%20patients%20%2829%25%29%20underwent%20curative%20surgery%20for%20significant%20involvement%20of%20a%20lesion%20in%20the%20EZN%2C%20and%20one%20case%20achieved%20an%20Engel%20class%20I%20outcome.%5CnSIGNIFICANCE%3A%20This%20is%20the%20first%20quantitative%20SEEG%20study%20in%20patients%20with%20LGS%20to%20demonstrate%20the%20utility%20of%20SEEG%20in%20identifying%20patients%20who%20may%20benefit%20from%20surgery%20and%20to%20perform%20SEEG-guided%20RF-TC.%20Nevertheless%2C%20the%20indications%20for%20SEEG%20should%20be%20carefully%20assessed%2C%20as%20localized%20EZN%20is%20uncommon%20in%20LGS.%22%2C%22date%22%3A%222025-01-27%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fepi.18283%22%2C%22ISSN%22%3A%221528-1167%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RMECNPE%22%5D%2C%22dateModified%22%3A%222025-03-18T16%3A34%3A52Z%22%7D%7D%2C%7B%22key%22%3A%2272AV5NNG%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pham%20et%20al.%22%2C%22parsedDate%22%3A%222025-01-22%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPham%2C%20S.%20D.%20T.%2C%20C.%20Chatziantoniou%2C%20J.%20T.%20van%20Vliet%2C%20R.%20J.%20van%20Tuijl%2C%20M.%20Bulk%2C%20M.%20Costagli%2C%20L.%20de%20Rochefort%2C%20et%20al.%20%26%23x201C%3BBlood%20Flow%20Velocity%20Analysis%20in%20Cerebral%20Perforating%20Arteries%20on%207T%202D%20Phase%20Contrast%20MRI%20with%20an%20Open-Source%20Software%20Tool%20%28SELMA%29.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeuroinformatics%26lt%3B%5C%2Fi%26gt%3B%2023%2C%20no.%202%20%28January%2022%2C%202025%29%3A%2011.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs12021-024-09703-4%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs12021-024-09703-4%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Blood%20Flow%20Velocity%20Analysis%20in%20Cerebral%20Perforating%20Arteries%20on%207T%202D%20Phase%20Contrast%20MRI%20with%20an%20Open-Source%20Software%20Tool%20%28SELMA%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20D.%20T.%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chatziantoniou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20T.%22%2C%22lastName%22%3A%22van%20Vliet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20J.%22%2C%22lastName%22%3A%22van%20Tuijl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Bulk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Costagli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22de%20Rochefort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Kraff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20E.%22%2C%22lastName%22%3A%22Ladd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Pine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Ronen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20C.%20W.%22%2C%22lastName%22%3A%22Siero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Tosetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Villringer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20J.%22%2C%22lastName%22%3A%22Biessels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%20M.%22%2C%22lastName%22%3A%22Zwanenburg%22%7D%5D%2C%22abstractNote%22%3A%22Blood%20flow%20velocity%20in%20the%20cerebral%20perforating%20arteries%20can%20be%20quantified%20in%20a%20two-dimensional%20plane%20with%20phase%20contrast%20magnetic%20imaging%20%282D%20PC-MRI%29.%20The%20velocity%20pulsatility%20index%20%28PI%29%20can%20inform%20on%20the%20stiffness%20of%20these%20perforating%20arteries%2C%20which%20is%20related%20to%20several%20cerebrovascular%20diseases.%20Currently%2C%20there%20is%20no%20open-source%20analysis%20tool%20for%202D%20PC-MRI%20data%20from%20these%20small%20vessels%2C%20impeding%20the%20usage%20of%20these%20measurements.%20In%20this%20study%20we%20present%20the%20Small%20vessEL%20MArker%20%28SELMA%29%20analysis%20software%20as%20a%20novel%2C%20user-friendly%2C%20open-source%20tool%20for%20velocity%20analysis%20in%20cerebral%20perforating%20arteries.%20The%20implementation%20of%20the%20analysis%20algorithm%20in%20SELMA%20was%20validated%20against%20previously%20published%20data%20with%20a%20Bland-Altman%20analysis.%20The%20inter-rater%20reliability%20of%20SELMA%20was%20assessed%20on%20PC-MRI%20data%20of%20sixty%20participants%20from%20three%20MRI%20vendors%20between%20eight%20different%20sites.%20The%20mean%20velocity%20%28vmean%29%20and%20velocity%20PI%20of%20SELMA%20was%20very%20similar%20to%20the%20original%20results%20%28vmean%3A%20mean%20difference%5Cu2009%5Cu00b1%5Cu2009standard%20deviation%3A%200.1%5Cu2009%5Cu00b1%5Cu20090.8%20cm%5C%2Fs%3B%20velocity%20PI%3A%20mean%20difference%5Cu2009%5Cu00b1%5Cu2009standard%20deviation%3A%200.01%5Cu2009%5Cu00b1%5Cu20090.1%29%20despite%20the%20slightly%20higher%20number%20of%20detected%20vessels%20in%20SELMA%20%28Ndetected%3A%20mean%20difference%5Cu2009%5Cu00b1%5Cu2009standard%20deviation%3A%204%5Cu2009%5Cu00b1%5Cu20099%20vessels%29%2C%20which%20can%20be%20explained%20by%20the%20vessel%20selection%20paradigm%20of%20SELMA.%20The%20Dice%20Similarity%20Coefficient%20of%20drawn%20regions%20of%20interest%20between%20two%20operators%20using%20SELMA%20was%200.91%20%28range%200.69-0.95%29%20and%20the%20overall%20intra-class%20coefficient%20for%20Ndetected%2C%20vmean%2C%20and%20velocity%20PI%20were%200.92%2C%200.84%2C%20and%200.85%2C%20respectively.%20The%20differences%20in%20the%20outcome%20measures%20was%20higher%20between%20sites%20than%20vendors%2C%20indicating%20the%20challenges%20in%20harmonizing%20the%202D%20PC-MRI%20sequence%20even%20across%20sites%20with%20the%20same%20vendor.%20We%20show%20that%20SELMA%20is%20a%20consistent%20and%20user-friendly%20analysis%20tool%20for%20small%20cerebral%20vessels.%22%2C%22date%22%3A%222025-01-22%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs12021-024-09703-4%22%2C%22ISSN%22%3A%221559-0089%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22DNKN89WD%22%5D%2C%22dateModified%22%3A%222025-01-27T09%3A49%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22N4FVE92U%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ramdani%20et%20al.%22%2C%22parsedDate%22%3A%222025-01-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRamdani%2C%20Ryan%2C%20Julie%20Pique%2C%20Romain%20Deschamps%2C%20Jonathan%20Ciron%2C%20Elisabeth%20Maillart%2C%20Bertrand%20Audoin%2C%20Mikael%20Cohen%2C%20et%20al.%20%26%23x201C%3BEvaluation%20of%20the%20Predictive%20Value%20of%20CSF-Restricted%20Oligoclonal%20Bands%20on%20Residual%20Disability%20and%20Risk%20of%20Relapse%20in%20Adult%20Patients%20with%20MOGAD%3A%20MOGADOC%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20%28Houndmills%2C%20Basingstoke%2C%20England%29%26lt%3B%5C%2Fi%26gt%3B%2C%20January%2015%2C%202025%2C%2013524585241311435.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585241311435%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585241311435%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20the%20predictive%20value%20of%20CSF-restricted%20oligoclonal%20bands%20on%20residual%20disability%20and%20risk%20of%20relapse%20in%20adult%20patients%20with%20MOGAD%3A%20MOGADOC%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ryan%22%2C%22lastName%22%3A%22Ramdani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Pique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lakhdar%22%2C%22lastName%22%3A%22Benyahya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22NOMADMUS%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20clinical%20course%20of%20myelin%20oligodendrocyte%20glycoprotein%20%28MOG%29%20antibody-associated%20disease%20%28MOGAD%29%20is%20variable.%20However%2C%20robust%20markers%20of%20poor%20outcome%20and%5C%2For%20relapse%20risk%20are%20still%20missing.%5CnOBJECTIVE%3A%20To%20evaluate%20the%20frequency%20of%20cerebrospinal%20fluid-restricted%20oligoclonal%20bands%20%28CSF-OCB%29%20in%20a%20national%20cohort%20of%20adult%20MOGAD%20patients%20and%20to%20assess%20their%20prognostic%20value%20for%20the%20risk%20of%20relapse%20and%20severity.%5CnMETHODS%3A%20We%20included%20MOGAD%20adult%20patients%20fulfilling%20the%20MOGAD%202023%20criteria%20who%20underwent%20CSF%20analysis%20at%20maximum%203%20months%20from%20onset.%5CnRESULTS%3A%20Data%20from%20190%20patients%20were%20collected.%20We%20found%20the%20presence%20of%20CSF-OCB%20in%2032%20patients%20%2816.8%25%29.%20Positive%20and%20negative%20CSF-OCB%20patients%20were%20similar%20for%20median%20age%20at%20onset%2C%20sex%2C%20clinical%20presentation%2C%20severity%20at%20onset%2C%20and%20residual%20disability.%20Relapses%20were%20more%20frequent%20in%20the%20CSF-OCB%2B%20group%20%28p%20%3D%200.049%29%2C%20particularly%20within%20the%20first%20year%20of%20follow-up%20%28p%20%3D%200.007%29.%20Although%20CSF-OCB%2B%20was%20more%20frequently%20associated%20with%20imaging%20features%20suggestive%20of%20multiple%20sclerosis%20%28MS%29%20%28p%20%3D%200.014%29%2C%2078%25%20of%20these%20patients%20fulfilled%20the%202023%20supportive%20features%20and%2065%25%20experienced%20lesion%20vanishing%20at%20follow-up%20magnetic%20resonance%20imaging%20%28MRI%29.%5CnCONCLUSION%3A%20We%20found%20a%20higher%20risk%20of%20relapse%20in%20MOGAD%20with%20CSF-OCB%20particularly%20during%20the%20first%20year.%20Close%20attention%20is%20recommended%20regarding%20the%20risk%20of%20misdiagnosis%20with%20MS.%22%2C%22date%22%3A%222025-01-15%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585241311435%22%2C%22ISSN%22%3A%221477-0970%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A42Z%22%7D%7D%2C%7B%22key%22%3A%228VEUSFK4%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Farah%20et%20al.%22%2C%22parsedDate%22%3A%222025-01-09%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFarah%2C%20Kaissar%2C%20Samira%20Mchinda%2C%20Laurianne%20Pini%2C%20Guillaume%20Baucher%2C%20Pierre-%20Hugues%20Roche%2C%20St%26%23xE9%3Bphane%20Fuentes%2C%20and%20Virginie%20Callot.%20%26%23x201C%3BT1%20Mapping%20Using%20MP2RAGE%20in%20Degenerative%20Cervical%20Myelopathy%3A%20A%20Longitudinal%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Spine%20Journal%26lt%3B%5C%2Fi%26gt%3B%2C%20January%209%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00586-025-08652-z%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00586-025-08652-z%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22T1%20mapping%20using%20MP2RAGE%20in%20degenerative%20cervical%20myelopathy%3A%20a%20longitudinal%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaissar%22%2C%22lastName%22%3A%22Farah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samira%22%2C%22lastName%22%3A%22Mchinda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurianne%22%2C%22lastName%22%3A%22Pini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Baucher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-%20Hugues%22%2C%22lastName%22%3A%22Roche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Fuentes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Callot%22%7D%5D%2C%22abstractNote%22%3A%22Degenerative%20cervical%20myelopathy%20%28DCM%29%20is%20the%20most%20common%20cause%20of%20spinal%20cord%20%28SC%29%20dysfunction.%20In%20routine%20clinical%20practice%2C%20SC%20changes%20are%20well%20depicted%20using%20conventional%20MRI%2C%20especially%20T2-weighted%20imaging.%20However%2C%20this%20modality%20usually%20fails%20to%20provide%20satisfactory%20clinico-radiological%20correlations.%20In%20this%20context%20we%20assessed%20the%20potential%20value%20of%20quantitative%20changes%20measured%20with%20a%20T1%20MP2RAGE%20sequence.%22%2C%22date%22%3A%222025-01-09%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00586-025-08652-z%22%2C%22ISSN%22%3A%221432-0932%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00586-025-08652-z%22%2C%22collections%22%3A%5B%22ZFC2Q648%22%5D%2C%22dateModified%22%3A%222025-11-27T09%3A21%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22UNYKAKZC%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Biagioni%20et%20al.%22%2C%22parsedDate%22%3A%222025%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBiagioni%2C%20Tommaso%2C%20Maria%20Fratello%2C%20Elodie%20Garnier%2C%20Stanislas%20Lagarde%2C%20Romain%20Carron%2C%20Samuel%20Medina%20Villalon%2C%20Isabelle%20Lambert%2C%20et%20al.%20%26%23x201C%3BInterictal%20Waking%20and%20Sleep%20Electrophysiological%20Properties%20of%20the%20Thalamus%20in%20Focal%20Epilepsies.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBrain%20Communications%26lt%3B%5C%2Fi%26gt%3B%207%2C%20no.%202%20%282025%29%3A%20fcaf102.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fbraincomms%5C%2Ffcaf102%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fbraincomms%5C%2Ffcaf102%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Interictal%20waking%20and%20sleep%20electrophysiological%20properties%20of%20the%20thalamus%20in%20focal%20epilepsies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tommaso%22%2C%22lastName%22%3A%22Biagioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Fratello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Garnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanislas%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Carron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Medina%20Villalon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Lambert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%22%2C%22lastName%22%3A%22Marchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Makhalova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agnes%22%2C%22lastName%22%3A%22Trebuchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Bonini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Scavarda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Benar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Bartolomei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Pizzo%22%7D%5D%2C%22abstractNote%22%3A%22Epilepsy%20is%20a%20cortico-subcortical%20network%20disease.%20Thalamo-cortical%20relationships%20in%20focal%20epilepsies%2C%20studied%20by%20stereoelectroencephalography%20in%20complex%20patients%20during%20pre-surgical%20evaluation%2C%20might%20help%20refine%20epilepsy%20surgery%20prognostic%20indicators%20and%20patient-specific%20treatments%20%28i.e.%20thalamic%20deep%20brain%20stimulation%29.%20To%20this%20aim%2C%20we%20studied%20interictal%20thalamic%20traces%2C%20during%20rest%20and%20sleep%20recordings%2C%20in%20a%20cohort%20of%20121%20patients%2C%20delving%20into%20thalamo-cortical%20connectivity%2C%20hyperexcitability%20biomarkers%20and%20their%20correlation%20with%20treatment%20outcome.%20We%20retrospectively%20gathered%20stereoelectroencephalography%20recordings%20and%20clinical%20variables%20from%20patients%20who%20underwent%20stereoelectroencephalography%20with%20mainly%20a%20posterior-thalamic%20implantation%2C%20aiming%20at%20the%20pulvinar.%20Interictal%20recordings%20during%20rest%20and%20sleep%20were%20analysed%20to%20detect%20spikes%20and%20fast%20ripples%20automatically.%20Functional%20connectivity%20between%20the%20thalamus%20and%20other%20brain%20regions%20%28involved%20or%20non-involved%20in%20the%20epileptogenic%20network%29%20was%20examined%20using%20linear%20regression%20analysis.%20Higher%20thalamic%20hyperexcitability%20biomarker%20rates%20during%20sleep%20were%20linked%20to%20unfavourable%20surgical%20outcomes%20%28Engel%20Class%20III%5C%2FIV%29%20compared%20to%20favourable%20outcomes%20%28Engel%20Class%20I%5C%2FII%29%20%28spikes%3A%20N%20%3D%20117%2C%20P%20%3D%200.009%2C%20effect%20size%20%3D%200.25%3B%20fast%20ripples%3A%20N%20%3D%2017%2C%20P%20%3D%200.036%2C%20effect%20size%20%3D%200.52%29.%20Thalamo-cortical%20functional%20connectivity%20analysis%20revealed%20heightened%20thalamic%20strength%2C%20particularly%20in%20the%20beta%20%28P%20%26lt%3B%200.001%2C%20effect%20size%20%3D%200.38%29%20and%20gamma%20%28P%20%3D%200.012%2C%20effect%20size%20%3D%200.24%29%20bands%20during%20sleep%2C%20among%20patients%20with%20poor%20surgical%20outcomes%2C%20especially%20with%20non-involved%20networks.%20Conversely%2C%20during%20rest%2C%20lower%20hyperexcitability%20biomarkers%20%28spikes%20r%20%3D%20-0.2%2C%20P%20%3D%200.048%3B%20fast%20ripples%20r%20%3D%20-0.52%2C%20P%20%3D%200.045%29%20and%20lower%20values%20of%20thalamic%20strength%20%28delta%20band%20r%20%3D%20-0.28%2C%20P%20%3D%200.025%3B%20broadband%20r%20%3D%20-0.23%2C%20P%20%3D%200.01%29%20were%20observed%20in%20patients%20with%20longer%20epilepsy%20duration.%20Furthermore%2C%20thalamic%20strength%20values%20during%20rest%20were%20lower%20in%20patients%20of%20older%20age%20%28broadband%20r%20%3D%20-0.19%2C%20P%20%3D%200.045%29.%20These%20findings%20confirmed%20the%20important%20role%20of%20the%20thalamus%20in%20focal%20epilepsy.%20According%20to%20this%20exploratory%20group-level%20study%2C%20thalamic%20recordings%20could%20potentially%20improve%20pre-surgical%20assessment%20and%20help%20identify%20patients%20who%20may%20have%20a%20less%20severe%20outcome.%20Additionally%2C%20diminished%20thalamic%20activity%20and%20connectivity%20associated%20with%20epilepsy%20duration%20and%20age%20prompt%20speculation%20on%20the%20role%20of%20thalamo-cortical%20interactions%20in%20ageing-related%20physiological%20and%20pathological%20processes.%22%2C%22date%22%3A%222025%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fbraincomms%5C%2Ffcaf102%22%2C%22ISSN%22%3A%222632-1297%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RMECNPE%22%5D%2C%22dateModified%22%3A%222025-11-21T09%3A02%3A38Z%22%7D%7D%2C%7B%22key%22%3A%229SENDUAS%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bratu%20et%20al.%22%2C%22parsedDate%22%3A%222025%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBratu%2C%20Ionu%26%23x21B%3B-Flavius%2C%20Lucie%20de%20Clerck%2C%20H%26%23xE9%3Bl%26%23xE8%3Bne%20Catenoix%2C%20Luc%20Valton%2C%20J%26%23xE9%3Br%26%23xF4%3Bme%20Aupy%2C%20Anca%20Nica%2C%20Sylvain%20Rheims%2C%20et%20al.%20%26%23x201C%3BCerebral%20Cavernous%20Malformations%20and%20Focal%20Drug-Resistant%20Epilepsy%3A%20Behind%20a%20Quid%20Pro%20Quo%20of%20Lesion%20and%20Epileptogenic%20Networks.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Neurology%26lt%3B%5C%2Fi%26gt%3B%2032%2C%20no.%207%20%282025%29%3A%20e70276.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.70276%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.70276%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cerebral%20Cavernous%20Malformations%20and%20Focal%20Drug-Resistant%20Epilepsy%3A%20Behind%20a%20Quid%20Pro%20Quo%20of%20Lesion%20and%20Epileptogenic%20Networks%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ionu%5Cu021b-Flavius%22%2C%22lastName%22%3A%22Bratu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22de%20Clerck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Catenoix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Valton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Aupy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anca%22%2C%22lastName%22%3A%22Nica%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Rheims%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Aubert-Conil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeanne%22%2C%22lastName%22%3A%22Benoit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Makhalova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oph%5Cu00e9lie%22%2C%22lastName%22%3A%22Galli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%20Medina%22%2C%22lastName%22%3A%22Villalon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Bartolomei%22%7D%5D%2C%22abstractNote%22%3A%22Background%20Cerebral%20cavernous%20malformations%20%28CCMs%29%20contribute%20to%20focal%20drug-resistant%20epilepsy%20%28fDRE%29%2C%20with%20surgical%20outcomes%20varying%20due%20to%20an%20incomplete%20understanding%20of%20the%20interplay%20between%20CCM-impacted%20regions%20and%20areas%20exhibiting%20ictal%20or%20interictal%20epileptogenicity.%20This%20study%20quantified%20the%20epileptogenicity%20of%20brain%20structures%20sampled%20by%20stereo-electroencephalography%20%28SEEG%29%20electrodes%20in%20patients%20with%20fDRE%20and%20supratentorial%20CCMs%2C%20focusing%20on%20the%20irritative%20zone%20%28IZN%29%20and%20epileptogenic-zone%20network%20%28EZN%29.%20It%20also%20established%20a%20framework%20for%20describing%20EZN%20organization%20relative%20to%20CCM-affected%20regions.%20Methods%20Retrospective%20multicentric%20cohort%20study%20involving%20fDRE%20patients%20with%20supratentorial%20CCMs%2C%20explored%20using%20SEEG%2C%20recruited%20from%20five%20French%20tertiary%20epilepsy%20centers.%20SEEG-sampled%20brain%20regions%20were%20classified%20as%20lesional%2C%20perilesional%2C%20or%20non-lesion-associated%20according%20to%20their%20anatomic%20relationship%20with%20the%20CCMs%20and%20using%20the%20Virtual%20Epileptic%20Patient%20brain%20atlas%20parcellation.%20IZN%20quantification%20was%20performed%20using%20spike%20rates%20per%20minute.%20EZN%20was%20evaluated%20using%20the%20Epileptogenicity%20Index%20or%20Permutation%20Entropy%20Index%20according%20to%20the%20seizure-onset%20pattern.%20Data%20were%20analyzed%20using%20both%20descriptive%20and%20inferential%20statistics.%20Results%20The%20study%20included%2022%20patients%2C%2010%20of%20whom%20underwent%20post-SEEG%20epilepsy%20surgery.%20IZN%20biomarkers%20differed%20significantly%20between%20lesional%2C%20perilesional%2C%20and%20non-lesion-associated%20areas%2C%20whereas%20EZN%20biomarkers%20did%20not.%20EZN%20included%20lesional%20areas%20in%2050%25%20of%20cases%2C%20with%20complex%20multi-lobar%20networks%20identified%20in%20most%20patients.%20Postsurgical%20seizure%20freedom%20was%20achieved%20in%2070%25%20of%20SEEG-explored%20patients.%20Conclusions%20Our%20findings%20highlight%20the%20complex%20relationship%20between%20CCMs%20and%20the%20EZN%2C%20supporting%20SEEG%20in%20the%20presurgical%20work-up%20of%20selected%20patients%20with%20CCMs%20and%20fDRE.%20A%20network-based%20surgical%20approach%20may%20improve%20outcomes%20by%20tailoring%20resections%20to%20the%20EZN.%22%2C%22date%22%3A%222025%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fene.70276%22%2C%22ISSN%22%3A%221468-1331%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1111%5C%2Fene.70276%22%2C%22collections%22%3A%5B%229RMECNPE%22%5D%2C%22dateModified%22%3A%222025-11-21T09%3A02%3A03Z%22%7D%7D%2C%7B%22key%22%3A%225WEUXZLI%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Desjardins%20et%20al.%22%2C%22parsedDate%22%3A%222025%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDesjardins%2C%20Cl%26%23xE9%3Bment%2C%20St%26%23xE9%3Bphan%20Grimaldi%2C%20Sheng%20Luo%2C%20Luowen%20Yu%2C%20Christopher%20G.%20Goetz%2C%20Glenn%20T.%20Stebbins%2C%20Pablo%20Martinez-Martin%2C%20et%20al.%20%26%23x201C%3BValidation%20of%20the%20French%20Translation%20of%20the%20Movement%20Disorder%20Society%20Non-Motor%20Symptoms%20Scale%20%28MDS-NMS%29%20in%20Parkinson%26%23x2019%3Bs%20Disease.%26%23x201D%3B%20%26lt%3Bi%26gt%3BMovement%20Disorders%20Clinical%20Practice%26lt%3B%5C%2Fi%26gt%3B%20n%5C%2Fa%2C%20no.%20n%5C%2Fa%20%282025%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmdc3.70323%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmdc3.70323%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Validation%20of%20the%20French%20Translation%20of%20the%20Movement%20Disorder%20Society%20Non-Motor%20Symptoms%20Scale%20%28MDS-NMS%29%20in%20Parkinson%27s%20Disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9ment%22%2C%22lastName%22%3A%22Desjardins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phan%22%2C%22lastName%22%3A%22Grimaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sheng%22%2C%22lastName%22%3A%22Luo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luowen%22%2C%22lastName%22%3A%22Yu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20G.%22%2C%22lastName%22%3A%22Goetz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Glenn%20T.%22%2C%22lastName%22%3A%22Stebbins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%22%2C%22lastName%22%3A%22Martinez-Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monica%20M.%22%2C%22lastName%22%3A%22Kurtis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tiago%20A.%22%2C%22lastName%22%3A%22Mestre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Sanchez-Ferro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michelle%20H.S.%22%2C%22lastName%22%3A%22Tosin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberta%22%2C%22lastName%22%3A%22Balestrino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chi-Ying%20R.%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carmen%22%2C%22lastName%22%3A%22Gasca-Salas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tatiana%22%2C%22lastName%22%3A%22Witjas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Colin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Maltete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Defebvre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Giordana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahmoud%22%2C%22lastName%22%3A%22Charif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Thiriez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Laurencin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lissa%22%2C%22lastName%22%3A%22Tir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwendoline%22%2C%22lastName%22%3A%22Dupont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Remy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Tranchant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Drapier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Samier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Benatru%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Sambin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Corvol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatma%22%2C%22lastName%22%3A%22Khelifi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margherita%22%2C%22lastName%22%3A%22Fabbri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Rascol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22the%20NS-Part%20Cohort%20study%20group%20and%20the%20MDS%20COA%20Translation%20Steering%20Committee%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222025%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1002%5C%2Fmdc3.70323%22%2C%22ISSN%22%3A%222330-1619%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1002%5C%2Fmdc3.70323%22%2C%22collections%22%3A%5B%22H8UPCNQI%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A32Z%22%7D%7D%5D%7D
Agripnidis, Thibault, Angela Ayobi, Sarah Quenet, Yasmina Chaibi, Christophe Avare, Alexis Jacquier, Nadine Girard, et al. “Performance of an Artificial Intelligence Tool for Multi-Step Acute Stroke Imaging: A Multicenter Diagnostic Study.” European Journal of Radiology Open 15 (December 2025): 100678. https://doi.org/10.1016/j.ejro.2025.100678.
Gauer, Lucas, Roy A. M. Haast, Mikhael Azilinon, Mohamed Mounir El Mendili, Julia Makhalova, Hugo Dary, Vera Dinkelacker, et al. “Investigating Sodium Homeostasis of Structural Brain Hubs in Focal Epilepsy Using 7 T MRI.” Brain: A Journal of Neurology, November 5, 2025, awaf409. https://doi.org/10.1093/brain/awaf409.
Stellmann, Jan-Patrick, Adil Maarouf, Mihaela Nicolescu, Clémence Boutiere, Audrey Rico, Wafaa Zaaraoui, Maxime Guye, Jean Pelletier, Jean-Phillipe Ranjeva, and Bertrand Audoin. “Early Structural Hub Disruption Leads to Premature Functional Adaption in Multiple Sclerosis.” Brain Structure & Function 230, no. 9 (November 5, 2025): 172. https://doi.org/10.1007/s00429-025-03023-2.
Grass, L., S. Grimaldi, and P. Damier. “Prodromal Parkinson’s Disease.” Revue Neurologique 181, no. 9 (November 2025): 863–80. https://doi.org/10.1016/j.neurol.2025.06.012.
Wilson, Sarah, Emmanuelle Leray, Floriane Calocer, Fabien Rollot, Mathieu Fauvernier, Laurent Remontet, Ludivine Launay, et al. “Influence of Geographical Accessibility to Specialist and Primary Care Givers on Excess Mortality of Multiple Sclerosis Patients in France.” BMC Neurology 25, no. 1 (October 27, 2025): 441. https://doi.org/10.1186/s12883-025-04459-z.
Mira, Valentin, Jan Patrick Stellman, and Stephan Grimaldi. “Paroxysmal Dystonia: An Etiology Not to Be Missed in an Older Adult Patient.” Movement Disorders Clinical Practice, October 23, 2025. https://doi.org/10.1002/mdc3.70407.
Perriguey, Marine, Camille Rigollet, Sean A. Freeman, Lisa Graille-Avy, Jean-Christophe Lafontaine, Bruno Lemarchant, Tifanie Alberto, et al. “Prevalence of Hypogammaglobulinemia after Non-Anti-CD20 Therapies and Impact of Switching to Rituximab/Ocrelizumab in Multiple Sclerosis.” Neurotherapeutics 22, no. 6 (October 1, 2025). https://doi.org/10.1016/j.neurot.2025.e00760.
Thakolwiboon, Smathorn, Vyanka Redenbaugh, Bo Chen, Sage Hewitt, Shailee Shah, Itay Lotan, Michael Levy, et al. “Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.” Neurology 105, no. 6 (September 23, 2025): e213903. https://doi.org/10.1212/WNL.0000000000213903.
Feys, Odile, Julia Makhalova, Thomas Manners, José-David Herrera-García, Romain Carron, and Fabrice Bartolomei. “Radiofrequency Thermocoagulation for the Treatment of Refractory Focal Status Epilepticus.” Epileptic Disorders: International Epilepsy Journal with Videotape, September 10, 2025. https://doi.org/10.1002/epd2.70091.
Gavoille, Antoine, Mikail Nourredine, Fabien Rollot, Romain Casey, Guillaume Mathey, Anne Kerbrat, Jonathan Ciron, et al. “Target Trial Emulation to Replicate Randomised Clinical Trials Using Registry Data in Multiple Sclerosis.” Journal of Neurology, Neurosurgery, and Psychiatry, September 4, 2025, jnnp-2025-336762. https://doi.org/10.1136/jnnp-2025-336762.
Andikoetxea, Begoña Garate, Antonio Martín-Bastida, Marta Vidorreta, María Cruz Rodríguez-Oroz, Lucas Soustelle, Thomas Troalen, and Maria A. Fernández-Seara. “Neuromelanin Contrast Optimization and Improved Visualization of the Substantia Nigra in a 3D Gradient-Echo Sequence With Magnetization Transfer.” NMR in Biomedicine 38, no. 9 (September 2025): e70123. https://doi.org/10.1002/nbm.70123.
Gavoille, Antoine, Emmanuelle Leray, Romain Marignier, Fabien Rollot, Romain Casey, Guillaume Mathey, Laure Michel, et al. “Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.” Neurology 105, no. 4 (August 26, 2025): e213907. https://doi.org/10.1212/WNL.0000000000213907.
Robin, Camille, Fabien Rollot, Mathilde Lefort, Romain Casey, Sandra Vukusic, Guillaume Mathey, Jonathan Ciron, et al. “Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis.” Neurology 105, no. 3 (August 12, 2025): e213744. https://doi.org/10.1212/WNL.0000000000213744.
Gavoille, Antoine, Fabien Rollot, Romain Casey, Guillaume Mathey, Emmanuelle Le Page, Jonathan Ciron, Jérôme De Sèze, et al. “Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis.” JAMA Neurology, August 4, 2025. https://doi.org/10.1001/jamaneurol.2025.2550.
Nimje, Swetali, Thierry Artières, Maxime Guye, and Ludovic de Rochefort. “Insights on Scan-Specific Deep-Learning Strategies for Brain MRI Parallel Imaging Reconstruction.” NMR in Biomedicine 38, no. 8 (August 2025): e70079. https://doi.org/10.1002/nbm.70079.
Attia, R., N. Stolowy, R. Fitoussi, and T. David. “Severe Corneal Flattening in Bilateral Cornea Plana.” Journal Francais D’ophtalmologie 48, no. 7 (July 22, 2025): 104587. https://doi.org/10.1016/j.jfo.2025.104587.
Küstner, Thomas, Roy Haast, Nikos Priovoulos, Patricia Clement, and Daniel Pinto Dos Santos. “ESMRMB 2025 Focus Topic: Cycle of Quality-from Concept to Clinical and Scientific Impact.” Magma (New York, N.Y.), June 14, 2025. https://doi.org/10.1007/s10334-025-01272-0.
Mostame, Parham, Jonathan Wirsich, Thomas Alderson, Ben Ridley, Anne-Lise Giraud, David W. Carmichael, Serge Vulliemoz, Maxime Guye, Louis Lemieux, and Sepideh Sadaghiani. “A Multiplex of Connectome Trajectories Enables Several Connectivity Patterns in Parallel.” eLife 13 (June 13, 2025): RP98777. https://doi.org/10.7554/eLife.98777.
Uher, Daniel, Gerhard S. Drenthen, Christianne M. Hoeberigs, Rick H. G. J. van Lanen, Albert J. Colon, Roy A. M. Haast, Vivianne H. J. M. van Kranen-Mastenbroek, et al. “The Role of Ultra-High Field MRI and Image Processing in the Presurgical Workup in MRI-Negative Focal Epilepsy: A Validated 7T MRI Case Study.” Epilepsy & Behavior Reports 30 (June 2025): 100761. https://doi.org/10.1016/j.ebr.2025.100761.
Alonso-Ortiz, Eva, Daniel Papp, Robert L. Barry, Kyota Poëti, Alan C. Seifert, Kyle M. Gilbert, Nibardo Lopez-Rios, et al. “Multi-Center Benchmarking of Cervical Spinal Cord RF Coils for 7 T MRI: A Traveling Spines Study.” Magnetic Resonance in Medicine, May 20, 2025. https://doi.org/10.1002/mrm.30551.
Mourre, Hélène, Julia Makhalova, Lisa Soncin, Elodie Garnier, Hugo Dary, Arnaud Le Troter, Roy A. M. Haast, et al. “Nuclei-Specific Amygdala Enlargement Is Linked to Psychiatric Comorbidities in Drug-Resistant Focal Epilepsy.” Annals of Clinical and Translational Neurology, May 19, 2025. https://doi.org/10.1002/acn3.70071.
Marignier, Romain, Javier Villacieros-Álvarez, Carmen Espejo, Georgin Arrambide, Nicolás Fissolo, Lucía Gutiérrez, Alessandro Dinoto, et al. “Assessment of Neuronal and Glial Serum Biomarkers in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: The MULTIMOGAD Study.” Journal of Neurology, Neurosurgery, and Psychiatry, May 16, 2025, jnnp-2024-335137. https://doi.org/10.1136/jnnp-2024-335137.
Demortiere, Sarah, Natacha Stolowy, Marine Perriguey, Clemence Boutiere, Audrey Rico, Frederic Hilezian, Blaise-Roger Ndjomo-Ndjomo, et al. “Diagnostic Utility of Kappa Free Light Chain Index in Adults With Inaugural Optic Neuritis.” Neurology(R) Neuroimmunology & Neuroinflammation 12, no. 3 (May 2025): e200386. https://doi.org/10.1212/NXI.0000000000200386.
Cohen, Mikael, Fabien Rollot, Marc Debouverie, Hélène Zephir, Sandra Vukusic, Jérome De Seze, Pierre Labauge, et al. “Secondary Progression Activity Monitoring in MS despite an Early Highly Active Treatment the SPAM Study.” European Journal of Neurology 32, no. 5 (May 2025): e16583. https://doi.org/10.1111/ene.16583.
Cotinat, Maëva, Noëlle Messaoudi, Emmanuelle Robinet, Laurent Suissa, Emilie Doche, Maxime Guye, Bertrand Audoin, Laurent Bensoussan, Jean-Philippe Ranjeva, and Wafaa Zaaraoui. “Dynamics of Ionic and Cytotoxic Edema During Acute and Subacute Stages of Patients With Ischemic Stroke: Complementarity of 23Na MRI and Diffusion MRI.” NMR in Biomedicine 38, no. 5 (May 2025): e70028. https://doi.org/10.1002/nbm.70028.
Dollomaja, Borana, Huifang E. Wang, Maxime Guye, Julia Makhalova, Fabrice Bartolomei, and Viktor K. Jirsa. “Virtual Epilepsy Patient Cohort: Generation and Evaluation.” PLoS Computational Biology 21, no. 4 (April 11, 2025): e1012911. https://doi.org/10.1371/journal.pcbi.1012911.
Cotinat, Maëva, Emmanuelle Robinet, Noëlle Messaoudi, Laurent Suissa, Emilie Doche, Maxime Guye, Laurent Bensoussan, Wafaa Zaaraoui, and Jean-Philippe Ranjeva. “Added Value of Sodium MR Imaging and Proton MR Spectroscopy to Conventional MR Imaging for a Better Characterization of the Ischemic Stroke: A Narrative Review.” Magnetic Resonance in Medical Sciences: MRMS: An Official Journal of Japan Society of Magnetic Resonance in Medicine, April 9, 2025. https://doi.org/10.2463/mrms.rev.2025-0002.
Hong, Jérémy, Malo Gaubert, Mathilde Lefort, Jean Christophe Ferré, Emmanuelle Le Page, Laure Michel, Pierre Labauge, et al. “Limited Added Value of Systematic Spinal Cord MRI vs Brain MRI Alone to Classify Patients with MS as Active or Inactive during Follow-Up.” Journal of Neurology 272, no. 4 (April 5, 2025): 316. https://doi.org/10.1007/s00415-025-13068-2.
Lodé, Baptiste, Burhan Rashid Hussein, Cédric Meurée, Ricky Walsh, Malo Gaubert, Nicolas Lassalle, Guilhem Courbon, et al. “Evaluation of a Deep Learning Segmentation Tool to Help Detect Spinal Cord Lesions from Combined T2 and STIR Acquisitions in People with Multiple Sclerosis.” European Radiology, April 4, 2025. https://doi.org/10.1007/s00330-025-11541-0.
Piazzola, Cecilia, Thomas Graillon, Nadine Girard, Henry Dufour, Thierry Brue, and Frederic Castinetti. “Desmopressin Is a Safe and Effective Secretagogue to Replace Corticotropin-Releasing Hormone in Petrosal Sinus Sampling.” Annales d’Endocrinologie 86, no. 2 (April 1, 2025): 101678. https://doi.org/10.1016/j.ando.2024.101678.
Bartolomei, F., J. Makhalova, J. Benoit, and S. Lagarde. “The Different Subtypes of Temporal Lobe Seizures Networks.” Revue Neurologique, March 29, 2025, S0035-3787(25)00485-0. https://doi.org/10.1016/j.neurol.2025.03.004.
Barrit, Sami, Nathan Torcida, Aurelien Mazeraud, Sebastien Boulogne, Jeanne Benoit, Timothée Carette, Thibault Carron, et al. “Specialized Large Language Model Outperforms Neurologists at Complex Diagnosis in Blinded Case-Based Evaluation.” Brain Sciences 15, no. 4 (March 27, 2025): 347. https://doi.org/10.3390/brainsci15040347.
Roger, Coleen, Adele Lasbleiz, Hugo Dary, Lauriane Pini, Patricia Ancel, Anezka Kovarova, Marie-Pierre Ranjeva, et al. “Structural Alterations of Individual Hypothalamic Nuclei in Young Females with Obesity and Anorexia Nervosa: An in Vivo 7-T MRI Study.” The American Journal of Clinical Nutrition, March 20, 2025, S0002-9165(25)00071-1. https://doi.org/10.1016/j.ajcnut.2025.02.003.
Testud, Benoit, Aurélien Destruel, Thomas Troalen, Jean-Philippe Ranjeva, and Maxime Guye. “Review of 7T MRI Imaging of Pituitary Microadenomas: Are We There Yet?” Neuroradiology, March 8, 2025. https://doi.org/10.1007/s00234-025-03554-9.
Schilling, Kurt G., Francesco Grussu, Andrada Ianus, Brian Hansen, Amy F. D. Howard, Rachel L. C. Barrett, Manisha Aggarwal, et al. “Considerations and Recommendations from the ISMRM Diffusion Study Group for Preclinical Diffusion MRI: Part 2-Ex Vivo Imaging: Added Value and Acquisition.” Magnetic Resonance in Medicine, March 4, 2025. https://doi.org/10.1002/mrm.30435.
Guttieres, Laura, Lea Vannelli, Sarah Demortiere, Marine Perriguey, Maya Elziere, Pierre Durozard, Clemence Boutiere, et al. “Fluorescein Angiography as a Surrogate Marker of Disease Activity in Susac Syndrome.” Neurology(R) Neuroimmunology & Neuroinflammation 12, no. 2 (March 2025): e200379. https://doi.org/10.1212/NXI.0000000000200379.
Villacieros-Álvarez, Javier, Carmen Espejo, Georgina Arrambide, Alessandro Dinoto, Patricia Mulero, Laura Rubio-Flores, Pablo Nieto, et al. “Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.” Neurology(R) Neuroimmunology & Neuroinflammation 12, no. 2 (March 2025): e200362. https://doi.org/10.1212/NXI.0000000000200362.
Mainguy, Marie, Romain Casey, Sandra Vukusic, Christine Lebrun-Frenay, Eric Berger, Anne Kerbrat, Abdullatif Al Khedr, et al. “Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis.” Neurology(R) Neuroimmunology & Neuroinflammation 12, no. 2 (March 2025): e200371. https://doi.org/10.1212/NXI.0000000000200371.
Schilling, Kurt G., Amy F. D. Howard, Francesco Grussu, Andrada Ianus, Brian Hansen, Rachel L. C. Barrett, Manisha Aggarwal, et al. “Considerations and Recommendations from the ISMRM Diffusion Study Group for Preclinical Diffusion MRI: Part 3-Ex Vivo Imaging: Data Processing, Comparisons with Microscopy, and Tractography.” Magnetic Resonance in Medicine, February 26, 2025. https://doi.org/10.1002/mrm.30424.
Jelescu, Ileana O., Francesco Grussu, Andrada Ianus, Brian Hansen, Rachel L. C. Barrett, Manisha Aggarwal, Stijn Michielse, et al. “Considerations and Recommendations from the ISMRM Diffusion Study Group for Preclinical Diffusion MRI: Part 1: In Vivo Small-Animal Imaging.” Magnetic Resonance in Medicine, February 26, 2025. https://doi.org/10.1002/mrm.30429.
Sèze, Jérôme de, Pierre Labauge, Roland Liblau, Mikel Martinez, Thibault Moreau, Laurent Suchet, Patrick Vermersch, et al. “LymphoTEC: A Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in France.” Advances in Therapy, February 19, 2025. https://doi.org/10.1007/s12325-024-03092-5.
Stolowy, Natacha, Lilija Gutmann, Margareta Lüpke, Thierry David, Michael Dorr, Christina Mayer, Christoph Heesen, et al. “OCT-Based Retina Assessment Reflects Visual Impairment in Multiple Sclerosis.” Investigative Ophthalmology & Visual Science 66, no. 2 (February 3, 2025): 39. https://doi.org/10.1167/iovs.66.2.39.
Lebret, Anna, Sabina Frese, Simon Lévy, Armin Curt, Virginie Callot, Patrick Freund, and Maryam Seif. “Spinal Cord Blood Perfusion Deficit Is Associated with Clinical Impairment after Spinal Cord Injury.” Journal of Neurotrauma 42, no. 3–4 (February 2025): 280–91. https://doi.org/10.1089/neu.2024.0267.
Cho, Soomi, Julia Makhalova, Samuel Medina Villalon, Nathalie Villeneuve, Agnes Trébuchon, Manel Krouma, Didier Scavarda, et al. “Stereoelectroencephalographic Exploration and Surgical Outcome in Lennox-Gastaut Syndrome.” Epilepsia, January 27, 2025. https://doi.org/10.1111/epi.18283.
Pham, S. D. T., C. Chatziantoniou, J. T. van Vliet, R. J. van Tuijl, M. Bulk, M. Costagli, L. de Rochefort, et al. “Blood Flow Velocity Analysis in Cerebral Perforating Arteries on 7T 2D Phase Contrast MRI with an Open-Source Software Tool (SELMA).” Neuroinformatics 23, no. 2 (January 22, 2025): 11. https://doi.org/10.1007/s12021-024-09703-4.
Ramdani, Ryan, Julie Pique, Romain Deschamps, Jonathan Ciron, Elisabeth Maillart, Bertrand Audoin, Mikael Cohen, et al. “Evaluation of the Predictive Value of CSF-Restricted Oligoclonal Bands on Residual Disability and Risk of Relapse in Adult Patients with MOGAD: MOGADOC Study.” Multiple Sclerosis (Houndmills, Basingstoke, England), January 15, 2025, 13524585241311435. https://doi.org/10.1177/13524585241311435.
Farah, Kaissar, Samira Mchinda, Laurianne Pini, Guillaume Baucher, Pierre- Hugues Roche, Stéphane Fuentes, and Virginie Callot. “T1 Mapping Using MP2RAGE in Degenerative Cervical Myelopathy: A Longitudinal Study.” European Spine Journal, January 9, 2025. https://doi.org/10.1007/s00586-025-08652-z.
Biagioni, Tommaso, Maria Fratello, Elodie Garnier, Stanislas Lagarde, Romain Carron, Samuel Medina Villalon, Isabelle Lambert, et al. “Interictal Waking and Sleep Electrophysiological Properties of the Thalamus in Focal Epilepsies.” Brain Communications 7, no. 2 (2025): fcaf102. https://doi.org/10.1093/braincomms/fcaf102.
Bratu, Ionuț-Flavius, Lucie de Clerck, Hélène Catenoix, Luc Valton, Jérôme Aupy, Anca Nica, Sylvain Rheims, et al. “Cerebral Cavernous Malformations and Focal Drug-Resistant Epilepsy: Behind a Quid Pro Quo of Lesion and Epileptogenic Networks.” European Journal of Neurology 32, no. 7 (2025): e70276. https://doi.org/10.1111/ene.70276.
Desjardins, Clément, Stéphan Grimaldi, Sheng Luo, Luowen Yu, Christopher G. Goetz, Glenn T. Stebbins, Pablo Martinez-Martin, et al. “Validation of the French Translation of the Movement Disorder Society Non-Motor Symptoms Scale (MDS-NMS) in Parkinson’s Disease.” Movement Disorders Clinical Practice n/a, no. n/a (2025). https://doi.org/10.1002/mdc3.70323.